<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Psychiatry</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Psychiatry</journal-id>
<journal-id journal-id-type="publisher-id">Front. Psychiatry</journal-id>
<journal-title-group>
<journal-title>Frontiers in Psychiatry</journal-title>
</journal-title-group>
<issn pub-type="epub">1664-0640</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30733689</article-id>
<article-id pub-id-type="pmc">6354568</article-id>
<article-id pub-id-type="doi">10.3389/fpsyt.2018.00751</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Psychiatry</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Characterizing the Interplay Between Autism Spectrum Disorder and Comorbid Medical Conditions: An Integrative Review</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Tye</surname>
<given-names>Charlotte</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">
<sup>*</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/618860/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Runicles</surname>
<given-names>Abigail K.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/619919/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Whitehouse</surname>
<given-names>Andrew J. O.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/61103/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alvares</surname>
<given-names>Gail A.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/79773/overview" xlink:type="simple"></uri>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Child &amp; Adolescent Psychiatry, Institute of Psychiatry, Psychology &amp; Neuroscience, King's College London</institution>, <addr-line>London</addr-line>, <country>United Kingdom</country></aff>
<aff id="aff2"><sup>2</sup><institution>Telethon Kids Institute, University of Western Australia</institution>, <addr-line>Perth, WA</addr-line>, <country>Australia</country></aff>
<aff id="aff3"><sup>3</sup><institution>Cooperative Research Centre for Living with Autism (Autism CRC)</institution>, <addr-line>Brisbane, QLD</addr-line>, <country>Australia</country></aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Manuel Fernando Casanova, University of South Carolina, United States</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Marco Carotenuto, Università degli Studi della Campania Luigi Vanvitelli Caserta, Italy; Catherine Doyen, Centre Hospitalier Sainte-Anne, France; Antonio Benítez-Burraco, Universidad de Sevilla, Spain</p>
</fn>
<corresp id="c001">*Correspondence: Charlotte Tye <email>charlotte.tye@kcl.ac.uk</email></corresp>
<fn fn-type="other" id="fn001">
<p>This article was submitted to Child and Adolescent Psychiatry, a section of the journal Frontiers in Psychiatry</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>23</day>
<month>1</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<year>2018</year>
</pub-date>
<volume>9</volume>
<elocation-id>751</elocation-id>
<history>
<date date-type="received">
<day>25</day>
<month>9</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>19</day>
<month>12</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2019 Tye, Runicles, Whitehouse and Alvares.</copyright-statement>
<copyright-year>2019</copyright-year>
<copyright-holder>Tye, Runicles, Whitehouse and Alvares</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>Co-occurring medical disorders and associated physiological abnormalities in individuals with autism spectrum disorder (ASD) may provide insight into causal pathways or underlying biological mechanisms. Here, we review medical conditions that have been repeatedly highlighted as sharing the strongest associations with ASD—epilepsy, sleep, as well as gastrointestinal and immune functioning. We describe within each condition their prevalence, associations with behavior, and evidence for successful treatment. We additionally discuss research aiming to uncover potential aetiological mechanisms. We then consider the potential interaction between each group of conditions and ASD and, based on the available evidence, propose a model that integrates these medical comorbidities in relation to potential shared aetiological mechanisms. Future research should aim to systematically examine the interactions between these physiological systems, rather than considering these in isolation, using robust and sensitive biomarkers across an individual's development. A consideration of the overlap between medical conditions and ASD may aid in defining biological subtypes within ASD and in the development of specific targeted interventions.</p>
</abstract>
<kwd-group>
<kwd>autism spectrum disorder</kwd>
<kwd>comorbidity</kwd>
<kwd>epilepsy</kwd>
<kwd>gastrointestinal disorders</kwd>
<kwd>immune function</kwd>
<kwd>sleep</kwd>
</kwd-group>
<counts>
<fig-count count="3"></fig-count>
<table-count count="7"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="250"></ref-count>
<page-count count="21"></page-count>
<word-count count="17833"></word-count>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>Autism spectrum disorders (ASD) are a group of complex and heterogeneous developmental conditions characterized by reduced social interaction and communication, as well as restricted range of interests and/or stereotypic behaviors (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>). Many of the core cognitive and behavioral symptoms associated with ASD are thought to arise from dysfunction of the central nervous system (<xref ref-type="bibr" rid="B3">3</xref>). However, accumulating and converging evidence across several areas of medicine have strongly emphasized comorbid medical conditions and associated peripheral/central physiological abnormalities in children with ASD as providing potential clues to additional etiological factors. Epidemiological evidence indicates that medical disorders are more prevalent in children with ASDs compared to children in the general population (<xref ref-type="bibr" rid="B4">4</xref>), with further evidence for specific clusters of medical conditions in ASD (<xref ref-type="bibr" rid="B5">5</xref>). Whilst multisystem dysfunction across a range of organs and physiological systems has been proposed in other brain-based conditions (including neurodegenerative disorders, schizophrenia, bipolar disorder and depression), the elevated incidence of medical conditions and associated markers of dysfunction appear to be particularly perturbed in ASD (<xref ref-type="bibr" rid="B6">6</xref>). These medical conditions, and accompanying disabilities, can have significant impacts on broader development outcomes, social functioning, and education/employment outcomes. Despite the high prevalence of medical comorbidities in this population, many of these conditions are not routinely screened for in ASD evaluations (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>). This may reflect variability in the symptoms expressed by individuals with varying language capacity as well as the ability of health professionals to recognize behavioral symptoms that may be better explained by other medical conditions. In addition to better medical treatment, the increasing understanding of systemic abnormalities in ASD may provide clues to etiological factors as well as identifying biological pathways for more targeted and effective treatments.</p>
<p>Prevalence estimates of medical comorbidities vary greatly depending on the population studied. One of the largest studies of hospital records of children and young adults with ASD in the US found that prevalence estimates of a range of co-morbid disorders, particularly gastrointestinal and seizure disorders, greatly exceeded that compared to the general hospital population (<xref ref-type="bibr" rid="B4">4</xref>). Other studies have highlighted greater prevalence of abnormal neurological findings and clinical neuropathology in children with ASD (<xref ref-type="bibr" rid="B9">9</xref>). Strikingly, reports indicate elevated mortality ratios of up to 2.4 in ASD (<xref ref-type="bibr" rid="B10">10</xref>–<xref ref-type="bibr" rid="B12">12</xref>), which is thought to be due to largely due to complications arising from comorbid medical conditions (<xref ref-type="bibr" rid="B13">13</xref>). Put another way, premature mortality in individuals with ASDs is over twice the rate of that experienced by the general population (<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B13">13</xref>). Although prevalence estimates for some conditions are higher in studies with smaller samples, the overall evidence suggests that at least 10% of individuals with ASD present with comorbid medical symptoms that require formal medical evaluation (<xref ref-type="bibr" rid="B4">4</xref>). This has significant implications for subsequent development, prognosis and treatment plans for individuals and families as well as the additional pressures comorbidities place on health care and disability systems to provide adequate and necessary supports across the lifespan.</p>
<p>There have been several reviews and empirical studies focusing on specific medical, [e.g., (<xref ref-type="bibr" rid="B14">14</xref>–<xref ref-type="bibr" rid="B17">17</xref>)], behavioral [e.g., (<xref ref-type="bibr" rid="B18">18</xref>–<xref ref-type="bibr" rid="B20">20</xref>)], and genetic [e.g., (<xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B22">22</xref>)] comorbidities of ASD. Here, we review medical disorders that have been repeatedly highlighted as sharing the strongest associations with ASD—epilepsy, sleep problems, gastrointestinal disorders and immune dysfunction—with the purpose of integrating mechanistic theories of their overlap. For each domain, we describe the prevalence and associations with behavior and cognition in ASD, before moving on to focus on work aiming to uncover shared aetiological mechanisms. A proposed mechanistic model integrating ASD and these medical comorbidities is then presented. We argue that a consideration of overlap between medical problems and ASD will provide insight into shared mechanisms and implications for treatment, based on proposed models of comorbidity (Figure <xref ref-type="fig" rid="F1">1</xref>).</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p>Possible models of the association between medical conditions and ASD: <bold>(A)</bold> Overlap between medical conditions and ASD arises from a <italic>common</italic> mechanism; <bold>(B)</bold> Overlap between medical conditions and ASD arises from the <italic>independent</italic> pathways or <italic>cumulative</italic> impact of impairments in two or more developmental pathways (possibly subgroups of individuals); <bold>(C)</bold> Overlap between medical conditions and ASD arises from the <italic>effect of medical abnormalities</italic> on underling mechanisms, or vice versa. These models are not mutually exclusive and more than one pathway may be involved.</p>
</caption>
<graphic xlink:href="fpsyt-09-00751-g0001"></graphic>
</fig>
</sec>
<sec id="s2">
<title>Meta-Synthesis of Theories Underlying Common Medical Comorbidities of ASD</title>
<sec>
<title>Epilepsy</title>
<sec>
<title>Prevalence</title>
<p>Epilepsy, defined as two unprovoked seizures of any type, can be extended out to include multiple disorders with various etiologies, pathophysiology and outcomes (<xref ref-type="bibr" rid="B23">23</xref>). Prevalence of epilepsy in the general population is between 1 and 2%, whilst general estimates suggest a prevalence of ~25–30% in individuals with ASD by adolescence (<xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B25">25</xref>). In particular, two peak periods of epilepsy onset have been described in ASD—one in early childhood and a second in adolescence (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B27">27</xref>), although prospective longitudinal studies have failed to replicate this bimodal distribution (<xref ref-type="bibr" rid="B28">28</xref>). Rates of ASD are higher in certain genetic disorders; for example, 47.4% of individuals with Dravet syndrome meet criteria for ASD, with the main seizure type being focal seizures manifesting in clusters (<xref ref-type="bibr" rid="B29">29</xref>). Whilst rates of ASD in tuberous sclerosis complex (TSC) are thought to approach 60%, individuals with TSC often experience different types of seizures (<xref ref-type="bibr" rid="B30">30</xref>, <xref ref-type="bibr" rid="B31">31</xref>). Even in the absence of diagnosed epilepsy, there is considerable debate concerning the significance of abnormal electroencephalography (EEG) findings observed in ASD not associated with clinical seizure activity (<xref ref-type="bibr" rid="B24">24</xref>). A significant proportion of individuals with ASD display significant EEG paroxysmal abnormalities during sleep without the presence of clinical seizures, with reports as high as 60% (<xref ref-type="bibr" rid="B32">32</xref>–<xref ref-type="bibr" rid="B34">34</xref>). Retrospective studies indicate similar rates of cognitive impairment and cerebral lesions in ASD patients with abnormal EEGs with and without epilepsy (<xref ref-type="bibr" rid="B27">27</xref>). Due to this debate, clinical EEGs are not generally recommended as routine practice for children with ASD unless seizure activity is suspected.</p>
<p>All seizure types appear to be associated with ASD but vary in prevalence depending on the population studied (see Table <xref ref-type="table" rid="T1">1</xref>). In a Swedish study, the most prevalent seizures in ASD were complex partial, atypical absence, myoclonic, and tonic-clonic seizures (<xref ref-type="bibr" rid="B35">35</xref>); by comparison, an American study reported that generalized tonic-clonic and atypical absence seizures were the most common in ASD (<xref ref-type="bibr" rid="B36">36</xref>). Some more recent studies argue that complex partial seizures are most prevalent in ASD (<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B34">34</xref>, <xref ref-type="bibr" rid="B37">37</xref>). Clinically, this latter seizure type is particularly significant as some symptoms of complex partial seizures may be difficult to differentiate from common associated behaviors in ASD, such as not responding to calling name or repetitive movements. Of significance for clinical intervention, it has also been reported that treatment-resistant epilepsy is also of particularly high prevalence in ASD (<xref ref-type="bibr" rid="B38">38</xref>). One of the most severe forms of comorbid epilepsy in ASD is epileptic encephalopathy, a process whereby the epileptic activity contributes to severe cognitive and behavioral impairments above and beyond the underlying pathology alone (<xref ref-type="bibr" rid="B39">39</xref>, <xref ref-type="bibr" rid="B40">40</xref>). It is characterized by intractable seizures as well as frequent ictal or interictal epileptiform activity (<xref ref-type="bibr" rid="B39">39</xref>), which may be idiopathic or syndromic. Infants with epileptic encephalopathy are at a higher risk for an ASD diagnosis and lasting cognitive impairments (<xref ref-type="bibr" rid="B41">41</xref>). In particular, 19.9% of children with infantile spasms will have ASD (<xref ref-type="bibr" rid="B29">29</xref>).</p>
<table-wrap id="T1" position="float">
<label>Table 1</label>
<caption>
<p>Overview of studies examining specific seizure types in individuals with ASD.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Study</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Sample size</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Prevalence</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Subtypes</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Steffenburg et al. (<xref ref-type="bibr" rid="B35">35</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>N</italic> = 90, 24 ASD, 53 with at least 1 psychiatric diagnosis.</td>
<td align="left" colspan="1" rowspan="1" valign="top">59% at least 1 psychiatric diagnosis, 27% ASD, 11% had ASD-like condition.</td>
<td align="left" colspan="1" rowspan="1" valign="top">Complex partial, atypical absence, myoclonic, tonic clonic.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Tuchman et al. (<xref ref-type="bibr" rid="B36">36</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>N</italic> = 314 ASD, <italic>N</italic> = 237 dysphasic non-ASD.</td>
<td align="left" colspan="1" rowspan="1" valign="top">14% of ASD and 8% of dysphasic had epilepsy.</td>
<td align="left" colspan="1" rowspan="1" valign="top">Generalized tonic-clonic and atypical absence seizures.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Matsuo et al. (<xref ref-type="bibr" rid="B37">37</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>N</italic> = 519 with epilepsy, <italic>N</italic> = 79 ASD.</td>
<td align="left" colspan="1" rowspan="1" valign="top">15.2% of sample with epilepsy had ASD.</td>
<td align="left" colspan="1" rowspan="1" valign="top">Most frequent type—complex partial seizures.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Yasuhara (<xref ref-type="bibr" rid="B34">34</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>N</italic> = 1,014 ASD.</td>
<td align="left" colspan="1" rowspan="1" valign="top">37% had epilepsy.</td>
<td align="left" colspan="1" rowspan="1" valign="top">Most frequent type—complex partial seizures.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Parmeggiani et al. (<xref ref-type="bibr" rid="B27">27</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>N</italic> = 345 ASD.</td>
<td align="left" colspan="1" rowspan="1" valign="top">24.9% epilepsy, 45.5% EEG paroxysmal abnormalities.</td>
<td align="left" colspan="1" rowspan="1" valign="top">Most frequent type—complex partial seizures.</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Of concern, is the increased 2-fold higher mortality rate in individuals with comorbid ASD and epilepsy compared to the general population, which is higher still in females with these comorbidities (<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B42">42</xref>). These studies describe sudden unexpected death due to epilepsy at a higher frequency than expected, indicating that these individuals are likely to require increased medical monitoring to prevent avoidable death over their lifespan.</p>
</sec>
<sec>
<title>Associations With Behavior and Cognition in ASD</title>
<p>Research has suggested that there is a relationship between specific symptoms and epilepsy in individuals with ASD. Turk et al. (<xref ref-type="bibr" rid="B43">43</xref>) found that a co-morbid diagnosis of ASD and epilepsy led to greater difficulties in in social interactions with peers and unusual eye contact. Those with epilepsy also received an ASD diagnosis later than those who were not diagnosed with epilepsy. Conversely, other studies have found that increased frequency of epilepsy has been associated with an earlier age of ASD diagnosis, higher rates of repetitive object use, and greater unusual sensory interests (<xref ref-type="bibr" rid="B44">44</xref>). Viscidi et al. (<xref ref-type="bibr" rid="B45">45</xref>) completed a large-scale study showing that children with both epilepsy and ASD displayed significantly more maladaptive behaviors linked to ASD. This included a decrease in scores on social cognition, communication and motivation when compared to ASD patients without epilepsy. Participants with both epilepsy and ASD also display higher levels of self-injurious, compulsive and sameness behaviors. Finally, a meta-analysis of social cognition in epilepsy and autism and found that rates of impaired facial recognition and theory of mind were higher in patients with epilepsy and ASD compared to controls (<xref ref-type="bibr" rid="B46">46</xref>). These studies suggest that there is a link between epilepsy and ASD symptoms and cognitive correlates. However, the close relationship with IQ suggests a dynamic interplay between ASD symptoms, and subsequent diagnostic age, IQ, and epilepsy.</p>
<p>Evidence from meta-analyses confirms an overall greater risk for epilepsy in children with ASD and intellectual disability (21.5%) compared to those without comorbid intellectual disability (8%) (<xref ref-type="bibr" rid="B47">47</xref>), as well as an increased risk in children with ASD and intellectual disability after the age of 12 years (<xref ref-type="bibr" rid="B48">48</xref>). This implies that the neurobiological mechanisms underpinning common associations between epilepsy and ASD may be derived from these subgroups within ASD. Other researchers have also pointed to the relationship between behavioral regression in ASD and greater incidence of epilepsy (<xref ref-type="bibr" rid="B49">49</xref>–<xref ref-type="bibr" rid="B51">51</xref>). Berg and Pliophys (<xref ref-type="bibr" rid="B52">52</xref>) suggest that the role of intellectual disability is so vital that it could explain most, if not all of the relationship between epilepsy and ASD. In a case study of TSC, the child's development was typical until 21 months of age at which seizure onset occurred; by 24 months of age the child met criteria for both ASD and intellectual disability (<xref ref-type="bibr" rid="B53">53</xref>). Taken together, this suggests that there is a dynamic interplay between seizures, intellectual disability and ASD with the onset of seizures playing a significant role in developmental regression and ASD diagnostic symptoms.</p>
<p>A diagnosis of comorbid epilepsy and ASD is a negative prognostic indicator, associated with greater risk of poorer outcomes (<xref ref-type="bibr" rid="B54">54</xref>). Children with both conditions report lower quality of life, score lower on social maturity scales, and exhibit higher use of psychotropic medications (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B55">55</xref>, <xref ref-type="bibr" rid="B56">56</xref>), in addition to poorer social outcomes (<xref ref-type="bibr" rid="B43">43</xref>). A large prospective follow-up study found significantly higher levels of cognitive impairments in adults followed from childhood, with seizure frequency reported to have the most significant impact on individual functioning (<xref ref-type="bibr" rid="B28">28</xref>). Even in children with ASD but without diagnosed epilepsy, EEG abnormalities and seizures have been associated with greater reports of aberrant behavior [(<xref ref-type="bibr" rid="B57">57</xref>); see Table <xref ref-type="table" rid="T2">2</xref>].</p>
<table-wrap id="T2" position="float">
<label>Table 2</label>
<caption>
<p>Overview of studies examining behavior and cognitive differences in individuals with ASD and epilepsy.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Study</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Sample size</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Features in ASD + epilepsy compared to ASD</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Turk et al. (<xref ref-type="bibr" rid="B43">43</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>N</italic> = 60 ASD + epilepsy, <italic>N</italic> = 60 ASD.</td>
<td align="left" colspan="1" rowspan="1" valign="top">Higher incidence of motor difficulties, developmental delays &amp; challenging behaviors.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Cuccaro et al. (<xref ref-type="bibr" rid="B44">44</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>N</italic> = 577 ASD, <italic>N</italic> = 64 ASD + epilepsy.</td>
<td align="left" colspan="1" rowspan="1" valign="top">Higher rates of repetitive object use and unusual sensory interests.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Viscidi et al. (<xref ref-type="bibr" rid="B45">45</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>N</italic> = 2,645 ASD, <italic>N</italic> = 139 ASD + epilepsy.</td>
<td align="left" colspan="1" rowspan="1" valign="top">Higher rates of irritability (20% higher) and hyperactivity (24% higher).</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec>
<title>Treatment Effects</title>
<p>As epilepsy may contribute to elevated mortality rates in ASD, appropriate detection and treatment of elevated seizure activity in individuals with ASD is a clear and urgent treatment need [(<xref ref-type="bibr" rid="B48">48</xref>); see Table <xref ref-type="table" rid="T3">3</xref>]. Treatment of children with both epilepsy and ASD is based on guidelines aimed at treating childhood epilepsy with anti-epileptic drugs (AEDs), chosen based on seizure type and response to medication. Research into treatments that best control seizures in children with ASD is critical, as some children with ASD appear to be more sensitive to the side effects of AEDs (<xref ref-type="bibr" rid="B24">24</xref>). When epileptiform activity is present, therapeutic interventions to reduce seizure activity may also improve language outcomes and ASD symptoms [reviewed in (<xref ref-type="bibr" rid="B62">62</xref>)]. Valproic acid, lamotrigine and Levetiacetam are the mostly highly rated AEDs in terms of effectiveness and tolerability in ASD, with valproic acid also found to improve core ASD symptoms (<xref ref-type="bibr" rid="B58">58</xref>). While alternative treatments, such as diets (e.g., ketogenic, modified Atkin's or gluten and casein free), have shown some efficacy for treating epilepsy, their suitability and safety for individuals with ASD require further study. Recent treatment advances for syndromic ASD may have particular relevance in improving either or both seizures and symptoms associated with ASD. For example, mTOR inhibitor treatment (Everolimus), associated with reduction in cell proliferation, angiogenesis and glucose uptake, has shown efficacy for some of the physical manifestations of TSC (<xref ref-type="bibr" rid="B63">63</xref>). In a case series, treatment with Everolimus was associated with a reduction in the severity and frequency of seizures, as well as improvements in repetitive behavior and social contact (<xref ref-type="bibr" rid="B59">59</xref>), although a recent study showed limited effect of everolimus on neuropsychiatric features in children (<xref ref-type="bibr" rid="B60">60</xref>). Furthermore, vigabatrin is recommended for children with infantile spasms and TSC, linked to improved later outcomes, including a decrease in adverse cognitive and behavioral outcomes such as ASD (<xref ref-type="bibr" rid="B61">61</xref>). Such treatment effects may help to explain the underlying pathophysiology and interaction between genetic mutations, epilepsy and ASD, for example, through normalization of altered brain activity and excitatory/inhibitory balance (see section Aetiological Mechanisms).</p>
<table-wrap id="T3" position="float">
<label>Table 3</label>
<caption>
<p>An overview of different therapeutic approaches to treating epileptic symptoms in ASD.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Studies</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Therapeutic approach</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Benefits of therapeutic approach</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Caveats of therapeutic approach</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Frye et al. (<xref ref-type="bibr" rid="B58">58</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Anti-epileptic drugs (AEDs; e.g., Valproic acid, lamotrigine, levetiracetam and ethosuximide)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Improvement in seizures and limited impact on other clinical factors</td>
<td align="left" colspan="1" rowspan="1" valign="top">Rate of side effects higher for AEDs compared to non-AED treatments</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Frye et al. (<xref ref-type="bibr" rid="B58">58</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Ketogenic diet</td>
<td align="left" colspan="1" rowspan="1" valign="top">Improvement in seizures, favorable effects on sleep, communication, behavior, attention and moodLow incidence of adverse effects</td>
<td align="left" colspan="1" rowspan="1" valign="top">Can result in severe acidosis</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Kilincaslan et al. (<xref ref-type="bibr" rid="B59">59</xref>) Krueger et al. (<xref ref-type="bibr" rid="B60">60</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">mTOR inhibitor (Everolimus)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduction in severity and frequency of seizures, improvements in repetitive behavior and social contact (<xref ref-type="bibr" rid="B59">59</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Limited effect on neuropsychiatric features (<xref ref-type="bibr" rid="B60">60</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Bombardieri et al. (<xref ref-type="bibr" rid="B61">61</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Vigabatrin</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decrease in adverse cognitive and behavioral outcomes</td>
<td align="left" colspan="1" rowspan="1" valign="top">Only indicated in patient with TSC and infantile spasms</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec>
<title>Aetiological Mechanisms</title>
<p>Seizure disorders can be due to many causes, including acute or chronic focal or diffuse brain pathology, genetic mutations, metabolic causes, or idiopathic reasons; as such, attempts to identify common causal pathways between ASD and epilepsy have proven to be a complex endeavor. While a number of reports have suggested common neuropathology in children with ASD and epilepsy (<xref ref-type="bibr" rid="B64">64</xref>), the vast majority of evidence suggests that epilepsy is not causal to the development of ASD, although the notable exception may be in the case of infants with an epileptic encephalopathy (see section Prevalence). It has been hypothesized that comorbidity of these conditions reflects shared neurodevelopmental pathways or common etiopathologies (<xref ref-type="bibr" rid="B65">65</xref>), such as abnormalities in synaptic plasticity and excitatory/inhibitory imbalance early in development and/or shared multiple genome variants (<xref ref-type="bibr" rid="B25">25</xref>, <xref ref-type="bibr" rid="B40">40</xref>).</p>
<p>Many candidate genes associated with ASD and epilepsy are involved in synaptic formation and maintenance (e.g., NRXN1, CNTNAP2) and GABAergic neurotransmission [e.g., ARX, Mecp2; for review see (<xref ref-type="bibr" rid="B66">66</xref>)]. The possibility of common genes is especially pertinent for those with intellectual disability. Recurrent structural abnormalities are shown at 15q13.3, 16p13.11, and 16p13.3 in patients with epilepsy, which overlap with genomic hotspots reported in ASD and ID (<xref ref-type="bibr" rid="B47">47</xref>, <xref ref-type="bibr" rid="B67">67</xref>, <xref ref-type="bibr" rid="B68">68</xref>). Likewise, copy number variations (CNVs) identified in patients with epileptic encephalopathies (Landau-Kleffner syndrome and continuous spike-wave during slow-wave sleep syndrome) corresponded to genomic regions or genes associated with ASD or related behaviors, particularly those encoding cell adhesion proteins (<xref ref-type="bibr" rid="B69">69</xref>).</p>
<p>The association between genetic disorders, epilepsy and ASD could provide a further indication of the aetiological mechanisms underlying ASD and epilepsy (<xref ref-type="bibr" rid="B40">40</xref>). Genetic disorders associated with epilepsy, such as TSC, Dravet syndrome and Angelman syndrome, have been linked to higher rates of ASD (<xref ref-type="bibr" rid="B30">30</xref>, <xref ref-type="bibr" rid="B70">70</xref>–<xref ref-type="bibr" rid="B72">72</xref>). For example, TSC is caused by a mutation of TSC1 or TSC2 that disrupt the mTOR pathway and is characterized by multisystem growths of tumor-like lesions called hamartomas, which can affect a wide-range of bodily systems. Cortical tubers and peritubular cortex act as epileptogenic foci which increase the risk of epilepsy up to 90% and are linked to intellectual impairment and behavioral disturbances including ASD (<xref ref-type="bibr" rid="B70">70</xref>, <xref ref-type="bibr" rid="B73">73</xref>). Likewise, Dravet syndrome (severe myoclonic epilepsy in infancy) is often caused by mutations in the SCN1A gene, which regulates movement of sodium ions, helping to propagate electrical signals along neurons (<xref ref-type="bibr" rid="B74">74</xref>). Dravet syndrome is associated with prolonged refractory seizures within the first year of life and later cognitive impairment, motor deficits and behavioral disorders such as ASD (<xref ref-type="bibr" rid="B71">71</xref>). Duplications on chromosome 15q11.3-q13.1 (Dup15q syndrome) lead to overexpression of several genes, including those involved in GABA transmission and are associated with high risk for early onset epilepsy, ASD and intellectual disability (<xref ref-type="bibr" rid="B75">75</xref>). The association between ASD and epilepsy within genetic syndromes may help to identify a shared etiology, whereby disruption downstream of the genetic mutation affects both epileptogenesis and behavior [for review see (<xref ref-type="bibr" rid="B76">76</xref>)]. The genes implicated in several of these syndromes are associated with synaptic function. The diverse genetic etiologies identified may therefore converge by altering excitatory/inhibitory balance in the cerebral cortex, due to defects in GABAergic fibers of GABA-receptor function (<xref ref-type="bibr" rid="B77">77</xref>).</p>
<p>Despite many common associations found in both disorders, there is a limited amount of evidence investigating shared environmental and/or neuroinflammation pathways leading to comorbid epilepsy and ASD, for example advanced maternal/paternal age (<xref ref-type="bibr" rid="B78">78</xref>) or increased activation of astroglia/microglia in children with ASD (<xref ref-type="bibr" rid="B79">79</xref>) or epilepsy (<xref ref-type="bibr" rid="B80">80</xref>).</p>
</sec>
<sec>
<title>Summary</title>
<p>The well-documented overlap between ASD and epilepsy points toward shared aetiological mechanisms. Current findings do not suggest a causative role for epilepsy and abnormal epileptiform activity in the development of ASD; rather, presence of comorbid conditions predicts poorer prognostic outcome in individuals, and as such, indicates need for greater monitoring and interventions for associated factors. Research to date has not yet been able to fully determine the anatomical or molecular causes of why these conditions converge, as it is difficult to distinguish the effects of the underlying pathology from the neurological effects of the seizures themselves (<xref ref-type="bibr" rid="B25">25</xref>).</p>
</sec>
</sec>
<sec>
<title>Sleep Problems</title>
<sec>
<title>Prevalence</title>
<p>Sleep problems occur in a significantly higher proportion of children with ASD compared to typically developing children and children with other developmental delays (<xref ref-type="bibr" rid="B81">81</xref>). Prevalence estimates range between 50 and 80% as compared with 9–50% of typically developing children (<xref ref-type="bibr" rid="B81">81</xref>–<xref ref-type="bibr" rid="B84">84</xref>). These sleep disturbances not only affect daytime functioning but impact on the quality of life of the whole family (<xref ref-type="bibr" rid="B85">85</xref>).</p>
<p>A range of sleep disorders may be present in children with ASD, including insomnia (including difficulties with sleep initiation, duration, consolidation, or sleep quality, bedtime resistance, night awakenings, or inability to sleep independently), sleep disordered breathing (that is, disorders related to airway obstruction, including obstructive sleep apnoea), parasomnias (including nightmares, wake screaming, complex movements, and dreams), and sleep related movement disorders (for example, rhythmical movement disorder and restless legs syndrome). Using parental reports, Goldman and colleagues found that younger children with ASD experienced more sleep anxiety, bedtime resistance, night wakefulness, and parasomnias; adolescents, however, tended to have more difficulty falling asleep, getting enough sleep, and experiencing daytime sleepiness (<xref ref-type="bibr" rid="B86">86</xref>). Actigraphy data confirms this, with children with ASD experiencing greater latency to fall asleep, longer periods of awakenings, and more night-time activity compared to typically developing children (<xref ref-type="bibr" rid="B87">87</xref>). Data from overnight polysomnography also demonstrates shorter sleep times and lower rapid eye movement (REM) sleep in children with ASD (<xref ref-type="bibr" rid="B88">88</xref>). Overall, insomnia (difficulty falling asleep and staying asleep) appears to be the most reliably observed phenomena to characterize sleep disturbances across the spectrum [(<xref ref-type="bibr" rid="B89">89</xref>–<xref ref-type="bibr" rid="B91">91</xref>); see Table <xref ref-type="table" rid="T4">4</xref>].</p>
<table-wrap id="T4" position="float">
<label>Table 4</label>
<caption>
<p>An overview of sleep difficulties in individuals with ASD.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Source</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Sample size</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Methodology</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Prevalence</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Sleep disturbance</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Goldman et al. (<xref ref-type="bibr" rid="B86">86</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>N</italic> = 1,859 ASD</td>
<td align="left" colspan="1" rowspan="1" valign="top">Parent-report questionnaire</td>
<td align="left" colspan="1" rowspan="1" valign="top">67.3% categorized as good sleepers, 31.5% as bad sleepers</td>
<td align="left" colspan="1" rowspan="1" valign="top">Younger children had sleep anxiety bedtime resistance, night waking and parasomnias. Adolescents had problems with falling asleep, getting enough consistently and daytime sleepiness</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Souders et al. (<xref ref-type="bibr" rid="B87">87</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>N</italic> = 59 ASD, <italic>N</italic> = 40 Controls</td>
<td align="left" colspan="1" rowspan="1" valign="top">Actigraphy</td>
<td align="left" colspan="1" rowspan="1" valign="top">66% in ASD group had moderate sleep disturbances compared to 45% mild sleep disturbance in controls</td>
<td align="left" colspan="1" rowspan="1" valign="top">Behavioral insomnia sleep-onset type</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Buckley et al. (<xref ref-type="bibr" rid="B88">88</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>N</italic> = 60 ASD, <italic>N</italic> = 15 Controls</td>
<td align="left" colspan="1" rowspan="1" valign="top">Overnight polysomnographic recording</td>
<td align="left" colspan="1" rowspan="1" valign="top">–</td>
<td align="left" colspan="1" rowspan="1" valign="top">Shorter total sleep time and smaller REM sleep percentage</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Baker et al. (<xref ref-type="bibr" rid="B90">90</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>N</italic> = 34 ASD, <italic>N</italic> = 27 Controls</td>
<td align="left" colspan="1" rowspan="1" valign="top">Sleep questionnaire, sleep diary, and actigraphy</td>
<td align="left" colspan="1" rowspan="1" valign="top">Three times more likely to report sleep problems compared to controls</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased sleep efficiency and fatigue</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec>
<title>Associations With Behavior and Cognition</title>
<p>Sleep has a vital role to play in child development as it serves multiple functions, such as energy conservation, brain growth, cognition and memory consolidation (<xref ref-type="bibr" rid="B15">15</xref>). The relationship between behavior in ASD and sleep dysfunction are likely to be bi-directional; whilst challenging daytime behaviors and associated comorbid conditions (e.g., attention deficit hyperactivity disorder (ADHD), anxiety and depression) contribute to sleep difficulties (see also section Treatment Effects), inefficient sleep can exacerbate or promote ASD behaviors. For example, sleep disorders are predictive of symptom severity in children with ASD (<xref ref-type="bibr" rid="B92">92</xref>, <xref ref-type="bibr" rid="B93">93</xref>), including the level of social interaction difficulties (<xref ref-type="bibr" rid="B94">94</xref>). Different sleep problems appear to be differentially related to behavioral difficulties. For example, decreased sleep duration (and associated daytime sleepiness) has been associated with increased severity of core ASD symptoms such as repetitive behaviors and social communication difficulties, as well as pronunciation of more specific features such as failure to develop peer relationships and adherence to non-functional routines or rituals (<xref ref-type="bibr" rid="B95">95</xref>). Sleep onset delay is associated with stereotyped behaviors and social interaction deficits, but not communication deficits (<xref ref-type="bibr" rid="B96">96</xref>), while parasomnias has been linked to symptom severity, communication problems and an increased in stereotyped behaviors (<xref ref-type="bibr" rid="B96">96</xref>). Alterations in specific sleep stages may also be associated with different ASD phenotypes; prolonged REM latency has been associated with regression (<xref ref-type="bibr" rid="B97">97</xref>). Other maladaptive behaviors, such as self-injury, tantrums and aggression, are associated with shorter sleep durations in ASD (<xref ref-type="bibr" rid="B15">15</xref>), and children with ASD with poorer sleep quality also have higher rates of internalizing and externalizing behavioral disorders and lower levels of adaptive functioning (<xref ref-type="bibr" rid="B98">98</xref>, <xref ref-type="bibr" rid="B99">99</xref>).</p>
<p>Sleep disorders may be caused by core ASD symptoms; for example, children may have reduced sensitivity to environmental cues that help signal the sleep/wake circadian systems, perseverate on activities or thoughts that may interfere with sleep onset or promote nocturnal awakenings, have limited communication to understand parental expectations for bedtime, or have more challenging behaviors such as hyperactivity or environmental hypersensitivities that may preclude ability to settle down to sleep (<xref ref-type="bibr" rid="B100">100</xref>). However, comorbidities such as anxiety or depression may also contribute; in typically developing children, sleep disorders are often related to anxiety and depression (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B101">101</xref>). Children with ASD are especially vulnerable to co-occurring psychopathologies with prevalence rates ranging from 25 to 70% within the ASD population (<xref ref-type="bibr" rid="B18">18</xref>). For example, insomnia can be a consequence of elevated levels of anxiety in individuals with ASD (<xref ref-type="bibr" rid="B102">102</xref>), and higher percentage of time spent in REM sleep is associated with greater internalizing behavior in ASD (<xref ref-type="bibr" rid="B103">103</xref>). Interestingly, melatonin treatment may alleviate symptoms of both insomnia and anxiety in ASD (<xref ref-type="bibr" rid="B104">104</xref>), supporting a shared etiology.</p>
<p>Rates of co-occurring ASD and ADHD are also high, with the prevalence of ADHD symptoms in individuals with ASD ranging from 40 to 70% (<xref ref-type="bibr" rid="B105">105</xref>). The key symptoms of ADHD, inattention and hyperactivity, can have an impact on both an individual's ASD symptoms and thus the development of a sleep disorder (<xref ref-type="bibr" rid="B85">85</xref>). It has been hypothesized that symptoms of sleeplessness do not always manifest as sleepiness but as overactivity, which at extreme levels can be classified as hyperactivity (<xref ref-type="bibr" rid="B85">85</xref>). Interestingly research has shown that melatonin treatment can also have a positive effect on reducing both sleep disorder and hyperactivity (<xref ref-type="bibr" rid="B104">104</xref>), suggesting that insufficient sleep may result in behavioral symptoms often seen in patients with co-morbid ASD and ADHD.</p>
</sec>
<sec>
<title>Treatment Effects</title>
<p>Potential treatments for sleep disturbances range from behavioral to pharmacological, with the goal to not only improve sleep quality and daytime functioning but also reduce caregiver stress (<xref ref-type="bibr" rid="B106">106</xref>). Although a number of behavioral and medical sleep interventions are available, only melatonin appears to have been systematically investigated for its efficacy in ASD (<xref ref-type="bibr" rid="B107">107</xref>, <xref ref-type="bibr" rid="B108">108</xref>). The summary evidence for melatonin supplementation for sleep problems in ASD suggests significantly improved sleep duration and sleep onset latency compared to placebo, and significantly improved daytime behaviors, with minimal side effects (<xref ref-type="bibr" rid="B107">107</xref>, <xref ref-type="bibr" rid="B108">108</xref>). Because sleep deprivation can contribute to emotional reactivity and interpretation of nonverbal social cues (<xref ref-type="bibr" rid="B109">109</xref>, <xref ref-type="bibr" rid="B110">110</xref>), sleep disturbances and daytime sleepiness may also contribute to efficacy of daytime behavioral interventions or impact on educational outcomes.</p>
<p>Conversely, it has also been argued that medications often prescribed to treat symptoms such as anxiety in individuals with ASD may negatively influence sleep. For example, it has been suggested that anti-psychotics and serotonin reuptake inhibitors (SSRIs) may disrupt the sleep cycle and thus have a role to play in sleep disorder (<xref ref-type="bibr" rid="B111">111</xref>). Some medications also increase risk of metabolic side effects like obesity (<xref ref-type="bibr" rid="B112">112</xref>); rates of overweight and obesity are increased in children with ASD, particularly those with co-occurring sleep disorders (<xref ref-type="bibr" rid="B113">113</xref>). The mechanisms and directional impact of sleep problems and treatment in ASD therefore remain complex.</p>
</sec>
<sec>
<title>Aetiological Mechanisms</title>
<p>Development of a circadian rhythm has a vital role to play in the development of a competent sleep cycle, controlling different biological rhythms within a 24-h period and modified by both internal and external factors. It is thought that this rhythm regulates both biological and behavioral functions and how an individual can anticipate and adapt to environmental changes (<xref ref-type="bibr" rid="B114">114</xref>). When the circadian cycle is dysregulated by underlying alterations in neurophysiological and neurochemistry, an individual can be vulnerable to sleep disorders and physiological disturbances (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B114">114</xref>). Neurochemistry factors involved in normal sleep include neurotransmitters such as GABA (<xref ref-type="bibr" rid="B115">115</xref>), serotonin, and melatonin (<xref ref-type="bibr" rid="B116">116</xref>).</p>
<p>Genes known to be associated with the human circadian clock have an important role to play in controlling sleep phase and duration (<xref ref-type="bibr" rid="B117">117</xref>) and have a widespread physiological effect on mood, cognition and reward-related behaviors. Mutations in clock genes have been implicated in ASD, thus resulting in the dysregulation of the circadian cycle (<xref ref-type="bibr" rid="B114">114</xref>, <xref ref-type="bibr" rid="B118">118</xref>). For example, mutations in the Per1 and NPAS2 clock genes are associated with ASD and related to the morningness-eveningness phenotype (<xref ref-type="bibr" rid="B119">119</xref>, <xref ref-type="bibr" rid="B120">120</xref>), and missense changes in six clock genes have been identified in individuals with ASD and sleep problems (<xref ref-type="bibr" rid="B118">118</xref>). In addition, the SCN controls the sleep-wake cycle by stimulating the pineal gland to produce melatonin through expression of melatonin-related genes (TPH2, DDC, AANAT, ASMT). Altered melatonin production appears to be feature of children with ASD, including below average physiological levels of melatonin or its metabolites and abnormal coupling of melatonin with the circadian rhythm (<xref ref-type="bibr" rid="B107">107</xref>). For example, studies have shown that variations in AMST are associated with decreased melatonin production in ASD (<xref ref-type="bibr" rid="B116">116</xref>). Exposure to external environmental factors, such as morning light and external clocks may also contribute to disruptions in sleep cycles. Some individuals with ASD may exhibit variations in light sensitivity, thus leading to a possible misalignment between the circadian phase and light/dark cycle (<xref ref-type="bibr" rid="B121">121</xref>). Bidirectional associations between genetic and environmental factors, as well as co-occurring behaviors, are likely to affect underlying biological networks involved in sleep (Figure <xref ref-type="fig" rid="F2">2</xref>).</p>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<p>Interdependent bidirectional associations between ASD and sleep problems. GI, gastrointestinal; RRBIs, restricted and repetitive behaviours and interest.</p>
</caption>
<graphic xlink:href="fpsyt-09-00751-g0002"></graphic>
</fig>
</sec>
<sec>
<title>Summary</title>
<p>Current findings suggest that sleep disorders in children with ASD may be associated with altered circadian rhythms, which may reflect mutations in clock genes and genes involved in melatonin production. Furthermore, sleep disorders in ASD have been associated with behavioral and psychiatric co-morbidities, such as anxiety or ADHD. The directional impact of these underlying mechanisms remains complex when additionally considering the impact of pharmacological interventions, however the broader evidence based suggests co-occurrence of sleep problems with behavioral symptoms, rather than an aetiological mechanism.</p>
</sec>
</sec>
<sec>
<title>Gastrointestinal Dysfunction</title>
<sec>
<title>Prevalence</title>
<p>Estimates for the prevalence of any gastrointestinal (GI) problem in children with ASD vary between 9 and 70% (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B122">122</xref>, <xref ref-type="bibr" rid="B123">123</xref>), but may even range to as high as 91% (<xref ref-type="bibr" rid="B124">124</xref>). These problems can range from mild gastro-esophageal reflux to more severe symptoms, such as chronic constipation, abdominal pain, and persistent diarrhea (<xref ref-type="bibr" rid="B125">125</xref>, <xref ref-type="bibr" rid="B126">126</xref>). The most common of these appears to be chronic constipation, with a median prevalence of 22% (<xref ref-type="bibr" rid="B14">14</xref>). Without treatment, these problems can lead to encopresis, delayed continence, pain, and maladaptive daytime behaviors (<xref ref-type="bibr" rid="B127">127</xref>–<xref ref-type="bibr" rid="B130">130</xref>). Although a subset of children with ASD have GI pathology related directly to ASD, many children also have functional Gl disorders relating to selective eating, medications that have effects on GI motility, and differences in sensory processing. For example, Prosperi et al. (<xref ref-type="bibr" rid="B131">131</xref>) found that 27% of children with ASD have problems with food selectivity and that this was frequently associated with GI problems. Despite differences in prevalence between studies, the collective evidence suggests that there is an unusually high prevalence of GI symptoms in children with ASD, implying a possible underlying pathophysiology contributing to both conditions. GI functioning in ASD also encompasses nutrition, including food allergies, metabolic abnormalities, pre-existing nutritional deficiencies, nutrition-related medication side effects, as well as behavioral factors including problematic eating [(<xref ref-type="bibr" rid="B132">132</xref>); see Table <xref ref-type="table" rid="T5">5</xref>].</p>
<table-wrap id="T5" position="float">
<label>Table 5</label>
<caption>
<p>An overview of gastrointestinal (GI) symptoms reported in individuals with ASD.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Source</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Sample size</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Prevalence</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>GI symptoms</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">McElhanon et al. (<xref ref-type="bibr" rid="B125">125</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>N</italic> = 15 studies</td>
<td align="left" colspan="1" rowspan="1" valign="top">Higher rates of diarrhea (OR, 3.63), constipation (OR, 3.96), abdominal pain (OR, 2.45).</td>
<td align="left" colspan="1" rowspan="1" valign="top">Diarrhea, constipation, abdomen pain</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Mazurek et al. (<xref ref-type="bibr" rid="B128">128</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>N</italic> = 2,973 ASD</td>
<td align="left" colspan="1" rowspan="1" valign="top">24% had at least one type of chronic GI problem.</td>
<td align="left" colspan="1" rowspan="1" valign="top">Constipation, abdominal pain, bloating, diarrhea and/or nausea lasting 3 months or more. Sensory over-responsivity and anxiety were highly associated with GI symptoms.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Mazefsky et al. (<xref ref-type="bibr" rid="B129">129</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>N</italic> = 95 ASD</td>
<td align="left" colspan="1" rowspan="1" valign="top">61% reported at least one GI symptom.</td>
<td align="left" colspan="1" rowspan="1" valign="top">Abdominal pain, not hungry, bloating. Participants with GI problems also had significantly higher levels of affective problems.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Chandler et al. (<xref ref-type="bibr" rid="B130">130</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>N</italic> = 132 ASD, <italic>N</italic> = 81 other developmental conditions, <italic>N</italic> = 82 Controls</td>
<td align="left" colspan="1" rowspan="1" valign="top">46.5% ASD had at least one individual GI symptom, relative to 29.2% other developmental conditions and 21.8% in Controls.</td>
<td align="left" colspan="1" rowspan="1" valign="top">Vomiting, diarrhea, abdominal pain, constipation. No association between GI symptoms and ASD severity.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Prosperi et al. (<xref ref-type="bibr" rid="B131">131</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>N</italic> = 163 ASD</td>
<td align="left" colspan="1" rowspan="1" valign="top">25.8% had at least one severe GI symptom.</td>
<td align="left" colspan="1" rowspan="1" valign="top">Constipated (22.1%), Painful bowel movement (7.4%).</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec>
<title>Associations With Behavior and Cognition in ASD</title>
<p>It has been speculated that underlying and undiagnosed GI problems may contribute to some of the behavioral difficulties observed in some children with ASD. Chaidez et al. (<xref ref-type="bibr" rid="B133">133</xref>) suggested that there is a strong and significant relationship between GI symptoms and increased instances of irritability, social withdrawal and hyperactivity. Furthermore, non-verbal children with ASD often come to clinical attention due to self-injurious behavior and aggression. It is thought that this behavior could be a result of being unable to communicate their pain and/or discomfort effectively. However, there has been limited evidence to suggest a significant association between presence or frequency of GI symptoms and ASD symptom severity over and above those without significant GI complaints (<xref ref-type="bibr" rid="B127">127</xref>, <xref ref-type="bibr" rid="B130">130</xref>, <xref ref-type="bibr" rid="B134">134</xref>, <xref ref-type="bibr" rid="B135">135</xref>), although there is some evidence for associations with language impairment (<xref ref-type="bibr" rid="B136">136</xref>). Whilst some reports suggest that increased ASD severity is associated with significantly more GI problems (<xref ref-type="bibr" rid="B133">133</xref>, <xref ref-type="bibr" rid="B137">137</xref>), a number of studies have failed to support this association (<xref ref-type="bibr" rid="B129">129</xref>). In addition, the interplay between GI problems and anxiety symptoms has been supported in both typical and ASD populations. A large-scale study indicated that anxiety, sensory over-responsivity and GI problems are interrelated in children with ASD (<xref ref-type="bibr" rid="B128">128</xref>).</p>
</sec>
<sec>
<title>Treatment Effects</title>
<p>A wide range of diets have been purported to exert some efficacy in alleviating GI symptoms in children with ASD. However, a systematic review found little evidence for the beneficial effect of nutritional supplements or gluten/casein-free diets on ASD symptoms (<xref ref-type="bibr" rid="B138">138</xref>). Further to this, the long-term effects of these therapies are not well understood and may have unintentional physical health consequences. For example unconventional food preference may result in reductions in bone cortical thickness in boys with autism, a reduction that is greater for those on casein-free diets (<xref ref-type="bibr" rid="B139">139</xref>). However, suboptimal bone development in ASD has also been linked to combinations of a lack of exercise, GI problems, as well as clinically compromised vitamin D and calcium intake due to restrictive diets.</p>
<p>Microbiota transfer therapy has recently been suggested as a potential therapy in ASD to target GI symptoms based on the premise of differences in microbiome composition (<xref ref-type="bibr" rid="B132">132</xref>). However, whilst the subject has been widely investigated, findings have been inconclusive and contradictory (see Table <xref ref-type="table" rid="T6">6</xref>). For example, in a review of the literature, researchers concluded that inconsistent findings in the field are complicated by use of different methodologies, high incidence of antibiotic use, special diets and/or have repetitive dietary behaviors (<xref ref-type="bibr" rid="B144">144</xref>). For example, Kang et al. (<xref ref-type="bibr" rid="B142">142</xref>) suggested that GI symptoms in ASD were characterized by less diverse gut microbial composition with findings indicating lower levels of Prevotella, Coproccus, and unclassified Veillonellaceae. It has been argued that a higher diversity of gut bacteria protects the human intestine from stresses such as pathogenic gut microbes and lower diversity in ASD may explain increased risk of GI disturbances. Conversely, Finegold et al. (<xref ref-type="bibr" rid="B143">143</xref>) found that there was a significantly higher diversity of bacteria found in feces of participants with ASD. Parracho et al. (<xref ref-type="bibr" rid="B124">124</xref>) conducted a study that found that there was a higher incidence of the Clostridium histolyticum group of bacteria. Clostridium histolyticum are known to be toxin-producers and it has been hypothesized that this may contribute toward gut dysfunction with metabolic products having a systemic effect. Based on this evidence, clinical trials have now started investigating whether alteration of microbiota profiles may impact on GI symptoms and ASD behaviors. In a recent open-label trial, microbiota transfer therapy incurred an 80% reduction in GI symptoms, including a significant improvement in symptoms such as constipation and abdominal pain that persisted after 8 weeks, in addition to ASD symptoms (<xref ref-type="bibr" rid="B145">145</xref>). These results provide very preliminary evidence that, by targeting the gut ecosystem, potentially both ASD and GI symptoms can be impacted, supporting a potential shared mechanism.</p>
<table-wrap id="T6" position="float">
<label>Table 6</label>
<caption>
<p>An overview of studies investigating microbiota composition in ASD.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>References</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Sample size</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Methodology</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Significantly increased in ASD</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Significantly decreased in ASD</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Williams et al. (<xref ref-type="bibr" rid="B140">140</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>N</italic> = 15 ASD, <italic>N</italic> = 7 Controls; all with GI symptoms</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pyrosequencing and PCR, biopsies from ileal and cecal region</td>
<td align="left" colspan="1" rowspan="1" valign="top">Firmicutes and proteobacteria; Sutterella</td>
<td align="left" colspan="1" rowspan="1" valign="top">Bacteroidetes</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Gondalia et al. (<xref ref-type="bibr" rid="B141">141</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>N</italic> = 23 ASD without GI dysfunction, <italic>N</italic> = 28 ASD with GI dysfunction, <italic>N</italic> = 53 siblings</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pyrosequencing of fecal material</td>
<td align="left" colspan="1" rowspan="1" valign="top">No significant difference</td>
<td align="left" colspan="1" rowspan="1" valign="top">No significant difference</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Kang et al. (<xref ref-type="bibr" rid="B142">142</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>N</italic> = 20 ASD, <italic>N</italic> = 20 Controls</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pyrosequencing—fecal DNA samples</td>
<td align="left" colspan="1" rowspan="1" valign="top">–</td>
<td align="left" colspan="1" rowspan="1" valign="top">Prevotella, Coproccus and unclassified Veillonellaceae</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Parracho et al. (<xref ref-type="bibr" rid="B124">124</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>N</italic> = 58 ASD, <italic>N</italic> = 10 Controls, <italic>N</italic> = 12 Siblings</td>
<td align="left" colspan="1" rowspan="1" valign="top">Fluorescence <italic>in situ</italic> hybridization—fecal material</td>
<td align="left" colspan="1" rowspan="1" valign="top">Clostridium histolyticum group (I &amp; II)</td>
<td align="left" colspan="1" rowspan="1" valign="top">–</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Finegold et al. (<xref ref-type="bibr" rid="B143">143</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>N</italic> = 33 ASD, <italic>N</italic> = 8 Controls, <italic>N</italic> = 7 Siblings</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pyrosequencing—fecal microflora</td>
<td align="left" colspan="1" rowspan="1" valign="top">Bacteroidetes, Desulfovibrio, Bacteroides vulgatus, Actinobacterium and Proteobacterium phyla</td>
<td align="left" colspan="1" rowspan="1" valign="top">Firmicutes</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec>
<title>Aetiological Mechanisms</title>
<p>The underlying mechanism of GI dysfunction and how this relates to the pathophysiology of ASD is still not well understood. One theory in particular has gained particular momentum, that abnormal neurodevelopment in ASD may be caused by increased GI permeability, so-called “leaky gut,” that facilitates the absorption of toxic by-products of incompletely digested proteins [see (<xref ref-type="bibr" rid="B146">146</xref>) for review]. The production of metabolites by certain microbiota produces neuroactive compounds, including 5-HT, dopamine and GABA. These can cross the “leaky gut” resulting in the entry of toxins and bacteria into the bloodstream, to influence brain function and the hypothalamic-pituitary-adrenal (HPA) axis [see (<xref ref-type="bibr" rid="B147">147</xref>) for review]. This theory has been so influential, that despite limited evidence for efficacy in improving core ASD symptoms, casein and gluten-free diets, as well as dietary supplementations, are increasingly popular alternative treatments pursued by families (<xref ref-type="bibr" rid="B148">148</xref>).</p>
<p>Serotonin is critical for gut function, with 80–95% of 5-HT receptors localized to the gut and alterations to 5-HT signaling related to many GI disorders (for example, Crohn's disease, ulcerative colitis, irritable bowel syndrome, and chronic constipation). It has been speculated that altered gut 5-HT signaling may be an important contributor to the presence of GI disorders in children with ASD (<xref ref-type="bibr" rid="B149">149</xref>, <xref ref-type="bibr" rid="B150">150</xref>); a cascade of events resulting from gut inflammation may lead to reduced levels of brain 5-HT, thereby resulting in mood and cognitive disturbances associated with ASD (<xref ref-type="bibr" rid="B149">149</xref>), although this may also be associated with an overall reduced brain availability of 5-HT (<xref ref-type="bibr" rid="B151">151</xref>). A well-established connection links the gut to the brain in a bidirectional pathway (see also Figure <xref ref-type="fig" rid="F3">3</xref>) (<xref ref-type="bibr" rid="B152">152</xref>)–autonomic projections from the brain regulate digestive reflexes, signals traveling from the gut signal satiety to the brain, whilst neural signals of stress and anxiety influence gut function and sensitivity. Dysregulation of the HPA axis has been implicated in children with GI problems and emerging evidence suggests a role in ASD (<xref ref-type="bibr" rid="B128">128</xref>, <xref ref-type="bibr" rid="B153">153</xref>). This may provide a strong rationale for use of selective serotonin reuptake inhibitors (SSRIs) in the treatment of ASD symptoms by increasing availability of 5-HT, although research to date has established limited efficacy (<xref ref-type="bibr" rid="B154">154</xref>). However, if reduced 5-HT results from intestinal inflammation, then possibly targeting 5-HT metabolism by restoring availability of tryptophan for 5-HT synthesis may represent a viable alternate therapeutic mechanism (<xref ref-type="bibr" rid="B149">149</xref>).</p>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption>
<p>Bidirectional associations between alterations in central nervous system circuitry (epilepsy, sleep), immune system and gastrointestinal function and behaviors characteristic of ASD interacting with genetic and environmental risk.</p>
</caption>
<graphic xlink:href="fpsyt-09-00751-g0003"></graphic>
</fig>
<p>Increasing evidence suggests GI complications can arise as a result of genetic and environmental risk factors for ASD. For example, variants in the c-Met gene encoding for MET receptor tyrosine kinase are associated with ASD in individuals with co-occurring GI dysfunction (<xref ref-type="bibr" rid="B155">155</xref>). The role of MET hypofunction is supported by decreased protein expression in post-mortem brains from autistic individuals compared to typical controls (<xref ref-type="bibr" rid="B156">156</xref>). In addition, alterations in the serotonin reuptake transporter (SERT) are implicated in ASD (<xref ref-type="bibr" rid="B157">157</xref>) and are likely to disrupt GI serotonin metabolism (<xref ref-type="bibr" rid="B158">158</xref>). Expression of the most common SERT variant (Ala56) in mice is associated with ASD-like behaviors [repetitive behaviors, reduced vocalizations, and social contact; (<xref ref-type="bibr" rid="B156">159</xref>)], as well as fewer gut neurons, a badly maintained gut lining and slow gut activity (<xref ref-type="bibr" rid="B160">160</xref>). Treatment with a 5-HT agonist prevented these GI manifestations (<xref ref-type="bibr" rid="B160">160</xref>).</p>
<p>Dysfunctional immune responses (see section Immune Dysfunction), in particular mucosal immune cells, may also have adverse effects on GI functioning in ASD. Endoscopic investigations suggest diffuse inflammation in the intestinal tract of children with ASD (<xref ref-type="bibr" rid="B7">7</xref>). There have also been reports of increased gastrointestinal complaints associated with autoimmune responses or a family history of autoimmunity in children in with ASD (<xref ref-type="bibr" rid="B161">161</xref>–<xref ref-type="bibr" rid="B163">163</xref>), although smaller studies have failed to replicate this increased prevalence (<xref ref-type="bibr" rid="B164">164</xref>). For example, increased autoantibodies directed toward central nervous system proteins have been observed in children with ASD and their mothers (<xref ref-type="bibr" rid="B165">165</xref>–<xref ref-type="bibr" rid="B168">168</xref>). One speculation is that these autoantibodies may signal presence of heightened inflammatory processes or an autoimmune component that could decrease the integrity of the mucosal barrier, or even reflect a downstream effect of previous mucosal infection (<xref ref-type="bibr" rid="B123">123</xref>). Notably, these maternal autoantibodies are strongly associated with the functional c-Met C allele associated with susceptibility to ASD and comorbid GI dysfunction (<xref ref-type="bibr" rid="B169">169</xref>), forming a promising convergent pathway (see section Immune Dysfunction).</p>
</sec>
<sec>
<title>Summary</title>
<p>Individuals with ASD are at higher risk of experiencing GI disturbances, with GI problems further linked to increased ASD symptoms. Abnormal neurodevelopment, dysfunctional immune responses and altered serotonergic transmission have been suggested potential mechanisms underlying the overlap between ASD and GI dysfunction.</p>
</sec>
</sec>
<sec>
<title>Immune Dysfunction</title>
<sec>
<title>Prevalence</title>
<p>The immune system comprises a group of defense mechanisms triggered to protect against disease or illness causing pathogens. Antigens, proteins found on the surface of pathogens, are recognized by a healthy immune system and trigger the production of antibodies that identify and neutralize or remove the antigen. The immune system comprises both innate and adaptive systems. The innate system develops early in fetal development, using genetically encoded receptors and nonspecific mechanisms for defense. In this way, the innate system plays more of a “housekeeping” role. The adaptive system is responsible for threat response, developing a memory of the response for future threats, and does not fully mature until early childhood. This system is more dynamic, responding to potential pathogens and toxins upon exposure. Both systems work together to achieve homeostasis, and importantly, disruption in either can affect neuronal development and functioning (<xref ref-type="bibr" rid="B170">170</xref>). Optimal immune functioning is characterized by the homeostatic maintenance of the innate and acquired immune responses, balancing pro- and anti-inflammatory signaling in response to potential pathogenic threats. Aberrant immune functioning can manifest in many ways, such as upregulation of inflammation or immune deficiency that comprises innate host defense mechanisms. Conditions associated with dysfunction of the immune system can include allergies, asthma, and autoimmune disorders.</p>
<p>Prevalence of immune conditions in individuals with ASD varies considerably between studies. Increased rates of food allergies, allergic rhinitis, and atopic dermatitis (i.e., eczema) (<xref ref-type="bibr" rid="B133">133</xref>, <xref ref-type="bibr" rid="B171">171</xref>, <xref ref-type="bibr" rid="B172">172</xref>), as well as autoimmune disorders such as psoriasis (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B173">173</xref>), have been reported in children with ASD in case-control analyses of electronic medical records. In general, asthma is reported at increased frequencies in children with ASD (<xref ref-type="bibr" rid="B171">171</xref>, <xref ref-type="bibr" rid="B174">174</xref>), however decreased rates have also been reported (<xref ref-type="bibr" rid="B173">173</xref>). Additionally, atopic conditions (asthma, atopic dermatitis, allergic rhinitis, or allergic conjunctivitis) in early childhood is associated with increased rates of later diagnosis of ASD and ADHD, with increased number of atopic conditions associated with stronger likelihood of a later ASD diagnosis (<xref ref-type="bibr" rid="B175">175</xref>). Taken together, these studies of medical records or retrospective parental reports support an increased prevalence of specific immune-related conditions, which may constitute an immune-mediated subtype of ASD; see Table <xref ref-type="table" rid="T7">7</xref>.</p>
<table-wrap id="T7" position="float">
<label>Table 7</label>
<caption>
<p>An overview of immune-mediated conditions reported at increased prevalence in individuals with ASD.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Study</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Sample size</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Conditions</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Prevalence</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Miyazaki et al. (<xref ref-type="bibr" rid="B172">172</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Meta-analysis; <italic>N</italic> = 10 studies</td>
<td align="left" colspan="1" rowspan="1" valign="top">Atopic dermatitis, asthma, atopic rhinitis, food allergies</td>
<td align="left" colspan="1" rowspan="1" valign="top">Increased rates of asthma (OR 1.66) and atopic rhinitis (OR 1.66) in ASD; no increase in prevalence of food allergies and trend for increase in atopic dermatitis</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Chen et al. (<xref ref-type="bibr" rid="B171">171</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>N</italic> = 1,598 ASD, <italic>N</italic> = 6,392 Controls</td>
<td align="left" colspan="1" rowspan="1" valign="top">Type 1 diabetes</td>
<td align="left" colspan="1" rowspan="1" valign="top">Trend for increase in Type 1 diabetes (0.3 vs. 0.1%); OR 4.00</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Chen et al. (<xref ref-type="bibr" rid="B171">171</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>N</italic> = 1,598 ASD, <italic>N</italic> = 6,392 Controls</td>
<td align="left" colspan="1" rowspan="1" valign="top">Crohn's disease</td>
<td align="left" colspan="1" rowspan="1" valign="top">Trend for increase in Crohn's disease (1.4 vs. 1.0%); OR 1.46</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Chen et al. (<xref ref-type="bibr" rid="B171">171</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>N</italic> = 1,598 ASD, <italic>N</italic> = 6,392 Controls</td>
<td align="left" colspan="1" rowspan="1" valign="top">Urticaria</td>
<td align="left" colspan="1" rowspan="1" valign="top">Increased rates of urticaria (8.4 vs. 6.3%); OR 1.38</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec>
<title>Associations With Behavior and Cognition in ASD</title>
<p>An extension of this research is the question of whether changes in peripheral cytokine expression are associated with differences in individual behaviors within individuals with ASD. If so, this would then suggest that interventions that target the immune system might have some benefit in improving symptoms. Chemokine levels have been associated with impaired communication, increased parent-reported behavior problems, decreased cognitive and adaptive functions, and worse adaptive behavior (<xref ref-type="bibr" rid="B176">176</xref>). Increased levels of proinflammatory cytokines (section Aetiological Mechanisms) have been associated with the severity of ASD in a sample of children with ASD in Egypt (<xref ref-type="bibr" rid="B177">177</xref>), whilst decreased levels of an immunosuppressant cytokine, transcription growth factor beta 1, significantly predicts worse behavioral symptoms and lower adaptive levels (<xref ref-type="bibr" rid="B178">178</xref>). Al-Ayadhi and Mostafa (<xref ref-type="bibr" rid="B179">179</xref>) also found that children with more severe ASD symptoms exhibited greater levels of a proinflammatory cytokine compared to children with more milder symptom presentations. More recently, we observed decreased levels of a range of cytokines associated with symptom severity in children with ASD, with differences in cytokine expressions between male and female children (<xref ref-type="bibr" rid="B180">180</xref>). There is also some evidence that different presentations of ASD symptoms may be associated with family histories of immune dysfunction; Molloy and colleagues reported that familial autoimmune thyroid disease was more common in children who regressed compared to those children with an early onset form of ASD (<xref ref-type="bibr" rid="B181">181</xref>). Combined, these results suggest a spectrum of altered inflammatory responses associated with differences in symptom profiles within individuals with ASD.</p>
</sec>
<sec>
<title>Treatment Effects</title>
<p>There is some preliminary evidence for cytokine changes in response to medical treatments in ASD. Choi et al. showed that levels of some cytokines significantly reduced after risperidone treatment in children with ASD, and interleukin 5 was specifically increased in a small sample of treatment responders (<xref ref-type="bibr" rid="B182">182</xref>). However, others have not observed changes in cytokine serum levels after risperidone treatment compared to placebo in a much larger sample of children (<xref ref-type="bibr" rid="B183">183</xref>). A further study demonstrated that anti-inflammatory agents combined with risperidone had a superior effect in treating symptoms in children, although inflammatory responses were not assessed (<xref ref-type="bibr" rid="B184">184</xref>). This latter study implies that modulating the inflammatory response in children with ASD may facilitate the efficacy of treatments such as risperidone. This idea has been supported by some historical and case study accounts of modest reductions in the severity of ASD symptoms when treating gastrointestinal inflammation with corticosteroids or antibiotics (<xref ref-type="bibr" rid="B185">185</xref>).</p>
<p>Immune-modulatory agents have also been trialed to specifically target ASD symptoms (<xref ref-type="bibr" rid="B186">186</xref>). Significant improvements have been described in open-label investigations of corticosteroids (<xref ref-type="bibr" rid="B187">187</xref>) and lenalidomide, an immune-modulatory agent (<xref ref-type="bibr" rid="B188">188</xref>), as well as double-blind investigations of celecoxib, an anti-inflammatory drug (<xref ref-type="bibr" rid="B189">189</xref>). However, varying clinical efficacy and limited randomized double-blind investigations, combined with serious side effects noted in corticosteroids (<xref ref-type="bibr" rid="B189">189</xref>), indicates that this area requires further investigation.</p>
</sec>
<sec>
<title>Aetiological Mechanisms</title>
<p>The mechanisms by which dysfunctional immune systems may contribute etiologically to ASD is an area of active investigation (<xref ref-type="bibr" rid="B190">190</xref>). Here, we briefly outline the main streams of research [see (<xref ref-type="bibr" rid="B191">191</xref>) for extensive recent review on aetiological mechanisms of immune dysfunction in ASD]. Several reports of associations between ASD and family history of autoimmune or immune-mediated disorders have emerged (<xref ref-type="bibr" rid="B161">161</xref>, <xref ref-type="bibr" rid="B192">192</xref>, <xref ref-type="bibr" rid="B193">193</xref>). Several high confidence genes identified for ASD converge on pathways important in synapse formation, neuronal migration, and immune function (<xref ref-type="bibr" rid="B194">194</xref>, <xref ref-type="bibr" rid="B195">195</xref>). Of relevance here, restriction of HLA genes has been reported as conferring a greater risk for the development of ASD, involved in immune function and also associated with risk for autoimmune conditions (<xref ref-type="bibr" rid="B196">196</xref>–<xref ref-type="bibr" rid="B199">199</xref>). Located within the large genome regions known as the major histocompatibility complex (MHC) on chromosome 6, several HLA haplotypes appear to be more frequent in children with ASD (<xref ref-type="bibr" rid="B200">200</xref>, <xref ref-type="bibr" rid="B201">201</xref>). Some failures to replicate this have suggested that possible genetic differences may lie more generally within this MHC region rather than specifically confined to the HLA genes only (<xref ref-type="bibr" rid="B202">202</xref>, <xref ref-type="bibr" rid="B203">203</xref>). For example, the gene coding for the complement protein C4 located in the MHC region is important for innate immunity. Deficiencies in the C4B allele, as well as several other complement proteins, may be differentially produced in some individuals with ASD (<xref ref-type="bibr" rid="B204">204</xref>–<xref ref-type="bibr" rid="B208">208</xref>). In addition, the MET receptor tyrosine kinase has been associated with ASD (<xref ref-type="bibr" rid="B209">209</xref>), which is implicated in both neurodevelopment and immune function.</p>
<p>In addition to examining diagnosed immune conditions, significant research has focused on measurements of cytokine signaling profiles as indicators of broader changes in inflammatory processes in individuals with ASD (<xref ref-type="bibr" rid="B17">17</xref>). Cytokines are proteins produced and expressed by neurons that regulate immune responses, including hematopoiesis, inflammation, and immune cell proliferation and differentiation (<xref ref-type="bibr" rid="B210">210</xref>). Some cytokines act to make disease worse (proinflammatory) whereas others reduce inflammation and promote healing by suppressing the activity of proinflammatory cytokines (anti-inflammatory). Cytokines also play a role in normal neurodevelopment, including the processes of neuronal migration and synaptic plasticity (<xref ref-type="bibr" rid="B211">211</xref>). These processes are tightly regulated and a dysregulation in the balance of signals mediated by cytokines can have a variety of detrimental effects that contribute to changes in neurodevelopment and behavior.</p>
<p>A recent meta-analysis of cytokine levels derived from plasma and serum in unmedicated individuals with ASD (mostly children) found an overall abnormal cytokine profile, characterized by elevations in proinflammatory cytokines and reduced levels of anti-inflammatory cytokines (<xref ref-type="bibr" rid="B17">17</xref>). This suggests that some individuals with ASD may exhibit a heightened inflammatory state and altered cytokine profile, observed in peripheral tissues, suggestive of broader immune system dysregulation in ASD. While elevated levels of inflammatory cytokines observed in the central nervous system of individuals with ASD may reflect inflammatory processes that modulate neuronal function and change behavior (<xref ref-type="bibr" rid="B79">79</xref>, <xref ref-type="bibr" rid="B212">212</xref>), altered cytokines in peripheral tissues indicate more widespread inflammatory involvement (<xref ref-type="bibr" rid="B213">213</xref>–<xref ref-type="bibr" rid="B216">216</xref>). This meta-analysis also observed significant heterogeneity between studies, likely reflecting important methodological differences between studies and the prevalent use of siblings as control subjects for analysis, who are at higher risk of exhibiting broader ASD symptoms themselves (<xref ref-type="bibr" rid="B217">217</xref>) or having similar immune system profiles (<xref ref-type="bibr" rid="B218">218</xref>).</p>
<p>One well-researched area has explored early maternal infection and inflammation during pregnancy and later risk for an ASD diagnosis (<xref ref-type="bibr" rid="B219">219</xref>–<xref ref-type="bibr" rid="B225">225</xref>). Pregnancy requires a complex and dynamic response from the maternal immune system to protect the mother from pathogens or infections but to also support the fetal tissue that contains many “non-self” antigens from the father to promote fetal health and development. As this is a complex regulatory system to maintain such balance, this period represents an extremely vulnerable period for both mother and the developing fetus. Disturbances in immune regulation during this period has been well-established to provide a substantial risk factor for alterations in neurodevelopment (<xref ref-type="bibr" rid="B226">226</xref>). Incidence of maternal viral and bacterial infections has been proposed as a risk factor for the development of ASD (<xref ref-type="bibr" rid="B220">220</xref>, <xref ref-type="bibr" rid="B227">227</xref>–<xref ref-type="bibr" rid="B229">229</xref>). Perturbation of the maternal immune system may modify either the placenta or the fetal brain to then later neurodevelopment (<xref ref-type="bibr" rid="B230">230</xref>, <xref ref-type="bibr" rid="B231">231</xref>), of which the cytokine IL-6 appears to play a major role (<xref ref-type="bibr" rid="B231">231</xref>, <xref ref-type="bibr" rid="B232">232</xref>). Involvement of the maternal immune system during pregnancy does not just appear to influence neurodevelopment, but may also modify ongoing immune dysfunction in offspring (<xref ref-type="bibr" rid="B233">233</xref>–<xref ref-type="bibr" rid="B236">236</xref>) and later symptom presentation (<xref ref-type="bibr" rid="B237">237</xref>). The maternal immune environment has also been proposed as a key factor influencing the increased risk of ASD diagnoses in children born very preterm (<xref ref-type="bibr" rid="B226">226</xref>).</p>
</sec>
<sec>
<title>Summary</title>
<p>Disruptions in both innate and adaptive immunity have clear consequences for neurodevelopment, with the cumulative evidence suggestive of a disrupted immune profile in for some individuals with ASD as well as links to the early maternal pregnancy environment in shaping later immune profiles and neurodevelopment. There evidence to suggest a direct association between perturbed immune profiles and impact on subsequent behavioral and symptomatic profiles, with limited studies for potential changes in immune profiles in response to treatment or changes in immune functioning through anti-inflammatory markers to facilitate reductions in core ASD symptoms. Taken together, this evidence suggests that an immune-mediated subtype of ASD may be amenable to specific, targeted and/or personalized treatments based on individual immune profiles.</p>
</sec>
</sec>
</sec>
<sec id="s3" sec-type="discussion">
<title>Discussion</title>
<sec>
<title>Mechanisms of Associations Between Medical Comorbidities and ASD</title>
<p>This review highlights that the interactions between observed comorbid medical conditions and physiological abnormalities in children with ASD are complex. Disorders of GI function and seizures appear to be parallel comorbid conditions, with possible common aetiological mechanisms resulting from yet unknown neurological causes. Sleep disorders, however, are likely to be a consequence of ASD symptoms or may be, in turn, associated with GI symptoms or other comorbidities that can cause sleep disturbances. Whilst the evidence discussed suggests a causative role for metabolic and immunological pathways for some individuals later diagnosed with ASD, evidence for these remains preliminary and based on group level findings, rather than evidence from prospective and longitudinal observations. What is clear, however, is that these systems and pathways do not work in isolation from each other; rather, complex interactions imply dysregulation in any one system may cause a cascade of events cumulating in a cluster of symptoms associated with ASD (Figure <xref ref-type="fig" rid="F3">3</xref>). Because these systems are very complex, and no perturbations in any one appear to be common across individuals with ASD, it is likely that the heterogeneity in ASD reflects the potential myriad of different disturbances along any one of these pathways. Further complicating this model is the high likelihood that any given individual with ASD may also present with multiple medical comorbidities or elevated abnormalities, which also interact with co-occurring behavioral comorbidities, such as hyperactivity and anxiety, and developmental delay (<xref ref-type="bibr" rid="B238">238</xref>). Thus, attempts to subgroup individuals based on medical conditions alone may be complicated by the prospects of individuals belonging to multiple subgroups. Importantly, identification of shared or distinct biochemical or neurocognitive mechanisms will be key in elucidating causal pathways.</p>
</sec>
<sec>
<title>Integrating Mechanistic Models of ASD: Implications for Etiology and Treatment</title>
<p>As discussed in each section, complicating interactions between these systems suggest a greater likelihood for individuals with alterations in one system to have alterations across multiple systems. Still, the overlap between medical and behavioral features associated with ASD may point toward convergent platforms for a final common pathway to ASD across varied causes, with implications for targeted treatment. For example, children who have sleep problems and ASD are two times more likely to have GI issues and seizures (<xref ref-type="bibr" rid="B6">6</xref>).</p>
<p>Review of the proposed aetiological mechanisms underlying the comorbidity between these medical comorbidities and ASD allows some degree of integration. Processes with shared involvement in ASD and multiple medical disorders include gene transcriptional regulation; cellular growth and proliferation; and synapse development, stability and function. Importantly, the potential role of the microbiota-gut-brain axis in multiple elements of medical comorbidity has been implicated (Figure <xref ref-type="fig" rid="F3">3</xref>), whereby short-chain fatty acids can cross the blood-brain barrier and enter the brain (section Gastrointestinal Dysfunction, Table <xref ref-type="table" rid="T6">6</xref>), gut microbiota modulate the immune response by stimulating secretion of cytokines and microbiota can deliver signals to the brain via the vagus nerve [see (<xref ref-type="bibr" rid="B239">239</xref>) for review]. Beneficial therapeutic effects may be afforded by focusing on the microbiota-gut-brain axis, although more systematic study of its role in ASD is required.</p>
<p>Associations between sleep and other disorders are also apparent; while classically functioning to regulate circadian and seasonal rhythms, melatonin additionally affects cardiovascular and immune systems, regulates body fat mass, insulin secretion, and metabolism of glucose and lipids, as a close derivative of serotonin (5-HT). Due to these additional functions, emerging research has highlighted a role for melatonin administration in humans to attenuate metabolic symptoms induced by antipsychotic use (<xref ref-type="bibr" rid="B240">240</xref>) and to potentially improve GI functioning via effects on intestinal permeability (<xref ref-type="bibr" rid="B241">241</xref>). Given additional physiological functions of melatonin, effective supplementation may have secondary effects in improving GI functioning in ASD; however there has not been any systematic investigation into this as yet.</p>
<p>Similarly, comorbid medical conditions and associated medication use may result in sleep disturbance; for example, physical symptoms such as abdominal pain in some GI disorders, or medications prescribed for seizures can cause difficulty sleeping. Children with epilepsy also exhibit significant alterations in sleep latency, sleep efficiency, and number of awakenings (<xref ref-type="bibr" rid="B242">242</xref>), and epilepsy may be characterized by seizures during sleep (e.g., Landau-Kleffner). It is therefore of critical importance to determine whether sleep problems are better explained by associated medical conditions which should be treated rather than attempting to address sleep difficulties alone (<xref ref-type="bibr" rid="B100">100</xref>).</p>
<p>Finally, alterations in immune system profiles, dysregulated gastrointestinal symptoms and disordered sleep patterns clearly impact upon behavioral profiles, including elevated anxiety, increased social and communication difficulties, reduced adaptive functioning, and increased maladaptive behaviors. Recent meta-analytic evidence confirms an association between sleep disturbances and increased inflammation, suggesting that improvements in one system could potentially positively impact upon other regulatory systems (<xref ref-type="bibr" rid="B243">243</xref>). Generating evidence for such hypotheses require large and detailed biological datasets from children with ASD across their developmental course [e.g., (<xref ref-type="bibr" rid="B244">244</xref>–<xref ref-type="bibr" rid="B246">246</xref>).</p>
<p>A key aim for future research will be to examine the interactions between these systems using established biomarkers along their pathways within ASD, rather than examining each in isolation (Box <xref ref-type="boxed-text" rid="Box1">1</xref>). Possible networks of disturbances may then be mapped out to determine potential subgroups of individuals with ASD classified by patterns of abnormal biological profiles. A second question of interest will be how modulation of these biological substrates through targeted pharmacological interventions may affect core ASD symptoms (<xref ref-type="bibr" rid="B247">247</xref>). Initial promising findings in small sampled trials suggest some efficacy for such approaches. However, if subgroups of individuals with specific biological profiles exist along the spectrum, then interventions must be appropriately targeted for individuals with certain profiles, rather than a universal approach. Lastly, the true efficacy of such targeted interventions will lie in the use of robust and sensitive biomarkers to determine treatment response, rather than a sole reliance on parent-reported and observational outcomes.</p>
<boxed-text id="Box1" position="float">
<label>Box 1</label>
<caption>
<title>Future directions and common themes.</title>
</caption>
<list list-type="simple">
<list-item>
<p>- Using expertise from a diverse range of disciplines—genetics, neuroscience, biochemistry and developmental psychology—to disentangle biological mechanisms underpinning medical comorbidity.</p>
</list-item>
<list-item>
<p>- Improved understanding of the link between comorbid medical conditions and co-occurring mental health problems and psychopathology in ASD.</p>
</list-item>
<list-item>
<p>- Understanding the longitudinal course of the full range of medical comorbidities in ASD.</p>
</list-item>
<list-item>
<p>- Treatment and intervention studies to systematically assess whether treating medical issues has additional positive effects on other medical issues (e.g., sleep) or on behavioral domains.</p>
</list-item>
</list>
</boxed-text>
<p>An important consideration is the time at which symptoms or markers are assessed. As a developmental condition, the symptoms of ASD change over the course of the child's lifespan, and there is increasing acknowledgment for the importance in understanding an individual's trajectory over time to grasp the full complexity of the heterogeneous symptoms presentations within ASD (<xref ref-type="bibr" rid="B248">248</xref>). Current physiological states are dependent on history of previously received interventions and past characteristics, such as regression, that may later affect developmental trajectories. In addition, there are likely to be sensitive periods within development where particular comorbidities may be more apparent or exhibit higher risk; for example, sensitive periods for prevalence of epilepsy-related disorders in childhood (<xref ref-type="bibr" rid="B249">249</xref>). Prospective longitudinal studies are required to systematically measure medical disorders and biomarkers within cohorts of individuals diagnosed or with clinical risk indicators of ASD. This may then provide sufficient power to identify subgroups of children with different clusters of symptoms that converge on similar pathways. Likewise, a developmental perspective will provide insight on the nature of the association with health conditions as a resulting or co-occurring model.</p>
</sec>
<sec>
<title>Clinical Implications</title>
<p>Assessment of co-occurring medical problems is of critical importance in the initial diagnostic procedure for individuals with ASD as well as in ongoing treatment management. As part of a multidisciplinary approach, systematic and evidence-based screening should be recommended at the time of diagnostic evaluations as well as during ongoing health monitoring. A key conclusion from this review is the importance of monitoring and maintaining general health and wellbeing in individuals with ASD. Although many of the medical conditions or abnormalities may not be present in many individuals with ASD, the overall increased risk of all-cause mortality in this population indicates a need for increased vigilance. For example, comorbid epilepsy, particularly accompanied by intellectual disability, is associated with an increased mortality risk; thus, there is a significant imperative for clinicians and parents/careers to provide additional care and monitoring around overall health and wellbeing for these individuals to potentially attenuate this risk. Cumulative evidence highlights increased prevalence of obesity and poor diet in individuals with ASD, and decreased use of general health services, such as for oral health, due to barriers to accessing health care that supports individuals with special needs. There is also a critical need for healthcare services to provide supportive and accessible environments for individuals with ASD.</p>
<p>The burden of such medical conditions in increasing mortality is likely compounded by impaired communication and increased sensory sensitivities that present a significant barrier to the delivery of health care services (both preventative and targeted treatment). A growing area of research has therefore focused on the necessity for effective and targeted health care services that are designed for ASD, as well as identifying potential barriers to access and use (<xref ref-type="bibr" rid="B250">250</xref>). Appropriately delivered health care services that can manage difficulties in communication and sensory sensitivities, particularly those that are pre-emptive, are likely to have benefits beyond just medical treatment but may drastically improve the quality of life for both the individual and their caregiver(s) and potentially decrease long-term financial burden. Despite higher health care utilization in this population, the decreased ability for the health care system to effectively manage behavioral symptoms, impaired communication, and specific sensory issues is a significant barrier for most preventative health care, especially for those on the severe end of the spectrum.</p>
</sec>
</sec>
<sec id="s4" sec-type="conclusions">
<title>Conclusion</title>
<p>The presence of comorbid medical conditions in ASD highlights the vast heterogeneity within the disorder. Using a model-based approach to understand the interacting systems potentially involved in the etiology and symptoms of ASD may lead to hypothesis generation and potential avenues for clinical trials. We require a better understanding of how variability in these systems results in similar or different functional profiles in ASD, and more integrative studies that consider the interaction between systems and the environment to produce behaviors characteristic of ASD. Such an approach can then lend hope to more specific biomedical treatments aimed at targeted these biomedical abnormalities and improving core and associated symptoms in ASD, ultimately to improve long-term outcomes.</p>
</sec>
<sec id="s5">
<title>Author Contributions</title>
<p>CT and GA led in the conception and design of the review. CT, AR, and GA drafted the paper. AW provided substantial revision.</p>
<sec>
<title>Conflict of Interest Statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</sec>
</body>
<back>
<ack>
<p>CT is supported by the NIHR Maudsley Biomedical Research Centre, UK Tuberous Sclerosis Association, University of London Basil Davies bequest and was supported by a Medical Research Council (MRC) studentship (G9817803). AW is supported by a Senior Research Fellowship from the National Health and Medical Research Fellowship (#1077966). GA is supported by the Cooperative Research Centre for Living with Autism (Autism CRC), established and supported under the Australian Government's Cooperative Research Centres Program.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1.</label>
<mixed-citation publication-type="book"><person-group person-group-type="author"><collab>American Psychiatric Association</collab></person-group>
<source/>Diagnostic and Statistical Manual of Mental Disorders, <edition>5th edn</edition>
<publisher-loc>Arlington, VA</publisher-loc>: <publisher-name>American Psychiatric Publishing</publisher-name> (<year>2013</year>). <pub-id pub-id-type="doi">10.1176/appi.books.9780890425596</pub-id></mixed-citation>
</ref>
<ref id="B2">
<label>2.</label>
<mixed-citation publication-type="book"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group>
<source/>The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines.
<publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name> (<year>1993</year>).</mixed-citation>
</ref>
<ref id="B3">
<label>3.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bourgeron</surname><given-names>T</given-names></name></person-group>. <article-title>From the genetic architecture to synaptic plasticity in autism spectrum disorder</article-title>. <source/>Nat Rev Neurosci. (<year>2015</year>) <volume>16</volume>:<fpage>551</fpage>–<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1038/nrn3992</pub-id><pub-id pub-id-type="pmid">26289574</pub-id></mixed-citation>
</ref>
<ref id="B4">
<label>4.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohane</surname><given-names>IS</given-names></name><name><surname>McMurry</surname><given-names>A</given-names></name><name><surname>Weber</surname><given-names>G</given-names></name><name><surname>MacFadden</surname><given-names>D</given-names></name><name><surname>Rappaport</surname><given-names>L</given-names></name><name><surname>Kunkel</surname><given-names>L</given-names></name><etal></etal></person-group>. <article-title>The co-morbidity burden of children and young adults with autism spectrum disorders</article-title>. <source/>PLoS ONE (<year>2012</year>) <volume>7</volume>:<fpage>e33224</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0033224</pub-id><pub-id pub-id-type="pmid">22511918</pub-id></mixed-citation>
</ref>
<ref id="B5">
<label>5.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doshi-Velez</surname><given-names>F</given-names></name><name><surname>Ge</surname><given-names>Y</given-names></name><name><surname>Kohane</surname><given-names>I</given-names></name></person-group>. <article-title>Comorbidity clusters in autism spectrum disorders: an electronic health record time-series analysis</article-title>. <source/>Pediatrics (<year>2014</year>) <volume>133</volume>:<fpage>e54</fpage>–<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1542/peds.2013-0819</pub-id><pub-id pub-id-type="pmid">24323995</pub-id></mixed-citation>
</ref>
<ref id="B6">
<label>6.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aldinger</surname><given-names>KA</given-names></name><name><surname>Lane</surname><given-names>CJ</given-names></name><name><surname>Veenstra-VanderWeele</surname><given-names>J</given-names></name><name><surname>Levitt</surname><given-names>P</given-names></name></person-group>. <article-title>Patterns of risk for multiple co-occurring medical conditions replicate across distinct cohorts of children with autism spectrum disorder</article-title>. <source/>Autism Res. (<year>2015</year>) <volume>8</volume>:<fpage>771</fpage>–<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1002/aur.1492</pub-id><pub-id pub-id-type="pmid">26011086</pub-id></mixed-citation>
</ref>
<ref id="B7">
<label>7.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buie</surname><given-names>T</given-names></name><name><surname>Campbell</surname><given-names>DB</given-names></name><name><surname>Fuchs</surname><given-names>GJ</given-names></name><name><surname>Furuta</surname><given-names>GT</given-names></name><name><surname>Levy</surname><given-names>J</given-names></name><name><surname>VandeWater</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>Evaluation, diagnosis, and treatment of gastrointestinal disorders in individuals with ASDs: a consensus report</article-title>. <source/>Pediatrics (<year>2010</year>) <volume>125</volume>(<issue>Suppl. 1</issue>):<fpage>S1</fpage>–<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1542/peds.2009-1878C</pub-id><pub-id pub-id-type="pmid">20048083</pub-id></mixed-citation>
</ref>
<ref id="B8">
<label>8.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malow</surname><given-names>BA</given-names></name><name><surname>Byars</surname><given-names>K</given-names></name><name><surname>Johnson</surname><given-names>K</given-names></name><name><surname>Weiss</surname><given-names>S</given-names></name><name><surname>Bernal</surname><given-names>P</given-names></name><name><surname>Goldman</surname><given-names>SE</given-names></name><etal></etal></person-group>. <article-title>A practice pathway for the identification, evaluation, and management of insomnia in children and adolescents with autism spectrum disorders</article-title>. <source/>Pediatrics (<year>2012</year>) <volume>130</volume>(<issue>Suppl. 2</issue>):<fpage>S106</fpage>–<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1542/peds.2012-0900I</pub-id><pub-id pub-id-type="pmid">23118242</pub-id></mixed-citation>
</ref>
<ref id="B9">
<label>9.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isaksen</surname><given-names>J</given-names></name><name><surname>Bryn</surname><given-names>V</given-names></name><name><surname>Diseth</surname><given-names>TH</given-names></name><name><surname>Heiberg</surname><given-names>A</given-names></name><name><surname>Schjølberg</surname><given-names>S</given-names></name><name><surname>Skjeldal</surname><given-names>OH</given-names></name></person-group>. <article-title>Children with autism spectrum disorders–the importance of medical investigations</article-title>. <source/>Eur J Paediatr Neurol. (<year>2013</year>) <volume>17</volume>:<fpage>68</fpage>–<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejpn.2012.08.004</pub-id><pub-id pub-id-type="pmid">22954514</pub-id></mixed-citation>
</ref>
<ref id="B10">
<label>10.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shavelle</surname><given-names>RM</given-names></name><name><surname>Strauss</surname><given-names>DJ</given-names></name><name><surname>Pickett</surname><given-names>J</given-names></name></person-group>. <article-title>Causes of death in autism</article-title>. <source/>J Autism Dev Disord. (<year>2001</year>) <volume>31</volume>:<fpage>569</fpage>–<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1023/A:1013247011483</pub-id><pub-id pub-id-type="pmid">11814268</pub-id></mixed-citation>
</ref>
<ref id="B11">
<label>11.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gillberg</surname><given-names>C</given-names></name><name><surname>Billstedt</surname><given-names>E</given-names></name><name><surname>Sundh</surname><given-names>V</given-names></name><name><surname>Gillberg</surname><given-names>IC</given-names></name></person-group>. <article-title>Mortality in autism: a prospective longitudinal community-based study</article-title>. <source/>J Autism Dev Disord. (<year>2010</year>) <volume>40</volume>:<fpage>352</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1007/s10803-009-0883-4</pub-id><pub-id pub-id-type="pmid">19838782</pub-id></mixed-citation>
</ref>
<ref id="B12">
<label>12.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mouridsen</surname><given-names>SE</given-names></name><name><surname>Brønnum-Hansen</surname><given-names>H</given-names></name><name><surname>Rich</surname><given-names>B</given-names></name><name><surname>Isager</surname><given-names>T</given-names></name></person-group>. <article-title>Mortality and causes of death in autism spectrum disorders: an update</article-title>. <source/>Autism (<year>2008</year>) <volume>12</volume>:<fpage>403</fpage>–<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1177/1362361308091653</pub-id><pub-id pub-id-type="pmid">18579647</pub-id></mixed-citation>
</ref>
<ref id="B13">
<label>13.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirvikoski</surname><given-names>T</given-names></name><name><surname>Mittendorfer-Rutz</surname><given-names>E</given-names></name><name><surname>Boman</surname><given-names>M</given-names></name><name><surname>Larsson</surname><given-names>H</given-names></name><name><surname>Lichtenstein</surname><given-names>P</given-names></name><name><surname>Bölte</surname><given-names>S</given-names></name></person-group>. <article-title>Premature mortality in autism spectrum disorder</article-title>. <source/>Br J Psychiatry (<year>2016</year>) <volume>208</volume>:<fpage>232</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1192/bjp.bp.114.160192</pub-id><pub-id pub-id-type="pmid">26541693</pub-id></mixed-citation>
</ref>
<ref id="B14">
<label>14.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holingue</surname><given-names>C</given-names></name><name><surname>Newill</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>L</given-names></name><name><surname>Pasricha</surname><given-names>PJ</given-names></name><name><surname>Daniele Fallin</surname><given-names>M</given-names></name></person-group>. <article-title>Gastrointestinal symptoms in autism spectrum disorder: a review of the literature on ascertainment and prevalence</article-title>. <source/>Autism Res. (<year>2018</year>) <volume>11</volume>:<fpage>24</fpage>–<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1002/aur.1854</pub-id><pub-id pub-id-type="pmid">28856868</pub-id></mixed-citation>
</ref>
<ref id="B15">
<label>15.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>S</given-names></name><name><surname>Conduit</surname><given-names>R</given-names></name><name><surname>Lockley</surname><given-names>SW</given-names></name><name><surname>Rajaratnam</surname><given-names>SMW</given-names></name><name><surname>Cornish</surname><given-names>KM</given-names></name></person-group>. <article-title>The relationship between sleep and behavior in autism spectrum disorder (ASD): a review</article-title>. <source/>J Neurodev Disord. (<year>2014</year>) <volume>6</volume>:<fpage>44</fpage>. <pub-id pub-id-type="doi">10.1186/1866-1955-6-44</pub-id><pub-id pub-id-type="pmid">25530819</pub-id></mixed-citation>
</ref>
<ref id="B16">
<label>16.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeste</surname><given-names>SS</given-names></name><name><surname>Tuchman</surname><given-names>R</given-names></name></person-group>. <article-title>Autism spectrum disorder and epilepsy: two sides of the same coin?</article-title>
<source/>J Child Neurol. (<year>2015</year>) <volume>30</volume>:<fpage>1963</fpage>–<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1177/0883073815601501</pub-id><pub-id pub-id-type="pmid">26374786</pub-id></mixed-citation>
</ref>
<ref id="B17">
<label>17.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masi</surname><given-names>A</given-names></name><name><surname>Quintana</surname><given-names>DS</given-names></name><name><surname>Glozier</surname><given-names>N</given-names></name><name><surname>Lloyd</surname><given-names>AR</given-names></name><name><surname>Hickie</surname><given-names>IB</given-names></name><name><surname>Guastella</surname><given-names>AJ</given-names></name></person-group>. <article-title>Cytokine aberrations in autism spectrum disorder: a systematic review and meta-analysis</article-title>. <source/>Mol Psychiatry (<year>2014</year>) <volume>20</volume>:<fpage>440</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2014.59</pub-id><pub-id pub-id-type="pmid">24934179</pub-id></mixed-citation>
</ref>
<ref id="B18">
<label>18.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simonoff</surname><given-names>E</given-names></name><name><surname>Pickles</surname><given-names>A</given-names></name><name><surname>Charman</surname><given-names>T</given-names></name><name><surname>Chandler</surname><given-names>S</given-names></name><name><surname>Loucas</surname><given-names>T</given-names></name><name><surname>Baird</surname><given-names>G</given-names></name></person-group>. <article-title>Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample</article-title>. <source/>J Am Acad Child Adolesc Psychiatry (<year>2008</year>) <volume>47</volume>:<fpage>921</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1097/CHI.0b013e318179964f</pub-id><pub-id pub-id-type="pmid">18645422</pub-id></mixed-citation>
</ref>
<ref id="B19">
<label>19.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leyfer</surname><given-names>OT</given-names></name><name><surname>Folstein</surname><given-names>SE</given-names></name><name><surname>Bacalman</surname><given-names>S</given-names></name><name><surname>Davis</surname><given-names>NO</given-names></name><name><surname>Dinh</surname><given-names>E</given-names></name><name><surname>Morgan</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>Comorbid psychiatric disorders in children with autism: interview development and rates of disorders</article-title>. <source/>J Autism Dev Disord. (<year>2006</year>) <volume>36</volume>:<fpage>849</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1007/s10803-006-0123-0</pub-id><pub-id pub-id-type="pmid">16845581</pub-id></mixed-citation>
</ref>
<ref id="B20">
<label>20.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rommelse</surname><given-names>NNJ</given-names></name><name><surname>Geurts</surname><given-names>HM</given-names></name><name><surname>Franke</surname><given-names>B</given-names></name><name><surname>Buitelaar</surname><given-names>JK</given-names></name><name><surname>Hartman</surname><given-names>CA</given-names></name></person-group>. <article-title>A review on cognitive and brain endophenotypes that may be common in autism spectrum disorder and attention-deficit/hyperactivity disorder and facilitate the search for pleiotropic genes</article-title>. <source/>Neurosci Biobehav Rev. (<year>2011</year>) <volume>35</volume>:<fpage>1363</fpage>–<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1016/j.neubiorev.2011.02.015</pub-id><pub-id pub-id-type="pmid">21382410</pub-id></mixed-citation>
</ref>
<ref id="B21">
<label>21.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richards</surname><given-names>C</given-names></name><name><surname>Jones</surname><given-names>C</given-names></name><name><surname>Groves</surname><given-names>L</given-names></name><name><surname>Moss</surname><given-names>J</given-names></name><name><surname>Oliver</surname><given-names>C</given-names></name></person-group>. <article-title>Prevalence of autism spectrum disorder phenomenology in genetic disorders: a systematic review and meta-analysis</article-title>. <source/>Lancet Psychiatry (<year>2015</year>) <volume>2</volume>:<fpage>909</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1016/S2215-0366(15)00376-4</pub-id><pub-id pub-id-type="pmid">26341300</pub-id></mixed-citation>
</ref>
<ref id="B22">
<label>22.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tye</surname><given-names>C</given-names></name><name><surname>Varcin</surname><given-names>KJ</given-names></name><name><surname>Bolton</surname><given-names>P</given-names></name><name><surname>Jeste</surname><given-names>SS</given-names></name></person-group>
<article-title>Early developmental pathways to autism spectrum disorder in tuberous sclerosis complex</article-title>. <source/>Advances in Autism (<year>2016</year>) <volume>2</volume>:<fpage>84</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1108/AIA-01-2016-0004</pub-id></mixed-citation>
</ref>
<ref id="B23">
<label>23.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guerrini</surname><given-names>R</given-names></name></person-group>. <article-title>Epilepsy in children</article-title>. <source/>Lancet (<year>2006</year>) <volume>367</volume>:<fpage>499</fpage>–<lpage>524</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(06)68182-8</pub-id><pub-id pub-id-type="pmid">16473127</pub-id></mixed-citation>
</ref>
<ref id="B24">
<label>24.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spence</surname><given-names>SJ</given-names></name><name><surname>Schneider</surname><given-names>MT</given-names></name></person-group>. <article-title>The role of epilepsy and epileptiform EEGs in autism spectrum disorders</article-title>. <source/>Pediatr Res. (<year>2009</year>) <volume>65</volume>:<fpage>599</fpage>–<lpage>606</lpage>. <pub-id pub-id-type="doi">10.1203/PDR.0b013e31819e7168</pub-id><pub-id pub-id-type="pmid">19454962</pub-id></mixed-citation>
</ref>
<ref id="B25">
<label>25.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tuchman</surname><given-names>R</given-names></name><name><surname>Cuccaro</surname><given-names>M</given-names></name></person-group>. <article-title>Epilepsy and autism: neurodevelopmental perspective</article-title>. <source/>Curr Neurol Neurosci Rep. (<year>2011</year>) <volume>11</volume>:<fpage>428</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1007/s11910-011-0195-x</pub-id><pub-id pub-id-type="pmid">21424677</pub-id></mixed-citation>
</ref>
<ref id="B26">
<label>26.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hara</surname><given-names>H</given-names></name></person-group>. <article-title>Autism and epilepsy: a retrospective follow-up study</article-title>. <source/>Brain Dev. (<year>2007</year>) <volume>29</volume>:<fpage>486</fpage>–<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1016/j.braindev.2006.12.012</pub-id><pub-id pub-id-type="pmid">17321709</pub-id></mixed-citation>
</ref>
<ref id="B27">
<label>27.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parmeggiani</surname><given-names>A</given-names></name><name><surname>Barcia</surname><given-names>G</given-names></name><name><surname>Posar</surname><given-names>A</given-names></name><name><surname>Raimondi</surname><given-names>E</given-names></name><name><surname>Santucci</surname><given-names>M</given-names></name><name><surname>Scaduto</surname><given-names>MC</given-names></name></person-group>. <article-title>Epilepsy and EEG paroxysmal abnormalities in autism spectrum disorders</article-title>. <source/>Brain Dev. (<year>2010</year>) <volume>32</volume>:<fpage>783</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.braindev.2010.07.003</pub-id><pub-id pub-id-type="pmid">20691552</pub-id></mixed-citation>
</ref>
<ref id="B28">
<label>28.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danielsson</surname><given-names>S</given-names></name><name><surname>Gillberg</surname><given-names>IC</given-names></name><name><surname>Billstedt</surname><given-names>E</given-names></name><name><surname>Gillberg</surname><given-names>C</given-names></name><name><surname>Olsson</surname><given-names>I</given-names></name></person-group>. <article-title>Epilepsy in young adults with autism: a prospective population-based follow-up study of 120 individuals diagnosed in childhood</article-title>. <source/>Epilepsia (<year>2005</year>) <volume>46</volume>:<fpage>918</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1111/j.1528-1167.2005.57504.x</pub-id><pub-id pub-id-type="pmid">15946331</pub-id></mixed-citation>
</ref>
<ref id="B29">
<label>29.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strasser</surname><given-names>L</given-names></name><name><surname>Downes</surname><given-names>M</given-names></name><name><surname>Kung</surname><given-names>J</given-names></name><name><surname>Cross</surname><given-names>JH</given-names></name><name><surname>De Haan</surname><given-names>M</given-names></name></person-group>. <article-title>Prevalence and risk factors for autism spectrum disorder in epilepsy: a systematic review and meta-analysis</article-title>. <source/>Dev Med Child Neurol. (<year>2018</year>) <volume>60</volume>:<fpage>19</fpage>–<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1111/dmcn.13598</pub-id><pub-id pub-id-type="pmid">29119560</pub-id></mixed-citation>
</ref>
<ref id="B30">
<label>30.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeste</surname><given-names>SS</given-names></name><name><surname>Sahin</surname><given-names>M</given-names></name><name><surname>Bolton</surname><given-names>P</given-names></name><name><surname>Ploubidis</surname><given-names>GB</given-names></name><name><surname>Humphrey</surname><given-names>A</given-names></name></person-group>. <article-title>Characterization of autism in young children with tuberous sclerosis complex</article-title>. <source/>J Child Neurol. (<year>2008</year>) <volume>23</volume>:<fpage>520</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1177/0883073807309788</pub-id><pub-id pub-id-type="pmid">18160549</pub-id></mixed-citation>
</ref>
<ref id="B31">
<label>31.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>V</given-names></name></person-group>. <article-title>Study of the relationship between tuberous sclerosis complex and autistic disorder</article-title>. <source/>J Child Neurol. (<year>2006</year>) <volume>21</volume>:<fpage>199</fpage>–<lpage>204</lpage>. <pub-id pub-id-type="doi">10.2310/7010.2006.00046</pub-id><pub-id pub-id-type="pmid">16901420</pub-id></mixed-citation>
</ref>
<ref id="B32">
<label>32.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chez</surname><given-names>MG</given-names></name><name><surname>Chang</surname><given-names>M</given-names></name><name><surname>Krasne</surname><given-names>V</given-names></name><name><surname>Coughlan</surname><given-names>C</given-names></name><name><surname>Kominsky</surname><given-names>M</given-names></name><name><surname>Schwartz</surname><given-names>A</given-names></name></person-group>. <article-title>Frequency of epileptiform EEG abnormalities in a sequential screening of autistic patients with no known clinical epilepsy from 1996 to 2005</article-title>. <source/>Epilepsy Behav. (<year>2006</year>) <volume>8</volume>:<fpage>267</fpage>–<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1016/j.yebeh.2005.11.001</pub-id><pub-id pub-id-type="pmid">16403678</pub-id></mixed-citation>
</ref>
<ref id="B33">
<label>33.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>HL</given-names></name><name><surname>Donnelly</surname><given-names>JH</given-names></name><name><surname>Tournay</surname><given-names>AE</given-names></name><name><surname>Book</surname><given-names>TM</given-names></name><name><surname>Filipek</surname><given-names>P</given-names></name></person-group>. <article-title>Absence of seizures despite high prevalence of epileptiform EEG abnormalities in children with autism monitored in a tertiary care center</article-title>. <source/>Epilepsia (<year>2006</year>) <volume>47</volume>:<fpage>394</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1111/j.1528-1167.2006.00434.x</pub-id><pub-id pub-id-type="pmid">16499766</pub-id></mixed-citation>
</ref>
<ref id="B34">
<label>34.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yasuhara</surname><given-names>A</given-names></name></person-group>. <article-title>Correlation between EEG abnormalities and symptoms of autism spectrum disorder (ASD)</article-title>. <source/>Brain Dev. (<year>2010</year>) <volume>32</volume>:<fpage>791</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.braindev.2010.08.010</pub-id><pub-id pub-id-type="pmid">20826075</pub-id></mixed-citation>
</ref>
<ref id="B35">
<label>35.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steffenburg</surname><given-names>S</given-names></name><name><surname>Gillberg</surname><given-names>C</given-names></name><name><surname>Steffenburg</surname><given-names>U</given-names></name></person-group>. <article-title>Psychiatric disorders in children and adolescents with mental retardation and active epilepsy</article-title>. <source/>Arch Neurol. (<year>1996</year>) <volume>53</volume>:<fpage>904</fpage>–<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1001/archneur.1996.00550090114017</pub-id><pub-id pub-id-type="pmid">8815856</pub-id></mixed-citation>
</ref>
<ref id="B36">
<label>36.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tuchman</surname><given-names>RF</given-names></name><name><surname>Rapin</surname><given-names>I</given-names></name><name><surname>Shinnar</surname><given-names>S</given-names></name></person-group>
<article-title>Autistic and dysphasic children</article-title>. II: Epilepsy. <source/>Pediatrics (<year>1991</year>) <volume>88</volume>:<fpage>1219</fpage>–<lpage>25</lpage>.<pub-id pub-id-type="pmid">1956740</pub-id></mixed-citation>
</ref>
<ref id="B37">
<label>37.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuo</surname><given-names>M</given-names></name><name><surname>Maeda</surname><given-names>T</given-names></name><name><surname>Sasaki</surname><given-names>K</given-names></name><name><surname>Ishii</surname><given-names>K</given-names></name><name><surname>Hamasaki</surname><given-names>Y</given-names></name></person-group>. <article-title>Frequent association of autism spectrum disorder in patients with childhood onset epilepsy</article-title>. <source/>Brain Dev. (<year>2010</year>) <volume>32</volume>:<fpage>759</fpage>–<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1016/j.braindev.2010.05.005</pub-id><pub-id pub-id-type="pmid">20542395</pub-id></mixed-citation>
</ref>
<ref id="B38">
<label>38.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sansa</surname><given-names>G</given-names></name><name><surname>Carlson</surname><given-names>C</given-names></name><name><surname>Doyle</surname><given-names>W</given-names></name><name><surname>Weiner</surname><given-names>HL</given-names></name><name><surname>Bluvstein</surname><given-names>J</given-names></name><name><surname>Barr</surname><given-names>W</given-names></name><etal></etal></person-group>. <article-title>Medically refractory epilepsy in autism</article-title>. <source/>Epilepsia (<year>2011</year>) <volume>52</volume>:<fpage>1071</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1111/j.1528-1167.2011.03069.x</pub-id><pub-id pub-id-type="pmid">21671922</pub-id></mixed-citation>
</ref>
<ref id="B39">
<label>39.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berg</surname><given-names>AT</given-names></name><name><surname>Berkovic</surname><given-names>SF</given-names></name><name><surname>Brodie</surname><given-names>MJ</given-names></name><name><surname>Buchhalter</surname><given-names>J</given-names></name><name><surname>Cross</surname><given-names>JH</given-names></name><name><surname>van Emde Boas</surname><given-names>W</given-names></name><etal></etal></person-group>. <article-title>Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE commission on classification and terminology, 2005–2009</article-title>. <source/>Epilepsia (<year>2010</year>) <volume>51</volume>:<fpage>676</fpage>–<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1111/j.1528-1167.2010.02522.x</pub-id><pub-id pub-id-type="pmid">20196795</pub-id></mixed-citation>
</ref>
<ref id="B40">
<label>40.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srivastava</surname><given-names>S</given-names></name><name><surname>Sahin</surname><given-names>M</given-names></name></person-group>. <article-title>Autism spectrum disorder and epileptic encephalopathy: common causes, many questions</article-title>. <source/>J Neurodev Disord. (<year>2017</year>) <volume>9</volume>:<fpage>23</fpage>. <pub-id pub-id-type="doi">10.1186/s11689-017-9202-0</pub-id><pub-id pub-id-type="pmid">28649286</pub-id></mixed-citation>
</ref>
<ref id="B41">
<label>41.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tuchman</surname><given-names>R</given-names></name><name><surname>Moshé</surname><given-names>SL</given-names></name><name><surname>Rapin</surname><given-names>I</given-names></name></person-group>. <article-title>Convulsing toward the pathophysiology of autism</article-title>. <source/>Brain Dev. (<year>2009</year>) <volume>31</volume>:<fpage>95</fpage>–<lpage>103</lpage>. <pub-id pub-id-type="doi">10.1016/j.braindev.2008.09.009</pub-id><pub-id pub-id-type="pmid">19006654</pub-id></mixed-citation>
</ref>
<ref id="B42">
<label>42.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mouridsen</surname><given-names>SE</given-names></name><name><surname>Rich</surname><given-names>B</given-names></name><name><surname>Isager</surname><given-names>T</given-names></name></person-group>. <article-title>A longitudinal study of epilepsy and other central nervous system diseases in individuals with and without a history of infantile autism</article-title>. <source/>Brain Dev. (<year>2011</year>) <volume>33</volume>:<fpage>361</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.braindev.2010.07.002</pub-id><pub-id pub-id-type="pmid">20655678</pub-id></mixed-citation>
</ref>
<ref id="B43">
<label>43.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turk</surname><given-names>J</given-names></name><name><surname>Bax</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>C</given-names></name><name><surname>Amin</surname><given-names>P</given-names></name><name><surname>Eriksson</surname><given-names>M</given-names></name><name><surname>Gillberg</surname><given-names>C</given-names></name></person-group>. <article-title>Autism spectrum disorder in children with and without epilepsy: impact on social functioning and communication</article-title>. <source/>Acta Paediatr. (<year>2009</year>) <volume>98</volume>:<fpage>675</fpage>–<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1111/j.1651-2227.2008.01184.x</pub-id><pub-id pub-id-type="pmid">19173683</pub-id></mixed-citation>
</ref>
<ref id="B44">
<label>44.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuccaro</surname><given-names>ML</given-names></name><name><surname>Tuchman</surname><given-names>RF</given-names></name><name><surname>Hamilton</surname><given-names>KL</given-names></name><name><surname>Wright</surname><given-names>HH</given-names></name><name><surname>Abramson</surname><given-names>RK</given-names></name><name><surname>Haines</surname><given-names>JL</given-names></name><etal></etal></person-group>. <article-title>Exploring the relationship between autism spectrum disorder and epilepsy using latent class cluster analysis</article-title>. <source/>J Autism Dev Disord. (<year>2012</year>) <volume>42</volume>:<fpage>1630</fpage>–<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1007/s10803-011-1402-y</pub-id><pub-id pub-id-type="pmid">22105141</pub-id></mixed-citation>
</ref>
<ref id="B45">
<label>45.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viscidi</surname><given-names>EW</given-names></name><name><surname>Johnson</surname><given-names>AL</given-names></name><name><surname>Spence</surname><given-names>SJ</given-names></name><name><surname>Buka</surname><given-names>SL</given-names></name><name><surname>Morrow</surname><given-names>EM</given-names></name><name><surname>Triche</surname><given-names>EW</given-names></name></person-group>. <article-title>The association between epilepsy and autism symptoms and maladaptive behaviors in children with autism spectrum disorder</article-title>. <source/>Autism (<year>2014</year>) <volume>18</volume>:<fpage>996</fpage>–<lpage>1006</lpage>. <pub-id pub-id-type="doi">10.1177/1362361313508027</pub-id><pub-id pub-id-type="pmid">24165273</pub-id></mixed-citation>
</ref>
<ref id="B46">
<label>46.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richard</surname><given-names>AE</given-names></name><name><surname>Scheffer</surname><given-names>IE</given-names></name><name><surname>Wilson</surname><given-names>SJ</given-names></name></person-group>. <article-title>Features of the broader autism phenotype in people with epilepsy support shared mechanisms between epilepsy and autism spectrum disorder</article-title>. <source/>Neurosci Biobehav Rev. (<year>2017</year>) <volume>75</volume>:<fpage>203</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1016/j.neubiorev.2016.12.036</pub-id><pub-id pub-id-type="pmid">28104412</pub-id></mixed-citation>
</ref>
<ref id="B47">
<label>47.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amiet</surname><given-names>C</given-names></name><name><surname>Gourfinkel-An</surname><given-names>I</given-names></name><name><surname>Bouzamondo</surname><given-names>A</given-names></name><name><surname>Tordjman</surname><given-names>S</given-names></name><name><surname>Baulac</surname><given-names>M</given-names></name><name><surname>Lechat</surname><given-names>P</given-names></name><etal></etal></person-group>. <article-title>Epilepsy in autism is associated with intellectual disability and gender: evidence from a meta-analysis</article-title>. <source/>Biol Psychiatry (<year>2008</year>) <volume>64</volume>:<fpage>577</fpage>–<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2008.04.030</pub-id><pub-id pub-id-type="pmid">18565495</pub-id></mixed-citation>
</ref>
<ref id="B48">
<label>48.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woolfenden</surname><given-names>SUE</given-names></name><name><surname>Sarkozy</surname><given-names>V</given-names></name><name><surname>Ridley</surname><given-names>G</given-names></name><name><surname>Coory</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>K</given-names></name></person-group>. <article-title>A systematic review of two outcomes in autism spectrum disorder–epilepsy and mortality</article-title>. <source/>Dev Med Child Neurol. (<year>2012</year>) <volume>54</volume>:<fpage>306</fpage>–<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1111/j.1469-8749.2012.04223.x</pub-id><pub-id pub-id-type="pmid">22348343</pub-id></mixed-citation>
</ref>
<ref id="B49">
<label>49.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hrdlicka</surname><given-names>M</given-names></name></person-group>. <article-title>EEG abnormalities, epilepsy and regression in autism: a review</article-title>. <source/>Neuro Endocrinol Lett. (<year>2008</year>) <volume>29</volume>:<fpage>405</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="pmid">18766157</pub-id></mixed-citation>
</ref>
<ref id="B50">
<label>50.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giannotti</surname><given-names>F</given-names></name><name><surname>Cortesi</surname><given-names>F</given-names></name><name><surname>Cerquiglini</surname><given-names>A</given-names></name><name><surname>Miraglia</surname><given-names>D</given-names></name><name><surname>Vagnoni</surname><given-names>C</given-names></name><name><surname>Sebastiani</surname><given-names>T</given-names></name><etal></etal></person-group>. <article-title>An investigation of sleep characteristics, EEG abnormalities and epilepsy in developmentally regressed and non-regressed children with autism</article-title>. <source/>J Autism Dev Disord. (<year>2008</year>) <volume>38</volume>:<fpage>1888</fpage>–<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1007/s10803-008-0584-4</pub-id><pub-id pub-id-type="pmid">18483842</pub-id></mixed-citation>
</ref>
<ref id="B51">
<label>51.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oslejskova</surname><given-names>H</given-names></name><name><surname>Dusek</surname><given-names>L</given-names></name><name><surname>Makovska</surname><given-names>Z</given-names></name><name><surname>Pejcochova</surname><given-names>J</given-names></name><name><surname>Autrata</surname><given-names>R</given-names></name><name><surname>Slapak</surname><given-names>I</given-names></name></person-group>. <article-title>Complicated relationship between autism with regression and epilepsy</article-title>. <source/>Neuro Endocrinol Lett. (<year>2008</year>) <volume>29</volume>:<fpage>558</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="pmid">18766162</pub-id></mixed-citation>
</ref>
<ref id="B52">
<label>52.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berg</surname><given-names>AT</given-names></name><name><surname>Plioplys</surname><given-names>S</given-names></name></person-group>. <article-title>Epilepsy and autism: is there a special relationship?</article-title>
<source/>Epilepsy Behav. (<year>2012</year>) <volume>23</volume>:<fpage>193</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.yebeh.2012.01.015</pub-id><pub-id pub-id-type="pmid">22381386</pub-id></mixed-citation>
</ref>
<ref id="B53">
<label>53.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Humphrey</surname><given-names>A</given-names></name><name><surname>Neville</surname><given-names>BGR</given-names></name><name><surname>Clarke</surname><given-names>A</given-names></name><name><surname>Bolton</surname><given-names>PF</given-names></name></person-group>. <article-title>Autistic regression associated with seizure onset in an infant with tuberous sclerosis</article-title>. <source/>Dev Med Child Neurol. (<year>2006</year>) <volume>48</volume>:<fpage>609</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1017/S0012162206001277</pub-id><pub-id pub-id-type="pmid">16780633</pub-id></mixed-citation>
</ref>
<ref id="B54">
<label>54.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tuchman</surname><given-names>R</given-names></name><name><surname>Alessandri</surname><given-names>M</given-names></name><name><surname>Cuccaro</surname><given-names>M</given-names></name></person-group>. <article-title>Autism spectrum disorders and epilepsy: moving towards a comprehensive approach to treatment</article-title>. <source/>Brain Dev. (<year>2010</year>) <volume>32</volume>:<fpage>719</fpage>–<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1016/j.braindev.2010.05.007</pub-id><pub-id pub-id-type="pmid">20558021</pub-id></mixed-citation>
</ref>
<ref id="B55">
<label>55.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shinnar</surname><given-names>S</given-names></name><name><surname>Pellock</surname><given-names>JM</given-names></name></person-group>. <article-title>Update on the epidemiology and prognosis of pediatric epilepsy</article-title>. <source/>J Child Neurol. (<year>2002</year>) <volume>17</volume>(<issue>Suppl. 1</issue>):<fpage>S4</fpage>–<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1177/08830738020170010201</pub-id><pub-id pub-id-type="pmid">11918462</pub-id></mixed-citation>
</ref>
<ref id="B56">
<label>56.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolton</surname><given-names>PF</given-names></name><name><surname>Carcani-Rathwell</surname><given-names>I</given-names></name><name><surname>Hutton</surname><given-names>J</given-names></name><name><surname>Goode</surname><given-names>S</given-names></name><name><surname>Howlin</surname><given-names>P</given-names></name><name><surname>Rutter</surname><given-names>M</given-names></name></person-group>. <article-title>Epilepsy in autism: features and correlates</article-title>. <source/>Br J Psychiatry (<year>2011</year>) <volume>198</volume>:<fpage>289</fpage>–<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1192/bjp.bp.109.076877</pub-id><pub-id pub-id-type="pmid">21972278</pub-id></mixed-citation>
</ref>
<ref id="B57">
<label>57.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartley-McAndrew</surname><given-names>M</given-names></name><name><surname>Weinstock</surname><given-names>A</given-names></name></person-group>. <article-title>Autism spectrum disorder: correlation between aberrant behaviors, EEG abnormalities and seizures</article-title>. <source/>Neurol Int. (<year>2010</year>) <volume>2</volume>:<fpage>e10</fpage>. <pub-id pub-id-type="doi">10.4081/ni.2010.e10</pub-id><pub-id pub-id-type="pmid">21577334</pub-id></mixed-citation>
</ref>
<ref id="B58">
<label>58.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frye</surname><given-names>RE</given-names></name><name><surname>Sreenivasula</surname><given-names>S</given-names></name><name><surname>Adams</surname><given-names>JB</given-names></name></person-group>. <article-title>Traditional and non-traditional treatments for autism spectrum disorder with seizures: an on-line survey</article-title>. <source/>BMC Pediatr. (<year>2011</year>) <volume>11</volume>:<fpage>37</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2431-11-37</pub-id><pub-id pub-id-type="pmid">21592359</pub-id></mixed-citation>
</ref>
<ref id="B59">
<label>59.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kilincaslan</surname><given-names>A</given-names></name><name><surname>Kok</surname><given-names>BE</given-names></name><name><surname>Tekturk</surname><given-names>P</given-names></name><name><surname>Yalcinkaya</surname><given-names>C</given-names></name><name><surname>Ozkara</surname><given-names>C</given-names></name><name><surname>Yapici</surname><given-names>Z</given-names></name></person-group>. <article-title>Beneficial effects of everolimus on autism and attention-deficit/hyperactivity disorder symptoms in a group of patients with tuberous sclerosis complex</article-title>. <source/>J Child Adolesc Psychopharmacol. (<year>2017</year>) <volume>27</volume>:<fpage>383</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1089/cap.2016.0100</pub-id><pub-id pub-id-type="pmid">27797585</pub-id></mixed-citation>
</ref>
<ref id="B60">
<label>60.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krueger</surname><given-names>DA</given-names></name><name><surname>Sadhwani</surname><given-names>A</given-names></name><name><surname>Byars</surname><given-names>AW</given-names></name><name><surname>de Vries</surname><given-names>PJ</given-names></name><name><surname>Franz</surname><given-names>DN</given-names></name><name><surname>Whittemore</surname><given-names>VH</given-names></name><etal></etal></person-group>. <article-title>Everolimus for treatment of tuberous sclerosis complex-associated neuropsychiatric disorders</article-title>. <source/>Ann Clin Transl Neurol. (<year>2017</year>) <volume>4</volume>:<fpage>877</fpage>–<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1002/acn3.494</pub-id><pub-id pub-id-type="pmid">29296616</pub-id></mixed-citation>
</ref>
<ref id="B61">
<label>61.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bombardieri</surname><given-names>R</given-names></name><name><surname>Pinci</surname><given-names>M</given-names></name><name><surname>Moavero</surname><given-names>R</given-names></name><name><surname>Cerminara</surname><given-names>C</given-names></name><name><surname>Curatolo</surname><given-names>P</given-names></name></person-group>. <article-title>Early control of seizures improves long-term outcome in children with tuberous sclerosis complex</article-title>. <source/>Eur J Paediatr Neurol. (<year>2010</year>) <volume>14</volume>:<fpage>146</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejpn.2009.03.003</pub-id><pub-id pub-id-type="pmid">19369101</pub-id></mixed-citation>
</ref>
<ref id="B62">
<label>62.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Martino</surname><given-names>A</given-names></name><name><surname>Tuchman</surname><given-names>RF</given-names></name></person-group>. <article-title>Antiepileptic drugs: affective use in autism spectrum disorders</article-title>. <source/>Pediatr Neurol. (<year>2001</year>) <volume>25</volume>:<fpage>199</fpage>–<lpage>207</lpage>. <pub-id pub-id-type="doi">10.1016/S0887-8994(01)00276-4</pub-id><pub-id pub-id-type="pmid">11587873</pub-id></mixed-citation>
</ref>
<ref id="B63">
<label>63.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krueger</surname><given-names>DA</given-names></name><name><surname>Care</surname><given-names>MM</given-names></name><name><surname>Holland</surname><given-names>K</given-names></name><name><surname>Agricola</surname><given-names>K</given-names></name><name><surname>Tudor</surname><given-names>C</given-names></name><name><surname>Mangeshkar</surname><given-names>P</given-names></name><etal></etal></person-group>. <article-title>Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis</article-title>. <source/>N Engl J Med. (<year>2010</year>) <volume>363</volume>:<fpage>1801</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1001671</pub-id><pub-id pub-id-type="pmid">21047224</pub-id></mixed-citation>
</ref>
<ref id="B64">
<label>64.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wegiel</surname><given-names>J</given-names></name><name><surname>Kuchna</surname><given-names>I</given-names></name><name><surname>Nowicki</surname><given-names>K</given-names></name><name><surname>Imaki</surname><given-names>H</given-names></name><name><surname>Wegiel</surname><given-names>J</given-names></name><name><surname>Marchi</surname><given-names>E</given-names></name><etal></etal></person-group>. <article-title>The neuropathology of autism: defects of neurogenesis and neuronal migration, and dysplastic changes</article-title>. <source/>Acta Neuropathol. (<year>2010</year>) <volume>119</volume>:<fpage>755</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1007/s00401-010-0655-4</pub-id><pub-id pub-id-type="pmid">20198484</pub-id></mixed-citation>
</ref>
<ref id="B65">
<label>65.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilby</surname><given-names>KL</given-names></name><name><surname>O'Brien</surname><given-names>TJ</given-names></name></person-group>. <article-title>Epilepsy, autism, and neurodevelopment: kindling a shared vulnerability?</article-title>
<source/>Epilepsy Behav. (<year>2013</year>) <volume>26</volume>:<fpage>370</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1016/j.yebeh.2012.11.002</pub-id><pub-id pub-id-type="pmid">23415480</pub-id></mixed-citation>
</ref>
<ref id="B66">
<label>66.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lo-Castro</surname><given-names>A</given-names></name><name><surname>Curatolo</surname><given-names>P</given-names></name></person-group>. <article-title>Epilepsy associated with autism and attention deficit hyperactivity disorder: is there a genetic link?</article-title>
<source/>Brain Dev. (<year>2014</year>) <volume>36</volume>:<fpage>185</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1016/j.braindev.2013.04.013</pub-id><pub-id pub-id-type="pmid">23726375</pub-id></mixed-citation>
</ref>
<ref id="B67">
<label>67.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tuchman</surname><given-names>R</given-names></name></person-group>. <article-title>Autism and social cognition in epilepsy: implications for comprehensive epilepsy care</article-title>. <source/>Curr Opin Neurol. (<year>2013</year>) <volume>26</volume>:<fpage>214</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1097/WCO.0b013e32835ee64f</pub-id><pub-id pub-id-type="pmid">23400237</pub-id></mixed-citation>
</ref>
<ref id="B68">
<label>68.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mefford</surname><given-names>HC</given-names></name><name><surname>Batshaw</surname><given-names>ML</given-names></name><name><surname>Hoffman</surname><given-names>EP</given-names></name></person-group>. <article-title>Genomics, intellectual disability, and autism</article-title>. <source/>N Engl J Med. (<year>2012</year>) <volume>366</volume>:<fpage>733</fpage>–<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMra1114194</pub-id><pub-id pub-id-type="pmid">22356326</pub-id></mixed-citation>
</ref>
<ref id="B69">
<label>69.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lesca</surname><given-names>G</given-names></name><name><surname>Rudolf</surname><given-names>G</given-names></name><name><surname>Labalme</surname><given-names>A</given-names></name><name><surname>Hirsch</surname><given-names>E</given-names></name><name><surname>Arzimanoglou</surname><given-names>A</given-names></name><name><surname>Genton</surname><given-names>P</given-names></name><etal></etal></person-group>. <article-title>Epileptic encephalopathies of the Landau-Kleffner and continuous spike and waves during slow-wave sleep types: genomic dissection makes the link with autism</article-title>. <source/>Epilepsia (<year>2012</year>) <volume>53</volume>:<fpage>1526</fpage>–<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1111/j.1528-1167.2012.03559.x</pub-id><pub-id pub-id-type="pmid">22738016</pub-id></mixed-citation>
</ref>
<ref id="B70">
<label>70.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolton</surname><given-names>PF</given-names></name><name><surname>Park</surname><given-names>RJ</given-names></name><name><surname>Higgins</surname><given-names>JNP</given-names></name><name><surname>Griffiths</surname><given-names>PD</given-names></name><name><surname>Pickles</surname><given-names>A</given-names></name></person-group>. <article-title>Neuro-epileptic determinants of autism spectrum disorders in tuberous sclerosis complex</article-title>. <source/>Brain (<year>2002</year>) <volume>125</volume>:<fpage>1247</fpage>–<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1093/brain/awf124</pub-id><pub-id pub-id-type="pmid">12023313</pub-id></mixed-citation>
</ref>
<ref id="B71">
<label>71.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolff</surname><given-names>M</given-names></name><name><surname>Cassé-Perrot</surname><given-names>C</given-names></name><name><surname>Dravet</surname><given-names>C</given-names></name></person-group>. <article-title>Severe myoclonic epilepsy of infants (Dravet syndrome): natural history and neuropsychological findings</article-title>. <source/>Epilepsia (<year>2006</year>) <volume>47</volume>:<fpage>45</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1111/j.1528-1167.2006.00688.x</pub-id><pub-id pub-id-type="pmid">17105460</pub-id></mixed-citation>
</ref>
<ref id="B72">
<label>72.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trillingsgaard</surname><given-names>A</given-names></name><name><surname>Østergaard</surname><given-names>JR</given-names></name></person-group>. <article-title>Autism in Angelman syndrome: an exploration of comorbidity</article-title>. <source/>Autism (<year>2004</year>) <volume>8</volume>:<fpage>163</fpage>–<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1177/1362361304042720</pub-id><pub-id pub-id-type="pmid">15165432</pub-id></mixed-citation>
</ref>
<ref id="B73">
<label>73.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tye</surname><given-names>C</given-names></name><name><surname>Thomas</surname><given-names>LE</given-names></name><name><surname>Sampson</surname><given-names>JR</given-names></name><name><surname>Lewis</surname><given-names>J</given-names></name><name><surname>O'Callaghan</surname><given-names>F</given-names></name><name><surname>Yates</surname><given-names>JRW</given-names></name><etal></etal></person-group>. <article-title>Secular changes in severity of intellectual disability in tuberous sclerosis complex: a reflection of improved identification and treatment of epileptic spasms?</article-title>
<source/>Epilepsia Open. (<year>2018</year>) <volume>3</volume>:<fpage>276</fpage>–<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1002/epi4.12111</pub-id><pub-id pub-id-type="pmid">29881807</pub-id></mixed-citation>
</ref>
<ref id="B74">
<label>74.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dravet</surname><given-names>C</given-names></name></person-group>. <article-title>The core Dravet syndrome phenotype</article-title>. <source/>Epilepsia (<year>2011</year>) <volume>52</volume>:<fpage>3</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1111/j.1528-1167.2011.02994.x</pub-id><pub-id pub-id-type="pmid">21463272</pub-id></mixed-citation>
</ref>
<ref id="B75">
<label>75.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al Ageeli</surname><given-names>E</given-names></name><name><surname>Drunat</surname><given-names>S</given-names></name><name><surname>Delanoë</surname><given-names>C</given-names></name><name><surname>Perrin</surname><given-names>L</given-names></name><name><surname>Baumann</surname><given-names>C</given-names></name><name><surname>Capri</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>Duplication of the 15q11-q13 region: clinical and genetic study of 30 new cases</article-title>. <source/>Eur J Med Genet. (<year>2014</year>) <volume>57</volume>:<fpage>5</fpage>–<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejmg.2013.10.008</pub-id><pub-id pub-id-type="pmid">24239951</pub-id></mixed-citation>
</ref>
<ref id="B76">
<label>76.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>BH</given-names></name><name><surname>Smith</surname><given-names>T</given-names></name><name><surname>Paciorkowski</surname><given-names>AR</given-names></name></person-group>. <article-title>Autism spectrum disorder and epilepsy: disorders with a shared biology</article-title>. <source/>Epilepsy Behav. (<year>2015</year>) <volume>47</volume>:<fpage>191</fpage>–<lpage>201</lpage>. <pub-id pub-id-type="doi">10.1016/j.yebeh.2015.03.017</pub-id><pub-id pub-id-type="pmid">25900226</pub-id></mixed-citation>
</ref>
<ref id="B77">
<label>77.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacob</surname><given-names>J</given-names></name></person-group>. <article-title>Cortical interneuron dysfunction in epilepsy associated with autism spectrum disorders</article-title>. <source/>Epilepsia (<year>2016</year>) <volume>57</volume>:<fpage>182</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1111/epi.13272</pub-id><pub-id pub-id-type="pmid">26682992</pub-id></mixed-citation>
</ref>
<ref id="B78">
<label>78.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vestergaard</surname><given-names>M</given-names></name><name><surname>Mork</surname><given-names>A</given-names></name><name><surname>Madsen</surname><given-names>KM</given-names></name><name><surname>Olsen</surname><given-names>J</given-names></name></person-group>. <article-title>Paternal age and epilepsy in the offspring</article-title>. <source/>Eur J Epidemiol. (<year>2005</year>) <volume>20</volume>:<fpage>1003</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1007/s10654-005-4250-2</pub-id><pub-id pub-id-type="pmid">16331431</pub-id></mixed-citation>
</ref>
<ref id="B79">
<label>79.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vargas</surname><given-names>DL</given-names></name><name><surname>Nascimbene</surname><given-names>C</given-names></name><name><surname>Krishnan</surname><given-names>C</given-names></name><name><surname>Zimmerman</surname><given-names>AW</given-names></name><name><surname>Pardo</surname><given-names>CA</given-names></name></person-group>. <article-title>Neuroglial activation and neuroinflammation in the brain of patients with autism</article-title>. <source/>Ann Neurol Off J Am Neurol Assoc Child Neurol Soc. (<year>2005</year>) <volume>57</volume>:<fpage>67</fpage>–<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1002/ana.20315</pub-id><pub-id pub-id-type="pmid">15546155</pub-id></mixed-citation>
</ref>
<ref id="B80">
<label>80.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vezzani</surname><given-names>A</given-names></name><name><surname>Aronica</surname><given-names>E</given-names></name><name><surname>Mazarati</surname><given-names>A</given-names></name><name><surname>Pittman</surname><given-names>QJ</given-names></name></person-group>. <article-title>Epilepsy and brain inflammation</article-title>. <source/>Exp Neurol. (<year>2013</year>) <volume>244</volume>:<fpage>11</fpage>–<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1016/j.expneurol.2011.09.033</pub-id><pub-id pub-id-type="pmid">21985866</pub-id></mixed-citation>
</ref>
<ref id="B81">
<label>81.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krakowiak</surname><given-names>P</given-names></name><name><surname>Goodlin-Jones</surname><given-names>B</given-names></name><name><surname>Hertz-Picciotto</surname><given-names>I</given-names></name><name><surname>Croen</surname><given-names>LA</given-names></name><name><surname>Hansen</surname><given-names>RL</given-names></name></person-group>. <article-title>Sleep problems in children with autism spectrum disorders, developmental delays, and typical development: a population-based study</article-title>. <source/>J Sleep Res. (<year>2008</year>) <volume>17</volume>:<fpage>197</fpage>–<lpage>206</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2869.2008.00650.x</pub-id><pub-id pub-id-type="pmid">18482108</pub-id></mixed-citation>
</ref>
<ref id="B82">
<label>82.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Hubbard</surname><given-names>JA</given-names></name><name><surname>Fabes</surname><given-names>RA</given-names></name><name><surname>Adam</surname><given-names>JB</given-names></name></person-group>. <article-title>Sleep disturbances and correlates of children with autism spectrum disorders</article-title>. <source/>Child Psychiatry Hum Dev. (<year>2006</year>) <volume>37</volume>:<fpage>179</fpage>–<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1007/s10578-006-0028-3</pub-id><pub-id pub-id-type="pmid">17001527</pub-id></mixed-citation>
</ref>
<ref id="B83">
<label>83.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polimeni</surname><given-names>MA</given-names></name><name><surname>Richdale</surname><given-names>AL</given-names></name><name><surname>Francis</surname><given-names>AJ</given-names></name></person-group>. <article-title>A survey of sleep problems in autism, Asperger's disorder and typically developing children</article-title>. <source/>J Intellect Disabil Res. (<year>2005</year>) <volume>49</volume>(<issue>Pt 4</issue>):<fpage>260</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2788.2005.00642.x</pub-id><pub-id pub-id-type="pmid">15816813</pub-id></mixed-citation>
</ref>
<ref id="B84">
<label>84.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiggs</surname><given-names>L</given-names></name><name><surname>Stores</surname><given-names>G</given-names></name></person-group>. <article-title>Sleep patterns and sleep disorders in children with autistic spectrum disorders: insights using parent report and actigraphy</article-title>. <source/>Dev Med Child Neurol. (<year>2004</year>) <volume>46</volume>:<fpage>372</fpage>–<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1017/S0012162204000611</pub-id><pub-id pub-id-type="pmid">15174528</pub-id></mixed-citation>
</ref>
<ref id="B85">
<label>85.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richdale</surname><given-names>AL</given-names></name><name><surname>Schreck</surname><given-names>KA</given-names></name></person-group>. <article-title>Sleep problems in autism spectrum disorders: prevalence, nature, &amp; possible biopsychosocial aetiologies</article-title>. <source/>Sleep Med Rev. (<year>2009</year>) <volume>13</volume>:<fpage>403</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1016/j.smrv.2009.02.003</pub-id><pub-id pub-id-type="pmid">19398354</pub-id></mixed-citation>
</ref>
<ref id="B86">
<label>86.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldman</surname><given-names>SE</given-names></name><name><surname>Richdale</surname><given-names>AL</given-names></name><name><surname>Clemons</surname><given-names>T</given-names></name><name><surname>Malow</surname><given-names>BA</given-names></name></person-group>. <article-title>Parental sleep concerns in autism spectrum disorders: variations from childhood to adolescence</article-title>. <source/>J Autism Dev Disord. (<year>2012</year>) <volume>42</volume>:<fpage>531</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1007/s10803-011-1270-5</pub-id><pub-id pub-id-type="pmid">21538171</pub-id></mixed-citation>
</ref>
<ref id="B87">
<label>87.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Souders</surname><given-names>MC</given-names></name><name><surname>Mason</surname><given-names>TB</given-names></name><name><surname>Valladares</surname><given-names>O</given-names></name><name><surname>Bucan</surname><given-names>M</given-names></name><name><surname>Levy</surname><given-names>SE</given-names></name><name><surname>Mandell</surname><given-names>DS</given-names></name><etal></etal></person-group>. <article-title>Sleep behaviors and sleep quality in children with autism spectrum disorders</article-title>. <source/>Sleep (<year>2009</year>) <volume>32</volume>:<fpage>1566</fpage>–<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1093/sleep/32.12.1566</pub-id><pub-id pub-id-type="pmid">20041592</pub-id></mixed-citation>
</ref>
<ref id="B88">
<label>88.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buckley</surname><given-names>AW</given-names></name><name><surname>Rodriguez</surname><given-names>AJ</given-names></name><name><surname>Jennison</surname><given-names>K</given-names></name><name><surname>Buckley</surname><given-names>J</given-names></name><name><surname>Thurm</surname><given-names>A</given-names></name><name><surname>Sato</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>Rapid eye movement sleep percentage in children with autism compared with children with developmental delay and typical development</article-title>. <source/>Arch Pediatr Adolesc Med. (<year>2010</year>) <volume>164</volume>:<fpage>1032</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1001/archpediatrics.2010.202</pub-id><pub-id pub-id-type="pmid">21041596</pub-id></mixed-citation>
</ref>
<ref id="B89">
<label>89.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipton</surname><given-names>J</given-names></name><name><surname>Becker</surname><given-names>RE</given-names></name><name><surname>Kothare</surname><given-names>S V</given-names></name></person-group>. <article-title>Insomnia of childhood</article-title>. <source/>Curr Opin Pediatr. (<year>2008</year>) <volume>20</volume>:<fpage>641</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1097/MOP.0b013e32831897cb</pub-id><pub-id pub-id-type="pmid">19005332</pub-id></mixed-citation>
</ref>
<ref id="B90">
<label>90.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>E</given-names></name><name><surname>Richdale</surname><given-names>A</given-names></name><name><surname>Short</surname><given-names>M</given-names></name><name><surname>Gradisar</surname><given-names>M</given-names></name></person-group>. <article-title>An investigation of sleep patterns in adolescents with high-functioning autism spectrum disorder compared with typically developing adolescents</article-title>. <source/>Dev Neurorehabil. (<year>2013</year>) <volume>16</volume>:<fpage>155</fpage>–<lpage>65</lpage>. <pub-id pub-id-type="doi">10.3109/17518423.2013.765518</pub-id><pub-id pub-id-type="pmid">23477662</pub-id></mixed-citation>
</ref>
<ref id="B91">
<label>91.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richdale</surname><given-names>AL</given-names></name><name><surname>Baker</surname><given-names>E</given-names></name><name><surname>Short</surname><given-names>M</given-names></name><name><surname>Gradisar</surname><given-names>M</given-names></name></person-group>. <article-title>The role of insomnia, pre-sleep arousal and psychopathology symptoms in daytime impairment in adolescents with high-functioning autism spectrum disorder</article-title>. <source/>Sleep Med. (<year>2014</year>) <volume>15</volume>:<fpage>1082</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.sleep.2014.05.005</pub-id><pub-id pub-id-type="pmid">24974199</pub-id></mixed-citation>
</ref>
<ref id="B92">
<label>92.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffman</surname><given-names>CD</given-names></name><name><surname>Sweeney</surname><given-names>DP</given-names></name><name><surname>Gilliam</surname><given-names>JE</given-names></name><name><surname>Apodaca</surname><given-names>DD</given-names></name><name><surname>Lopez-Wagner</surname><given-names>MC</given-names></name><name><surname>Castillo</surname><given-names>MM</given-names></name></person-group>
<article-title>Sleep problems and symptomology in children with autism</article-title>. <source/>Focus Autism Other Dev Disabl. (<year>2005</year>) <volume>20</volume>:<fpage>194</fpage>–<lpage>200</lpage>. <pub-id pub-id-type="doi">10.1177/10883576050200040101</pub-id></mixed-citation>
</ref>
<ref id="B93">
<label>93.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schreck</surname><given-names>KA</given-names></name><name><surname>Mulick</surname><given-names>JA</given-names></name><name><surname>Smith</surname><given-names>AF</given-names></name></person-group>. <article-title>Sleep problems as possible predictors of intensified symptoms of autism</article-title>. <source/>Res Dev Disabil. (<year>2004</year>) <volume>25</volume>:<fpage>57</fpage>–<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1016/j.ridd.2003.04.007</pub-id><pub-id pub-id-type="pmid">14733976</pub-id></mixed-citation>
</ref>
<ref id="B94">
<label>94.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malow</surname><given-names>BA</given-names></name><name><surname>Marzec</surname><given-names>ML</given-names></name><name><surname>McGrew</surname><given-names>SG</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Henderson</surname><given-names>LM</given-names></name><name><surname>Stone</surname><given-names>WL</given-names></name></person-group>. <article-title>Characterizing sleep in children with autism spectrum disorders: a multidimensional approach</article-title>. <source/>Sleep (<year>2006</year>) <volume>29</volume>:<fpage>1563</fpage>–<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1093/sleep/29.12.1563</pub-id><pub-id pub-id-type="pmid">17252887</pub-id></mixed-citation>
</ref>
<ref id="B95">
<label>95.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veatch</surname><given-names>OJ</given-names></name><name><surname>Sutcliffe</surname><given-names>JS</given-names></name><name><surname>Warren</surname><given-names>ZE</given-names></name><name><surname>Keenan</surname><given-names>BT</given-names></name><name><surname>Potter</surname><given-names>MH</given-names></name><name><surname>Malow</surname><given-names>BA</given-names></name></person-group>. <article-title>Shorter sleep duration is associated with social impairment and comorbidities in ASD</article-title>. <source/>Autism Res. (<year>2017</year>) <volume>10</volume>:<fpage>1221</fpage>–<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1002/aur.1765</pub-id><pub-id pub-id-type="pmid">28301091</pub-id></mixed-citation>
</ref>
<ref id="B96">
<label>96.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tudor</surname><given-names>ME</given-names></name><name><surname>Hoffman</surname><given-names>CD</given-names></name><name><surname>Sweeney</surname><given-names>DP</given-names></name></person-group>
<article-title>Children with autism: sleep problems and symptom severity</article-title>. <source/>Focus Autism Other Dev Disabl. (<year>2012</year>) <volume>27</volume>:<fpage>254</fpage>–<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1177/1088357612457989</pub-id></mixed-citation>
</ref>
<ref id="B97">
<label>97.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giannotti</surname><given-names>F</given-names></name><name><surname>Cortesi</surname><given-names>F</given-names></name><name><surname>Cerquiglini</surname><given-names>A</given-names></name><name><surname>Vagnoni</surname><given-names>C</given-names></name><name><surname>Valente</surname><given-names>D</given-names></name></person-group>. <article-title>Sleep in children with autism with and without autistic regression</article-title>. <source/>J Sleep Res. (<year>2011</year>) <volume>20</volume>:<fpage>338</fpage>–<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2869.2010.00882.x</pub-id><pub-id pub-id-type="pmid">21518065</pub-id></mixed-citation>
</ref>
<ref id="B98">
<label>98.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>S</given-names></name><name><surname>Fulcher</surname><given-names>BD</given-names></name><name><surname>Rajaratnam</surname><given-names>SMW</given-names></name><name><surname>Conduit</surname><given-names>R</given-names></name><name><surname>Sullivan</surname><given-names>JP</given-names></name><name><surname>St Hilaire</surname><given-names>MA</given-names></name><etal></etal></person-group>. <article-title>Behaviorally-determined sleep phenotypes are robustly associated with adaptive functioning in individuals with low functioning autism</article-title>. <source/>Sci Rep. (<year>2017</year>) <volume>7</volume>:<fpage>14228</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-017-14611-6</pub-id><pub-id pub-id-type="pmid">29079761</pub-id></mixed-citation>
</ref>
<ref id="B99">
<label>99.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>S</given-names></name><name><surname>Fulcher</surname><given-names>BD</given-names></name><name><surname>Rajaratnam</surname><given-names>SMW</given-names></name><name><surname>Conduit</surname><given-names>R</given-names></name><name><surname>Sullivan</surname><given-names>JP</given-names></name><name><surname>St Hilaire</surname><given-names>MA</given-names></name><etal></etal></person-group>. <article-title>Sleep patterns predictive of daytime challenging behavior in individuals with low-functioning autism</article-title>. <source/>Autism Res. (<year>2018</year>) <volume>11</volume>:<fpage>391</fpage>–<lpage>403</lpage>. <pub-id pub-id-type="doi">10.1002/aur.1899</pub-id><pub-id pub-id-type="pmid">29197172</pub-id></mixed-citation>
</ref>
<ref id="B100">
<label>100.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reynolds</surname><given-names>AM</given-names></name><name><surname>Malow</surname><given-names>BA</given-names></name></person-group>. <article-title>Sleep and autism spectrum disorders</article-title>. <source/>Pediatr Clin North Am. (<year>2011</year>) <volume>58</volume>:<fpage>685</fpage>–<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1016/j.pcl.2011.03.009</pub-id><pub-id pub-id-type="pmid">21600349</pub-id></mixed-citation>
</ref>
<ref id="B101">
<label>101.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallace</surname><given-names>ML</given-names></name><name><surname>McMakin</surname><given-names>DL</given-names></name><name><surname>Tan</surname><given-names>PZ</given-names></name><name><surname>Rosen</surname><given-names>D</given-names></name><name><surname>Forbes</surname><given-names>EE</given-names></name><name><surname>Ladouceur</surname><given-names>CD</given-names></name><etal></etal></person-group>. <article-title>The role of day-to-day emotions, sleep, and social interactions in pediatric anxiety treatment</article-title>. <source/>Behav Res Ther. (<year>2017</year>) <volume>90</volume>:<fpage>87</fpage>–<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1016/j.brat.2016.12.012</pub-id><pub-id pub-id-type="pmid">28013054</pub-id></mixed-citation>
</ref>
<ref id="B102">
<label>102.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tani</surname><given-names>P</given-names></name><name><surname>Lindberg</surname><given-names>N</given-names></name><name><surname>Nieminen-von Wendt</surname><given-names>T</given-names></name><name><surname>von Wendt</surname><given-names>L</given-names></name><name><surname>Virkkala</surname><given-names>J</given-names></name><name><surname>Appelberg</surname><given-names>B</given-names></name><etal></etal></person-group>. <article-title>Sleep in young adults with Asperger syndrome</article-title>. <source/>Neuropsychobiology (<year>2004</year>) <volume>50</volume>:<fpage>147</fpage>–<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1159/000079106</pub-id><pub-id pub-id-type="pmid">15292669</pub-id></mixed-citation>
</ref>
<ref id="B103">
<label>103.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruni</surname><given-names>O</given-names></name><name><surname>Ferri</surname><given-names>R</given-names></name><name><surname>Vittori</surname><given-names>E</given-names></name><name><surname>Novelli</surname><given-names>L</given-names></name><name><surname>Vignati</surname><given-names>M</given-names></name><name><surname>Porfirio</surname><given-names>MC</given-names></name><etal></etal></person-group>. <article-title>Sleep architecture and NREM alterations in children and adolescents with Asperger syndrome</article-title>. <source/>Sleep (<year>2007</year>) <volume>30</volume>:<fpage>1577</fpage>–<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1093/sleep/30.11.1577</pub-id><pub-id pub-id-type="pmid">18041490</pub-id></mixed-citation>
</ref>
<ref id="B104">
<label>104.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paavonen</surname><given-names>EJ</given-names></name><name><surname>Nieminen-von Wendt</surname><given-names>T</given-names></name><name><surname>Vanhala</surname><given-names>R</given-names></name><name><surname>Aronen</surname><given-names>ET</given-names></name><name><surname>von Wendt</surname><given-names>L</given-names></name></person-group>. <article-title>Effectiveness of melatonin in the treatment of sleep disturbances in children with Asperger disorder</article-title>. <source/>J Child Adolesc Psychopharmacol. (<year>2003</year>) <volume>13</volume>:<fpage>83</fpage>–<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1089/104454603321666225</pub-id><pub-id pub-id-type="pmid">12804129</pub-id></mixed-citation>
</ref>
<ref id="B105">
<label>105.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antshel</surname><given-names>KM</given-names></name><name><surname>Zhang-James</surname><given-names>Y</given-names></name><name><surname>Wagner</surname><given-names>KE</given-names></name><name><surname>Ledesma</surname><given-names>A</given-names></name><name><surname>Faraone</surname><given-names>S V</given-names></name></person-group>. <article-title>An update on the comorbidity of ADHD and ASD: a focus on clinical management</article-title>. <source/>Expert Rev Neurother. (<year>2016</year>) <volume>16</volume>:<fpage>279</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1586/14737175.2016.1146591</pub-id><pub-id pub-id-type="pmid">26807870</pub-id></mixed-citation>
</ref>
<ref id="B106">
<label>106.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldman</surname><given-names>SE</given-names></name><name><surname>Surdyka</surname><given-names>K</given-names></name><name><surname>Cuevas</surname><given-names>R</given-names></name><name><surname>Adkins</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Malow</surname><given-names>BA</given-names></name></person-group>. <article-title>Defining the sleep phenotype in children with autism</article-title>. <source/>Dev Neuropsychol. (<year>2009</year>) <volume>34</volume>:<fpage>560</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1080/87565640903133509</pub-id><pub-id pub-id-type="pmid">20183719</pub-id></mixed-citation>
</ref>
<ref id="B107">
<label>107.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossignol</surname><given-names>DA</given-names></name><name><surname>Frye</surname><given-names>RE</given-names></name></person-group>. <article-title>Melatonin in autism spectrum disorders: a systematic review and meta-analysis</article-title>. <source/>Dev Med Child Neurol. (<year>2011</year>) <volume>53</volume>:<fpage>783</fpage>–<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1111/j.1469-8749.2011.03980.x</pub-id><pub-id pub-id-type="pmid">21518346</pub-id></mixed-citation>
</ref>
<ref id="B108">
<label>108.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gringras</surname><given-names>P</given-names></name><name><surname>Findling</surname><given-names>RL</given-names></name><name><surname>Nir</surname><given-names>T</given-names></name><name><surname>Zisapel</surname><given-names>N</given-names></name></person-group>
<article-title>Short and long term prolonged release melatonin treatment for sleep disorders in children with autism spectrum disorders: results of a phase III randomized clinical trial</article-title>. <source/>Sleep Med. (<year>2017</year>) <volume>40</volume>:<fpage>e119</fpage>
<pub-id pub-id-type="doi">10.1016/j.sleep.2017.11.347</pub-id></mixed-citation>
</ref>
<ref id="B109">
<label>109.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gujar</surname><given-names>N</given-names></name><name><surname>McDonald</surname><given-names>SA</given-names></name><name><surname>Nishida</surname><given-names>M</given-names></name><name><surname>Walker</surname><given-names>MP</given-names></name></person-group>. <article-title>A role for REM sleep in recalibrating the sensitivity of the human brain to specific emotions</article-title>. <source/>Cereb Cortex (<year>2011</year>) <volume>21</volume>:<fpage>115</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1093/cercor/bhq064</pub-id><pub-id pub-id-type="pmid">20421251</pub-id></mixed-citation>
</ref>
<ref id="B110">
<label>110.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Helm</surname><given-names>E</given-names></name><name><surname>Gujar</surname><given-names>N</given-names></name><name><surname>Walker</surname><given-names>MP</given-names></name></person-group>. <article-title>Sleep deprivation impairs the accurate recognition of human emotions</article-title>. <source/>Sleep (<year>2010</year>) <volume>33</volume>:<fpage>335</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1093/sleep/33.3.335</pub-id><pub-id pub-id-type="pmid">20337191</pub-id></mixed-citation>
</ref>
<ref id="B111">
<label>111.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hollway</surname><given-names>JA</given-names></name><name><surname>Aman</surname><given-names>MG</given-names></name></person-group>. <article-title>Pharmacological treatment of sleep disturbance in developmental disabilities: a review of the literature</article-title>. <source/>Res Dev Disabil. (<year>2011</year>) <volume>32</volume>:<fpage>939</fpage>–<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/j.ridd.2010.12.035</pub-id><pub-id pub-id-type="pmid">21296553</pub-id></mixed-citation>
</ref>
<ref id="B112">
<label>112.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maayan</surname><given-names>L</given-names></name><name><surname>Correll</surname><given-names>CU</given-names></name></person-group>. <article-title>Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents</article-title>. <source/>J Child Adolesc Psychopharmacol. (<year>2011</year>) <volume>21</volume>:<fpage>517</fpage>–<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1089/cap.2011.0015</pub-id><pub-id pub-id-type="pmid">22166172</pub-id></mixed-citation>
</ref>
<ref id="B113">
<label>113.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broder-Fingert</surname><given-names>S</given-names></name><name><surname>Brazauskas</surname><given-names>K</given-names></name><name><surname>Lindgren</surname><given-names>K</given-names></name><name><surname>Iannuzzi</surname><given-names>D</given-names></name><name><surname>Van Cleave</surname><given-names>J</given-names></name></person-group>. <article-title>Prevalence of overweight and obesity in a large clinical sample of children with autism</article-title>. <source/>Acad Pediatr. (<year>2014</year>) <volume>14</volume>:<fpage>408</fpage>–<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1016/j.acap.2014.04.004</pub-id><pub-id pub-id-type="pmid">24976353</pub-id></mixed-citation>
</ref>
<ref id="B114">
<label>114.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charrier</surname><given-names>A</given-names></name><name><surname>Olliac</surname><given-names>B</given-names></name><name><surname>Roubertoux</surname><given-names>P</given-names></name><name><surname>Tordjman</surname><given-names>S</given-names></name></person-group>. <article-title>Clock genes and altered sleep–wake rhythms: their role in the development of psychiatric disorders</article-title>. <source/>Int J Mol Sci. (<year>2017</year>) <volume>18</volume>:<fpage>938</fpage>. <pub-id pub-id-type="doi">10.3390/ijms18050938</pub-id><pub-id pub-id-type="pmid">28468274</pub-id></mixed-citation>
</ref>
<ref id="B115">
<label>115.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pizzarelli</surname><given-names>R</given-names></name><name><surname>Cherubini</surname><given-names>E</given-names></name></person-group>. <article-title>Alterations of GABAergic signaling in autism spectrum disorders</article-title>. <source/>Neural Plast. (<year>2011</year>) <volume>2011</volume>:<fpage>297153</fpage>. <pub-id pub-id-type="doi">10.1155/2011/297153</pub-id><pub-id pub-id-type="pmid">21766041</pub-id></mixed-citation>
</ref>
<ref id="B116">
<label>116.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melke</surname><given-names>J</given-names></name><name><surname>Botros</surname><given-names>HG</given-names></name><name><surname>Chaste</surname><given-names>P</given-names></name><name><surname>Betancur</surname><given-names>C</given-names></name><name><surname>Nygren</surname><given-names>G</given-names></name><name><surname>Anckarsäter</surname><given-names>H</given-names></name><etal></etal></person-group>. <article-title>Abnormal melatonin synthesis in autism spectrum disorders</article-title>. <source/>Mol Psychiatry (<year>2007</year>) <volume>13</volume>:<fpage>90</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1038/sj.mp.4002016</pub-id><pub-id pub-id-type="pmid">17505466</pub-id></mixed-citation>
</ref>
<ref id="B117">
<label>117.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bourgeron</surname><given-names>T</given-names></name></person-group>. <article-title>The possible interplay of synaptic and clock genes in autism spectrum disorders</article-title>. <source/>Cold Spring Harb Symp Quant Biol. (<year>2007</year>) <volume>72</volume>:<fpage>645</fpage>–<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1101/sqb.2007.72.020</pub-id><pub-id pub-id-type="pmid">18419324</pub-id></mixed-citation>
</ref>
<ref id="B118">
<label>118.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Matsumoto</surname><given-names>A</given-names></name><name><surname>Nakayama</surname><given-names>K</given-names></name><name><surname>Jimbo</surname><given-names>EF</given-names></name><name><surname>Kojima</surname><given-names>K</given-names></name><name><surname>Nagata</surname><given-names>K</given-names></name><etal></etal></person-group>. <article-title>Circadian-relevant genes are highly polymorphic in autism spectrum disorder patients</article-title>. <source/>Brain Dev. (<year>2016</year>) <volume>38</volume>:<fpage>91</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.braindev.2015.04.006</pub-id><pub-id pub-id-type="pmid">25957987</pub-id></mixed-citation>
</ref>
<ref id="B119">
<label>119.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ebisawa</surname><given-names>T</given-names></name></person-group>. <article-title>Circadian rhythms in the CNS and peripheral clock disorders: human sleep disorders and clock genes</article-title>. <source/>J Pharmacol Sci. (<year>2007</year>) <volume>103</volume>:<fpage>150</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1254/jphs.FMJ06003X5</pub-id><pub-id pub-id-type="pmid">17299246</pub-id></mixed-citation>
</ref>
<ref id="B120">
<label>120.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicholas</surname><given-names>B</given-names></name><name><surname>Rudrasingham</surname><given-names>V</given-names></name><name><surname>Nash</surname><given-names>S</given-names></name><name><surname>Kirov</surname><given-names>G</given-names></name><name><surname>Owen</surname><given-names>MJ</given-names></name><name><surname>Wimpory</surname><given-names>DC</given-names></name></person-group>. <article-title>Association of Per1 and Npas2 with autistic disorder: support for the clock genes/social timing hypothesis</article-title>. <source/>Mol Psychiatry (<year>2007</year>) <volume>12</volume>:<fpage>581</fpage>. <pub-id pub-id-type="doi">10.1038/sj.mp.4001953</pub-id><pub-id pub-id-type="pmid">17264841</pub-id></mixed-citation>
</ref>
<ref id="B121">
<label>121.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glickman</surname><given-names>G</given-names></name></person-group>. <article-title>Circadian rhythms and sleep in children with autism</article-title>. <source/>Neurosci Biobehav Rev. (<year>2010</year>) <volume>34</volume>:<fpage>755</fpage>–<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1016/j.neubiorev.2009.11.017</pub-id><pub-id pub-id-type="pmid">19963005</pub-id></mixed-citation>
</ref>
<ref id="B122">
<label>122.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>DJ</given-names></name><name><surname>Chang</surname><given-names>J</given-names></name><name><surname>Chawarska</surname><given-names>K</given-names></name></person-group>. <article-title>Early generalized overgrowth in autism spectrum disorder: prevalence rates, gender effects, and clinical outcomes</article-title>. <source/>J Am Acad Child Adolesc Psychiatry (<year>2014</year>) <volume>53</volume>:<fpage>1063</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaac.2014.07.008</pub-id><pub-id pub-id-type="pmid">25245350</pub-id></mixed-citation>
</ref>
<ref id="B123">
<label>123.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coury</surname><given-names>DL</given-names></name><name><surname>Ashwood</surname><given-names>P</given-names></name><name><surname>Fasano</surname><given-names>A</given-names></name><name><surname>Fuchs</surname><given-names>G</given-names></name><name><surname>Geraghty</surname><given-names>M</given-names></name><name><surname>Kaul</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Gastrointestinal conditions in children with autism spectrum disorder: developing a research agenda</article-title>. <source/>Pediatrics (<year>2012</year>) <volume>130</volume>(<issue>Suppl. 2</issue>):<fpage>S160</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1542/peds.2012-0900N</pub-id><pub-id pub-id-type="pmid">23118247</pub-id></mixed-citation>
</ref>
<ref id="B124">
<label>124.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parracho</surname><given-names>HMRT</given-names></name><name><surname>Bingham</surname><given-names>MO</given-names></name><name><surname>Gibson</surname><given-names>GR</given-names></name><name><surname>McCartney</surname><given-names>AL</given-names></name></person-group>. <article-title>Differences between the gut microflora of children with autistic spectrum disorders and that of healthy children</article-title>. <source/>J Med Microbiol. (<year>2005</year>) <volume>54</volume>:<fpage>987</fpage>–<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1099/jmm.0.46101-0</pub-id><pub-id pub-id-type="pmid">16157555</pub-id></mixed-citation>
</ref>
<ref id="B125">
<label>125.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McElhanon</surname><given-names>BO</given-names></name><name><surname>McCracken</surname><given-names>C</given-names></name><name><surname>Karpen</surname><given-names>S</given-names></name><name><surname>Sharp</surname><given-names>WG</given-names></name></person-group>. <article-title>Gastrointestinal symptoms in autism spectrum disorder: a meta-analysis</article-title>. <source/>Pediatrics (<year>2014</year>) <volume>133</volume>:<fpage>872</fpage>–<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1542/peds.2013-3995</pub-id><pub-id pub-id-type="pmid">24777214</pub-id></mixed-citation>
</ref>
<ref id="B126">
<label>126.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buie</surname><given-names>T</given-names></name><name><surname>Fuchs</surname><given-names>GJ</given-names></name><name><surname>Furuta</surname><given-names>GT</given-names></name><name><surname>Kooros</surname><given-names>K</given-names></name><name><surname>Levy</surname><given-names>J</given-names></name><name><surname>Lewis</surname><given-names>JD</given-names></name><etal></etal></person-group>. <article-title>Recommendations for evaluation and treatment of common gastrointestinal problems in children with ASDs</article-title>. <source/>Pediatrics (<year>2010</year>) <volume>125</volume>(<issue>Suppl. 1</issue>):<fpage>S19</fpage>–<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1542/peds.2009-1878D</pub-id><pub-id pub-id-type="pmid">20048084</pub-id></mixed-citation>
</ref>
<ref id="B127">
<label>127.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nikolov</surname><given-names>RN</given-names></name><name><surname>Bearss</surname><given-names>KE</given-names></name><name><surname>Lettinga</surname><given-names>J</given-names></name><name><surname>Erickson</surname><given-names>C</given-names></name><name><surname>Rodowski</surname><given-names>M</given-names></name><name><surname>Aman</surname><given-names>MG</given-names></name><etal></etal></person-group>. <article-title>Gastrointestinal symptoms in a sample of children with pervasive developmental disorders</article-title>. <source/>J Autism Dev Disord. (<year>2009</year>) <volume>39</volume>:<fpage>405</fpage>–<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1007/s10803-008-0637-8</pub-id><pub-id pub-id-type="pmid">18791817</pub-id></mixed-citation>
</ref>
<ref id="B128">
<label>128.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazurek</surname><given-names>MO</given-names></name><name><surname>Vasa</surname><given-names>RA</given-names></name><name><surname>Kalb</surname><given-names>LG</given-names></name><name><surname>Kanne</surname><given-names>SM</given-names></name><name><surname>Rosenberg</surname><given-names>D</given-names></name><name><surname>Keefer</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Anxiety, sensory over-responsivity, and gastrointestinal problems in children with autism spectrum disorders</article-title>. <source/>J Abnorm Child Psychol. (<year>2013</year>) <volume>41</volume>:<fpage>165</fpage>–<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1007/s10802-012-9668-x</pub-id><pub-id pub-id-type="pmid">22850932</pub-id></mixed-citation>
</ref>
<ref id="B129">
<label>129.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazefsky</surname><given-names>CA</given-names></name><name><surname>Schreiber</surname><given-names>DR</given-names></name><name><surname>Olino</surname><given-names>TM</given-names></name><name><surname>Minshew</surname><given-names>NJ</given-names></name></person-group>. <article-title>The association between emotional and behavioral problems and gastrointestinal symptoms among children with high-functioning autism</article-title>. <source/>Autism (<year>2014</year>) <volume>18</volume>:<fpage>493</fpage>–<lpage>501</lpage>. <pub-id pub-id-type="doi">10.1177/1362361313485164</pub-id><pub-id pub-id-type="pmid">24104507</pub-id></mixed-citation>
</ref>
<ref id="B130">
<label>130.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chandler</surname><given-names>S</given-names></name><name><surname>Carcani-Rathwell</surname><given-names>I</given-names></name><name><surname>Charman</surname><given-names>T</given-names></name><name><surname>Pickles</surname><given-names>A</given-names></name><name><surname>Loucas</surname><given-names>T</given-names></name><name><surname>Meldrum</surname><given-names>D</given-names></name><etal></etal></person-group>. <article-title>Parent-reported gastro-intestinal symptoms in children with autism spectrum disorders</article-title>. <source/>J Autism Dev Disord. (<year>2013</year>) <volume>43</volume>:<fpage>2737</fpage>–<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1007/s10803-013-1768-0</pub-id><pub-id pub-id-type="pmid">23371507</pub-id></mixed-citation>
</ref>
<ref id="B131">
<label>131.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prosperi</surname><given-names>M</given-names></name><name><surname>Santocchi</surname><given-names>E</given-names></name><name><surname>Balboni</surname><given-names>G</given-names></name><name><surname>Narzisi</surname><given-names>A</given-names></name><name><surname>Bozza</surname><given-names>M</given-names></name><name><surname>Fulceri</surname><given-names>F</given-names></name><etal></etal></person-group>
<article-title>Behavioral phenotype of ASD preschoolers with gastrointestinal symptoms or food selectivity</article-title>. <source/>J Autism Dev Disord. (<year>2017</year>) <volume>47</volume>:<fpage>3574</fpage>–<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1007/s10803-017-3271-5</pub-id><pub-id pub-id-type="pmid">28861653</pub-id></mixed-citation>
</ref>
<ref id="B132">
<label>132.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geraghty</surname><given-names>ME</given-names></name><name><surname>Depasquale</surname><given-names>GM</given-names></name><name><surname>Lane</surname><given-names>AE</given-names></name></person-group>
<article-title>Nutritional intake and therapies in autism: a spectrum of what we know: part 1</article-title>. <source/>ICAN Infant Child Adolesc Nutr. (<year>2010</year>) <volume>2</volume>:<fpage>62</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1177/1941406409358437</pub-id></mixed-citation>
</ref>
<ref id="B133">
<label>133.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaidez</surname><given-names>V</given-names></name><name><surname>Hansen</surname><given-names>RL</given-names></name><name><surname>Hertz-Picciotto</surname><given-names>I</given-names></name></person-group>
<article-title>Gastrointestinal problems in children with autism, developmental delays or typical development</article-title>. <source/>J Autism Dev Disord. (<year>2014</year>) <volume>44</volume>:<fpage>1117</fpage>–<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1007/s10803-013-1973-x</pub-id><pub-id pub-id-type="pmid">24193577</pub-id></mixed-citation>
</ref>
<ref id="B134">
<label>134.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maenner</surname><given-names>MJ</given-names></name><name><surname>Arneson</surname><given-names>CL</given-names></name><name><surname>Levy</surname><given-names>SE</given-names></name><name><surname>Kirby</surname><given-names>RS</given-names></name><name><surname>Nicholas</surname><given-names>JS</given-names></name><name><surname>Durkin</surname><given-names>MS</given-names></name></person-group>. <article-title>Brief report: association between behavioral features and gastrointestinal problems among children with autism spectrum disorder</article-title>. <source/>J Autism Dev Disord. (<year>2012</year>) <volume>42</volume>:<fpage>1520</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1007/s10803-011-1379-6</pub-id><pub-id pub-id-type="pmid">22012246</pub-id></mixed-citation>
</ref>
<ref id="B135">
<label>135.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molloy</surname><given-names>CA</given-names></name><name><surname>Manning-Courtney</surname><given-names>P</given-names></name></person-group>. <article-title>Prevalence of chronic gastrointestinal symptoms in children with autism and autistic spectrum disorders</article-title>. <source/>Autism (<year>2003</year>) <volume>7</volume>:<fpage>165</fpage>–<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1177/1362361303007002004</pub-id><pub-id pub-id-type="pmid">12846385</pub-id></mixed-citation>
</ref>
<ref id="B136">
<label>136.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorrindo</surname><given-names>P</given-names></name><name><surname>Williams</surname><given-names>KC</given-names></name><name><surname>Lee</surname><given-names>EB</given-names></name><name><surname>Walker</surname><given-names>LS</given-names></name><name><surname>McGrew</surname><given-names>SG</given-names></name><name><surname>Levitt</surname><given-names>P</given-names></name></person-group>. <article-title>Gastrointestinal dysfunction in autism: parental report, clinical evaluation, and associated factors</article-title>. <source/>Autism Res. (<year>2012</year>) <volume>5</volume>:<fpage>101</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1002/aur.237</pub-id><pub-id pub-id-type="pmid">22511450</pub-id></mixed-citation>
</ref>
<ref id="B137">
<label>137.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>LW</given-names></name><name><surname>Tancredi</surname><given-names>DJ</given-names></name><name><surname>Thomas</surname><given-names>DW</given-names></name></person-group>. <article-title>The prevalence of gastrointestinal problems in children across the United States with autism spectrum disorders from families with multiple affected members</article-title>. <source/>J Dev Behav Pediatr. (<year>2011</year>) <volume>32</volume>:<fpage>351</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1097/DBP.0b013e31821bd06a</pub-id><pub-id pub-id-type="pmid">21555957</pub-id></mixed-citation>
</ref>
<ref id="B138">
<label>138.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sathe</surname><given-names>N</given-names></name><name><surname>Andrews</surname><given-names>JC</given-names></name><name><surname>McPheeters</surname><given-names>ML</given-names></name><name><surname>Warren</surname><given-names>ZE</given-names></name></person-group>. <article-title>Nutritional and dietary interventions for autism spectrum disorder: a systematic review</article-title>. <source/>Pediatrics (<year>2017</year>) <volume>139</volume>:<fpage>e20170346</fpage>. <pub-id pub-id-type="doi">10.1542/peds.2017-0346</pub-id><pub-id pub-id-type="pmid">28562286</pub-id></mixed-citation>
</ref>
<ref id="B139">
<label>139.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hediger</surname><given-names>ML</given-names></name><name><surname>England</surname><given-names>LJ</given-names></name><name><surname>Molloy</surname><given-names>CA</given-names></name><name><surname>Yu</surname><given-names>KF</given-names></name><name><surname>Manning-Courtney</surname><given-names>P</given-names></name><name><surname>Mills</surname><given-names>JL</given-names></name></person-group>
<article-title>Reduced bone cortical thickness in boys with autism or autism spectrum disorder</article-title>. <source/>J Autism Dev Disord. (<year>2008</year>) <volume>38</volume>:<fpage>848</fpage>–<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1007/s10803-007-0453-6</pub-id><pub-id pub-id-type="pmid">17879151</pub-id></mixed-citation>
</ref>
<ref id="B140">
<label>140.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>BL</given-names></name><name><surname>Hornig</surname><given-names>M</given-names></name><name><surname>Buie</surname><given-names>T</given-names></name><name><surname>Bauman</surname><given-names>ML</given-names></name><name><surname>Cho Paik</surname><given-names>M</given-names></name><name><surname>Wick</surname><given-names>I</given-names></name><etal></etal></person-group>. <article-title>Impaired carbohydrate digestion and transport and mucosal dysbiosis in the intestines of children with autism and gastrointestinal disturbances</article-title>. <source/>PLoS ONE (<year>2011</year>) <volume>6</volume>:<fpage>e24585</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0024585</pub-id><pub-id pub-id-type="pmid">21949732</pub-id></mixed-citation>
</ref>
<ref id="B141">
<label>141.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gondalia</surname><given-names>S V</given-names></name><name><surname>Palombo</surname><given-names>EA</given-names></name><name><surname>Knowles</surname><given-names>SR</given-names></name><name><surname>Cox</surname><given-names>SB</given-names></name><name><surname>Meyer</surname><given-names>D</given-names></name><name><surname>Austin</surname><given-names>DW</given-names></name></person-group>. <article-title>Molecular characterisation of gastrointestinal microbiota of children with autism (with and without gastrointestinal dysfunction) and their neurotypical siblings</article-title>. <source/>Autism Res. (<year>2012</year>) <volume>5</volume>:<fpage>419</fpage>–<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1002/aur.1253</pub-id><pub-id pub-id-type="pmid">22997101</pub-id></mixed-citation>
</ref>
<ref id="B142">
<label>142.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>D-W</given-names></name><name><surname>Park</surname><given-names>JG</given-names></name><name><surname>Ilhan</surname><given-names>ZE</given-names></name><name><surname>Wallstrom</surname><given-names>G</given-names></name><name><surname>LaBaer</surname><given-names>J</given-names></name><name><surname>Adams</surname><given-names>JB</given-names></name><etal></etal></person-group>. <article-title>Reduced incidence of Prevotella and other fermenters in intestinal microflora of autistic children</article-title>. <source/>PLoS ONE (<year>2013</year>) <volume>8</volume>:<fpage>e68322</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0068322</pub-id><pub-id pub-id-type="pmid">23844187</pub-id></mixed-citation>
</ref>
<ref id="B143">
<label>143.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finegold</surname><given-names>SM</given-names></name><name><surname>Dowd</surname><given-names>SE</given-names></name><name><surname>Gontcharova</surname><given-names>V</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Henley</surname><given-names>KE</given-names></name><name><surname>Wolcott</surname><given-names>RD</given-names></name><etal></etal></person-group>. <article-title>Pyrosequencing study of fecal microflora of autistic and control children</article-title>. <source/>Anaerobe (<year>2010</year>) <volume>16</volume>:<fpage>444</fpage>–<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1016/j.anaerobe.2010.06.008</pub-id><pub-id pub-id-type="pmid">20603222</pub-id></mixed-citation>
</ref>
<ref id="B144">
<label>144.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Louis</surname><given-names>P</given-names></name></person-group>. <article-title>Does the human gut microbiota contribute to the etiology of autism spectrum disorders?</article-title>
<source/>Dig Dis Sci. (<year>2012</year>) <volume>57</volume>:<fpage>1987</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1007/s10620-012-2286-1</pub-id><pub-id pub-id-type="pmid">22736019</pub-id></mixed-citation>
</ref>
<ref id="B145">
<label>145.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>D-W</given-names></name><name><surname>Adams</surname><given-names>JB</given-names></name><name><surname>Gregory</surname><given-names>AC</given-names></name><name><surname>Borody</surname><given-names>T</given-names></name><name><surname>Chittick</surname><given-names>L</given-names></name><name><surname>Fasano</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Microbiota transfer therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study</article-title>. <source/>Microbiome (<year>2017</year>) <volume>5</volume>:<fpage>10</fpage>. <pub-id pub-id-type="doi">10.1186/s40168-016-0225-7</pub-id><pub-id pub-id-type="pmid">28122648</pub-id></mixed-citation>
</ref>
<ref id="B146">
<label>146.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>HT</given-names></name><name><surname>Taur</surname><given-names>Y</given-names></name><name><surname>Walkup</surname><given-names>JT</given-names></name></person-group>. <article-title>Gut microbiota and autism: key concepts and findings</article-title>. <source/>J Autism Dev Disord. (<year>2017</year>) <volume>47</volume>:<fpage>480</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1007/s10803-016-2960-9</pub-id><pub-id pub-id-type="pmid">27882443</pub-id></mixed-citation>
</ref>
<ref id="B147">
<label>147.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Dy</surname><given-names>ABC</given-names></name><name><surname>Hagerman</surname><given-names>RJ</given-names></name></person-group>. <article-title>The gut microbiota and autism spectrum disorders</article-title>. <source/>Front Cell Neurosci. (<year>2017</year>) <volume>11</volume>:<fpage>120</fpage>. <pub-id pub-id-type="doi">10.3389/fncel.2017.00120</pub-id><pub-id pub-id-type="pmid">28503135</pub-id></mixed-citation>
</ref>
<ref id="B148">
<label>148.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulloy</surname><given-names>A</given-names></name><name><surname>Lang</surname><given-names>R</given-names></name><name><surname>O'Reilly</surname><given-names>M</given-names></name><name><surname>Sigafoos</surname><given-names>J</given-names></name><name><surname>Lancioni</surname><given-names>G</given-names></name><name><surname>Rispoli</surname><given-names>M</given-names></name></person-group>
<article-title>Gluten-free and casein-free diets in the treatment of autism spectrum disorders: a systematic review</article-title>. <source/>Res Autism Spectr Disord. (<year>2010</year>) <volume>4</volume>:<fpage>328</fpage>–<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1016/j.rasd.2009.10.008</pub-id></mixed-citation>
</ref>
<ref id="B149">
<label>149.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Theije</surname><given-names>CGM</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>da Silva</surname><given-names>SL</given-names></name><name><surname>Kamphuis</surname><given-names>PJ</given-names></name><name><surname>Garssen</surname><given-names>J</given-names></name><name><surname>Korte</surname><given-names>SM</given-names></name><etal></etal></person-group>. <article-title>Pathways underlying the gut-to-brain connection in autism spectrum disorders as future targets for disease management</article-title>. <source/>Eur J Pharmacol. (<year>2011</year>) <volume>668</volume>(<issue>Suppl. 1</issue>):<fpage>S70</fpage>–<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2011.07.013</pub-id><pub-id pub-id-type="pmid">21810417</pub-id></mixed-citation>
</ref>
<ref id="B150">
<label>150.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Israelyan</surname><given-names>N</given-names></name><name><surname>Margolis</surname><given-names>KG</given-names></name></person-group>. <article-title>Serotonin as a link between the gut-brain-microbiome axis in autism spectrum disorders</article-title>. <source/>Pharmacol Res. (<year>2018</year>) <volume>132</volume>:<fpage>1</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2018.03.020</pub-id><pub-id pub-id-type="pmid">29614380</pub-id></mixed-citation>
</ref>
<ref id="B151">
<label>151.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chugani</surname><given-names>DC</given-names></name><name><surname>Muzik</surname><given-names>O</given-names></name><name><surname>Behen</surname><given-names>M</given-names></name><name><surname>Rothermel</surname><given-names>R</given-names></name><name><surname>Janisse</surname><given-names>JJ</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children</article-title>. <source/>Ann Neurol. (<year>1999</year>) <volume>45</volume>:<fpage>287</fpage>–<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1002/1531-8249(199903)45:3&lt;287::AID-ANA3&gt;3.0.CO;2-9</pub-id><pub-id pub-id-type="pmid">10072042</pub-id></mixed-citation>
</ref>
<ref id="B152">
<label>152.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayer</surname><given-names>EA</given-names></name></person-group>. <article-title>Gut feelings: the emerging biology of gut-brain communication</article-title>. <source/>Nat Rev Neurosci. (<year>2011</year>) <volume>12</volume>:<fpage>453</fpage>–<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1038/nrn3071</pub-id><pub-id pub-id-type="pmid">21750565</pub-id></mixed-citation>
</ref>
<ref id="B153">
<label>153.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Palma</surname><given-names>G</given-names></name><name><surname>Collins</surname><given-names>SM</given-names></name><name><surname>Bercik</surname><given-names>P</given-names></name><name><surname>Verdu</surname><given-names>EF</given-names></name></person-group>. <article-title>The microbiota–gut–brain axis in gastrointestinal disorders: stressed bugs, stressed brain or both?</article-title>
<source/>J Physiol. (<year>2014</year>) <volume>592</volume>:<fpage>2989</fpage>–<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1113/jphysiol.2014.273995</pub-id><pub-id pub-id-type="pmid">24756641</pub-id></mixed-citation>
</ref>
<ref id="B154">
<label>154.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>K</given-names></name><name><surname>Wheeler</surname><given-names>DM</given-names></name><name><surname>Silove</surname><given-names>N</given-names></name><name><surname>Hazell</surname><given-names>P</given-names></name></person-group>
<article-title>Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)</article-title>. <source/>Cochrane Database Syst Rev. (<year>2013</year>) <volume>6</volume>:<fpage>CD004677</fpage>
<pub-id pub-id-type="doi">10.1002/14651858.CD004677.pub3</pub-id></mixed-citation>
</ref>
<ref id="B155">
<label>155.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>DB</given-names></name><name><surname>Buie</surname><given-names>TM</given-names></name><name><surname>Winter</surname><given-names>H</given-names></name><name><surname>Bauman</surname><given-names>M</given-names></name><name><surname>Sutcliffe</surname><given-names>JS</given-names></name><name><surname>Perrin</surname><given-names>JM</given-names></name><etal></etal></person-group>. <article-title>Distinct genetic risk based on association of MET in families with co-occurring autism and gastrointestinal conditions</article-title>. <source/>Pediatrics (<year>2009</year>) <volume>123</volume>:<fpage>1018</fpage>–<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1542/peds.2008-0819</pub-id><pub-id pub-id-type="pmid">19255034</pub-id></mixed-citation>
</ref>
<ref id="B156">
<label>156.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>DB</given-names></name><name><surname>D'Oronzio</surname><given-names>R</given-names></name><name><surname>Garbett</surname><given-names>K</given-names></name><name><surname>Ebert</surname><given-names>PJ</given-names></name><name><surname>Mirnics</surname><given-names>K</given-names></name><name><surname>Levitt</surname><given-names>P</given-names></name><etal></etal></person-group>. <article-title>Disruption of cerebral cortex MET signaling in autism spectrum disorder</article-title>. <source/>Ann Neurol Off J Am Neurol Assoc Child Neurol Soc. (<year>2007</year>) <volume>62</volume>:<fpage>243</fpage>–<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1002/ana.21180</pub-id><pub-id pub-id-type="pmid">17696172</pub-id></mixed-citation>
</ref>
<ref id="B157">
<label>157.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prasad</surname><given-names>HC</given-names></name><name><surname>Steiner</surname><given-names>JA</given-names></name><name><surname>Sutcliffe</surname><given-names>JS</given-names></name><name><surname>Blakely</surname><given-names>RD</given-names></name></person-group>. <article-title>Enhanced activity of human serotonin transporter variants associated with autism</article-title>. <source/>Philos Trans R Soc B Biol Sci. (<year>2009</year>) <volume>364</volume>:<fpage>163</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1098/rstb.2008.0143</pub-id><pub-id pub-id-type="pmid">18957375</pub-id></mixed-citation>
</ref>
<ref id="B158">
<label>158.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berger</surname><given-names>M</given-names></name><name><surname>Gray</surname><given-names>JA</given-names></name><name><surname>Roth</surname><given-names>BL</given-names></name></person-group>. <article-title>The expanded biology of serotonin</article-title>. <source/>Annu Rev Med. (<year>2009</year>) <volume>60</volume>:<fpage>355</fpage>–<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.med.60.042307.110802</pub-id><pub-id pub-id-type="pmid">19630576</pub-id></mixed-citation>
</ref>
<ref id="B159">
<label>159.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veenstra-VanderWeele</surname><given-names>J</given-names></name><name><surname>Muller</surname><given-names>CL</given-names></name><name><surname>Iwamoto</surname><given-names>H</given-names></name><name><surname>Sauer</surname><given-names>JE</given-names></name><name><surname>Owens</surname><given-names>WA</given-names></name><name><surname>Shah</surname><given-names>CR</given-names></name><etal></etal></person-group>. <article-title>Autism gene variant causes hyperserotonemia, serotonin receptor hypersensitivity, social impairment and repetitive behavior</article-title>. <source/>Proc Natl Acad Sci USA. (<year>2012</year>) <volume>109</volume>:<fpage>5469</fpage>–<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1112345109</pub-id><pub-id pub-id-type="pmid">22431635</pub-id></mixed-citation>
</ref>
<ref id="B160">
<label>160.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Margolis</surname><given-names>KG</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Stevanovic</surname><given-names>K</given-names></name><name><surname>Saurman</surname><given-names>V</given-names></name><name><surname>Israelyan</surname><given-names>N</given-names></name><name><surname>Anderson</surname><given-names>GM</given-names></name><etal></etal></person-group>. <article-title>Serotonin transporter variant drives preventable gastrointestinal abnormalities in development and function</article-title>. <source/>J Clin Invest. (<year>2016</year>) <volume>126</volume>:<fpage>2221</fpage>–<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1172/JCI84877</pub-id><pub-id pub-id-type="pmid">27111230</pub-id></mixed-citation>
</ref>
<ref id="B161">
<label>161.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atladóttir</surname><given-names>HÓ</given-names></name><name><surname>Pedersen</surname><given-names>MG</given-names></name><name><surname>Thorsen</surname><given-names>P</given-names></name><name><surname>Mortensen</surname><given-names>PB</given-names></name><name><surname>Deleuran</surname><given-names>B</given-names></name><name><surname>Eaton</surname><given-names>WW</given-names></name><etal></etal></person-group>. <article-title>Association of family history of autoimmune diseases and autism spectrum disorders</article-title>. <source/>Pediatrics (<year>2009</year>) <volume>124</volume>:<fpage>687</fpage>–<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1542/peds.2008-2445</pub-id><pub-id pub-id-type="pmid">19581261</pub-id></mixed-citation>
</ref>
<ref id="B162">
<label>162.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Comi</surname><given-names>AM</given-names></name><name><surname>Zimmerman</surname><given-names>AW</given-names></name><name><surname>Frye</surname><given-names>VH</given-names></name><name><surname>Law</surname><given-names>PA</given-names></name><name><surname>Peeden</surname><given-names>JN</given-names></name></person-group>. <article-title>Familial clustering of autoimmune disorders and evaluation of medical risk factors in autism</article-title>. <source/>J Child Neurol. (<year>1999</year>) <volume>14</volume>:<fpage>388</fpage>–<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1177/088307389901400608</pub-id><pub-id pub-id-type="pmid">10385847</pub-id></mixed-citation>
</ref>
<ref id="B163">
<label>163.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Enstrom</surname><given-names>AM</given-names></name><name><surname>Van de Water</surname><given-names>JA</given-names></name><name><surname>Ashwood</surname><given-names>P</given-names></name></person-group>. <article-title>Autoimmunity in autism</article-title>. <source/>Curr Opin Investig Drugs (<year>2009</year>) <volume>10</volume>:<fpage>463</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="pmid">19431079</pub-id></mixed-citation>
</ref>
<ref id="B164">
<label>164.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valicenti-McDermott</surname><given-names>M</given-names></name><name><surname>McVicar</surname><given-names>K</given-names></name><name><surname>Rapin</surname><given-names>I</given-names></name><name><surname>Wershil</surname><given-names>BK</given-names></name><name><surname>Cohen</surname><given-names>H</given-names></name><name><surname>Shinnar</surname><given-names>S</given-names></name></person-group>. <article-title>Frequency of gastrointestinal symptoms in children with autistic spectrum disorders and association with family history of autoimmune disease</article-title>. <source/>J Dev Behav Pediatr. (<year>2006</year>) <volume>27</volume>(<issue>Suppl. 2</issue>):<fpage>S128</fpage>–<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1097/00004703-200604002-00011</pub-id><pub-id pub-id-type="pmid">16685179</pub-id></mixed-citation>
</ref>
<ref id="B165">
<label>165.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wills</surname><given-names>S</given-names></name><name><surname>Cabanlit</surname><given-names>M</given-names></name><name><surname>Bennett</surname><given-names>J</given-names></name><name><surname>Ashwood</surname><given-names>P</given-names></name><name><surname>Amaral</surname><given-names>DG</given-names></name><name><surname>Van de Water</surname><given-names>J</given-names></name></person-group>. <article-title>Detection of autoantibodies to neural cells of the cerebellum in the plasma of subjects with autism spectrum disorders</article-title>. <source/>Brain Behav Immun. (<year>2009</year>) <volume>23</volume>:<fpage>64</fpage>–<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2008.07.007</pub-id><pub-id pub-id-type="pmid">18706993</pub-id></mixed-citation>
</ref>
<ref id="B166">
<label>166.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Croen</surname><given-names>LA</given-names></name><name><surname>Braunschweig</surname><given-names>D</given-names></name><name><surname>Haapanen</surname><given-names>L</given-names></name><name><surname>Yoshida</surname><given-names>CK</given-names></name><name><surname>Fireman</surname><given-names>B</given-names></name><name><surname>Grether</surname><given-names>JK</given-names></name><etal></etal></person-group>. <article-title>Maternal mid-pregnancy autoantibodies to fetal brain protein: the early markers for autism study</article-title>. <source/>Biol Psychiatry (<year>2008</year>) <volume>64</volume>:<fpage>583</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2008.05.006</pub-id><pub-id pub-id-type="pmid">18571628</pub-id></mixed-citation>
</ref>
<ref id="B167">
<label>167.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singer</surname><given-names>HS</given-names></name><name><surname>Morris</surname><given-names>CM</given-names></name><name><surname>Gause</surname><given-names>CD</given-names></name><name><surname>Gillin</surname><given-names>PK</given-names></name><name><surname>Crawford</surname><given-names>S</given-names></name><name><surname>Zimmerman</surname><given-names>AW</given-names></name></person-group>. <article-title>Antibodies against fetal brain in sera of mothers with autistic children</article-title>. <source/>J Neuroimmunol. (<year>2008</year>) <volume>194</volume>:<fpage>165</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1016/j.jneuroim.2007.11.004</pub-id><pub-id pub-id-type="pmid">18093664</pub-id></mixed-citation>
</ref>
<ref id="B168">
<label>168.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zimmerman</surname><given-names>AW</given-names></name><name><surname>Connors</surname><given-names>SL</given-names></name><name><surname>Matteson</surname><given-names>KJ</given-names></name><name><surname>Lee</surname><given-names>LC</given-names></name><name><surname>Singer</surname><given-names>HS</given-names></name><name><surname>Castaneda</surname><given-names>JA</given-names></name><etal></etal></person-group>. <article-title>Maternal antibrain antibodies in autism</article-title>. <source/>Brain Behav Immun. (<year>2007</year>) <volume>21</volume>:<fpage>351</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2006.08.005</pub-id><pub-id pub-id-type="pmid">17029701</pub-id></mixed-citation>
</ref>
<ref id="B169">
<label>169.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heuer</surname><given-names>L</given-names></name><name><surname>Braunschweig</surname><given-names>D</given-names></name><name><surname>Ashwood</surname><given-names>P</given-names></name><name><surname>Van de Water</surname><given-names>J</given-names></name><name><surname>Campbell</surname><given-names>DB</given-names></name></person-group>. <article-title>Association of a MET genetic variant with autism-associated maternal autoantibodies to fetal brain proteins and cytokine expression</article-title>. <source/>Transl Psychiatry (<year>2011</year>) <volume>1</volume>:<fpage>e48</fpage>. <pub-id pub-id-type="doi">10.1038/tp.2011.48</pub-id><pub-id pub-id-type="pmid">22833194</pub-id></mixed-citation>
</ref>
<ref id="B170">
<label>170.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moynihan</surname><given-names>JA</given-names></name><name><surname>Santiago</surname><given-names>FM</given-names></name></person-group>. <article-title>Brain behavior and immunity: twenty years of T cells</article-title>. <source/>Brain Behav Immun. (<year>2007</year>) <volume>21</volume>:<fpage>872</fpage>–<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2007.06.010</pub-id><pub-id pub-id-type="pmid">17681745</pub-id></mixed-citation>
</ref>
<ref id="B171">
<label>171.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>M-H</given-names></name><name><surname>Su</surname><given-names>T-P</given-names></name><name><surname>Chen</surname><given-names>Y-S</given-names></name><name><surname>Hsu</surname><given-names>J-W</given-names></name><name><surname>Huang</surname><given-names>K-L</given-names></name><name><surname>Chang</surname><given-names>W-H</given-names></name><etal></etal></person-group>
<article-title>Comorbidity of allergic and autoimmune diseases in patients with autism spectrum disorder: a nationwide population-based study</article-title>. <source/>Res Autism Spectr Disord. (<year>2013</year>) <volume>7</volume>:<fpage>205</fpage>–<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1016/j.rasd.2012.08.008</pub-id></mixed-citation>
</ref>
<ref id="B172">
<label>172.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyazaki</surname><given-names>C</given-names></name><name><surname>Koyama</surname><given-names>M</given-names></name><name><surname>Ota</surname><given-names>E</given-names></name><name><surname>Swa</surname><given-names>T</given-names></name><name><surname>Amiya</surname><given-names>RM</given-names></name><name><surname>Mlunde</surname><given-names>LB</given-names></name><etal></etal></person-group>
<article-title>Allergies in children with autism spectrum disorder: a systematic review and meta-analysis</article-title>. Rev <source/>J Autism Dev Disord. (<year>2015</year>) <volume>2</volume>:<fpage>374</fpage>–<lpage>401</lpage>. <pub-id pub-id-type="doi">10.1007/s40489-015-0059-4</pub-id></mixed-citation>
</ref>
<ref id="B173">
<label>173.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zerbo</surname><given-names>O</given-names></name><name><surname>Leong</surname><given-names>A</given-names></name><name><surname>Barcellos</surname><given-names>L</given-names></name><name><surname>Bernal</surname><given-names>P</given-names></name><name><surname>Fireman</surname><given-names>B</given-names></name><name><surname>Croen</surname><given-names>LA</given-names></name></person-group>. <article-title>Immune mediated conditions in autism spectrum disorders</article-title>. <source/>Brain Behav Immun. (<year>2015</year>) <volume>46</volume>:<fpage>232</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2015.02.001</pub-id><pub-id pub-id-type="pmid">25681541</pub-id></mixed-citation>
</ref>
<ref id="B174">
<label>174.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gurney</surname><given-names>JG</given-names></name><name><surname>McPheeters</surname><given-names>ML</given-names></name><name><surname>Davis</surname><given-names>MM</given-names></name></person-group>. <article-title>Parental report of health conditions and health care use among children with and without autism: National Survey of Children's Health</article-title>. <source/>Arch Pediatr Adolesc Med. (<year>2006</year>) <volume>160</volume>:<fpage>825</fpage>–<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1001/archpedi.160.8.825</pub-id><pub-id pub-id-type="pmid">16894082</pub-id></mixed-citation>
</ref>
<ref id="B175">
<label>175.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>M-H</given-names></name><name><surname>Su</surname><given-names>T-P</given-names></name><name><surname>Chen</surname><given-names>Y-S</given-names></name><name><surname>Hsu</surname><given-names>J-W</given-names></name><name><surname>Huang</surname><given-names>K-L</given-names></name><name><surname>Chang</surname><given-names>W-H</given-names></name><etal></etal></person-group>. <article-title>Is atopy in early childhood a risk factor for ADHD and ASD? A longitudinal study</article-title>. <source/>J Psychosom Res. (<year>2014</year>) <volume>77</volume>:<fpage>316</fpage>–<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1016/j.jpsychores.2014.06.006</pub-id><pub-id pub-id-type="pmid">25280829</pub-id></mixed-citation>
</ref>
<ref id="B176">
<label>176.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashwood</surname><given-names>P</given-names></name><name><surname>Krakowiak</surname><given-names>P</given-names></name><name><surname>Hertz-Picciotto</surname><given-names>I</given-names></name><name><surname>Hansen</surname><given-names>R</given-names></name><name><surname>Pessah</surname><given-names>IN</given-names></name><name><surname>Van de Water</surname><given-names>J</given-names></name></person-group>. <article-title>Associations of impaired behaviors with elevated plasma chemokines in autism spectrum disorders</article-title>. <source/>J Neuroimmunol. (<year>2011</year>) <volume>232</volume>:<fpage>196</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.jneuroim.2010.10.025</pub-id><pub-id pub-id-type="pmid">21095018</pub-id></mixed-citation>
</ref>
<ref id="B177">
<label>177.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashim</surname><given-names>H</given-names></name><name><surname>Abdelrahman</surname><given-names>H</given-names></name><name><surname>Mohammed</surname><given-names>D</given-names></name><name><surname>Karam</surname><given-names>R</given-names></name></person-group>
<article-title>Association between plasma levels of transforming growth factor-β1, IL-23 and IL-17 and the severity of autism in Egyptian children</article-title>. <source/>Res Autism Spectr Disord. (<year>2013</year>) <volume>7</volume>:<fpage>199</fpage>–<lpage>204</lpage>. <pub-id pub-id-type="doi">10.1016/j.rasd.2012.08.007</pub-id></mixed-citation>
</ref>
<ref id="B178">
<label>178.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashwood</surname><given-names>P</given-names></name><name><surname>Enstrom</surname><given-names>A</given-names></name><name><surname>Krakowiak</surname><given-names>P</given-names></name><name><surname>Hertz-Picciotto</surname><given-names>I</given-names></name><name><surname>Hansen</surname><given-names>RL</given-names></name><name><surname>Croen</surname><given-names>LA</given-names></name><etal></etal></person-group>. <article-title>Decreased transforming growth factor beta1 in autism: a potential link between immune dysregulation and impairment in clinical behavioral outcomes</article-title>. <source/>J Neuroimmunol. (<year>2008</year>) <volume>204</volume>:<fpage>149</fpage>–<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1016/j.jneuroim.2008.07.006</pub-id><pub-id pub-id-type="pmid">18762342</pub-id></mixed-citation>
</ref>
<ref id="B179">
<label>179.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Ayadhi</surname><given-names>LY</given-names></name><name><surname>Mostafa</surname><given-names>GA</given-names></name></person-group>. <article-title>Elevated serum levels of interleukin-17A in children with autism</article-title>. <source/>J Neuroinflammation (<year>2012</year>) <volume>9</volume>:<fpage>158</fpage>. <pub-id pub-id-type="doi">10.1186/1742-2094-9-158</pub-id><pub-id pub-id-type="pmid">22748016</pub-id></mixed-citation>
</ref>
<ref id="B180">
<label>180.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masi</surname><given-names>A</given-names></name><name><surname>Breen</surname><given-names>EJ</given-names></name><name><surname>Alvares</surname><given-names>GA</given-names></name><name><surname>Glozier</surname><given-names>N</given-names></name><name><surname>Hickie</surname><given-names>IB</given-names></name><name><surname>Hunt</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Cytokine levels and associations with symptom severity in male and female children with autism spectrum disorder</article-title>. <source/>Mol Autism. (<year>2017</year>) <volume>8</volume>:<fpage>63</fpage>. <pub-id pub-id-type="doi">10.1186/s13229-017-0176-2</pub-id><pub-id pub-id-type="pmid">29214007</pub-id></mixed-citation>
</ref>
<ref id="B181">
<label>181.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molloy</surname><given-names>CA</given-names></name><name><surname>Morrow</surname><given-names>AL</given-names></name><name><surname>Meinzen-Derr</surname><given-names>J</given-names></name><name><surname>Dawson</surname><given-names>G</given-names></name><name><surname>Bernier</surname><given-names>R</given-names></name><name><surname>Dunn</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Familial autoimmune thyroid disease as a risk factor for regression in children with autism spectrum disorder: a CPEA study</article-title>. <source/>J Autism Dev Disord. (<year>2006</year>) <volume>36</volume>:<fpage>317</fpage>–<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1007/s10803-005-0071-0</pub-id><pub-id pub-id-type="pmid">16598435</pub-id></mixed-citation>
</ref>
<ref id="B182">
<label>182.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>JE</given-names></name><name><surname>Widjaja</surname><given-names>F</given-names></name><name><surname>Careaga</surname><given-names>M</given-names></name><name><surname>Bent</surname><given-names>S</given-names></name><name><surname>Ashwood</surname><given-names>P</given-names></name><name><surname>Hendren</surname><given-names>RL</given-names></name></person-group>. <article-title>Change in plasma cytokine levels during risperidone treatment in children with autism</article-title>. <source/>J Child Adolesc Psychopharmacol. (<year>2014</year>) <volume>24</volume>:<fpage>586</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1089/cap.2013.0108</pub-id><pub-id pub-id-type="pmid">24828014</pub-id></mixed-citation>
</ref>
<ref id="B183">
<label>183.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tobiasova</surname><given-names>Z</given-names></name><name><surname>van der Lingen</surname><given-names>KHB</given-names></name><name><surname>Scahill</surname><given-names>L</given-names></name><name><surname>Leckman</surname><given-names>JF</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Chae</surname><given-names>W</given-names></name><etal></etal></person-group>
<article-title>Risperidone-related improvement of irritability in children with autism is not associated with changes in serum of epidermal growth factor and interleukin-13</article-title>. <source/>J Child Adolesc Psychopharmacol. (<year>2011</year>) <volume>21</volume>:<fpage>555</fpage>–<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1089/cap.2010.0134</pub-id><pub-id pub-id-type="pmid">22070180</pub-id></mixed-citation>
</ref>
<ref id="B184">
<label>184.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asadabadi</surname><given-names>M</given-names></name><name><surname>Mohammadi</surname><given-names>MR</given-names></name><name><surname>Ghanizadeh</surname><given-names>A</given-names></name><name><surname>Modabbernia</surname><given-names>A</given-names></name><name><surname>Ashrafi</surname><given-names>M</given-names></name><name><surname>Hassanzadeh</surname><given-names>E</given-names></name><etal></etal></person-group>. <article-title>Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial</article-title>. <source/>Psychopharmacol. (<year>2013</year>) <volume>225</volume>:<fpage>51</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-012-2796-8</pub-id><pub-id pub-id-type="pmid">22782459</pub-id></mixed-citation>
</ref>
<ref id="B185">
<label>185.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chez</surname><given-names>MG</given-names></name><name><surname>Guido-Estrada</surname><given-names>N</given-names></name></person-group>. <article-title>Immune therapy in autism: historical experience and future directions with immunomodulatory therapy</article-title>. <source/>Neurotherapeutics (<year>2010</year>) <volume>7</volume>:<fpage>293</fpage>–<lpage>301</lpage>. <pub-id pub-id-type="doi">10.1016/j.nurt.2010.05.008</pub-id><pub-id pub-id-type="pmid">20643382</pub-id></mixed-citation>
</ref>
<ref id="B186">
<label>186.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDougle</surname><given-names>CJ</given-names></name><name><surname>Landino</surname><given-names>SM</given-names></name><name><surname>Vahabzadeh</surname><given-names>A</given-names></name><name><surname>O'Rourke</surname><given-names>J</given-names></name><name><surname>Zurcher</surname><given-names>NR</given-names></name><name><surname>Finger</surname><given-names>BC</given-names></name><etal></etal></person-group>. <article-title>Toward an immune-mediated subtype of autism spectrum disorder</article-title>. <source/>Brain Res. (<year>2014</year>) <volume>1617</volume>:<fpage>72</fpage>–<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainres.2014.09.048</pub-id><pub-id pub-id-type="pmid">25445995</pub-id></mixed-citation>
</ref>
<ref id="B187">
<label>187.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chez</surname><given-names>MG</given-names></name><name><surname>Loeffel</surname><given-names>M</given-names></name><name><surname>Buchanan</surname><given-names>CP</given-names></name><name><surname>Field-Chez</surname><given-names>M</given-names></name></person-group>
<article-title>Pulse high-dose steroids as combination therapy with valproic acid in epileptic aphasia patients with pervasive developmental delay or autism</article-title>. <source/>Ann Neurol. (<year>1998</year>) <volume>44</volume>:<fpage>539</fpage>.</mixed-citation>
</ref>
<ref id="B188">
<label>188.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chez</surname><given-names>M</given-names></name><name><surname>Low</surname><given-names>R</given-names></name><name><surname>Parise</surname><given-names>C</given-names></name><name><surname>Donnel</surname><given-names>T</given-names></name></person-group>. <article-title>Safety and observations in a pilot study of lenalidomide for treatment in autism</article-title>. <source/>Autism Res Treat. (<year>2012</year>) <volume>2012</volume>:<fpage>291601</fpage>. <pub-id pub-id-type="doi">10.1155/2012/291601</pub-id><pub-id pub-id-type="pmid">22997574</pub-id></mixed-citation>
</ref>
<ref id="B189">
<label>189.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deshmukh</surname><given-names>CT</given-names></name></person-group>. <article-title>Minimizing side effects of systemic corticosteroids in children</article-title>. <source/>Indian J Dermatol Venereol Leprol. (<year>2007</year>) <volume>73</volume>:<fpage>218</fpage>–<lpage>21</lpage>. <pub-id pub-id-type="doi">10.4103/0378-6323.33633</pub-id><pub-id pub-id-type="pmid">17675727</pub-id></mixed-citation>
</ref>
<ref id="B190">
<label>190.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Onore</surname><given-names>C</given-names></name><name><surname>Careaga</surname><given-names>M</given-names></name><name><surname>Ashwood</surname><given-names>P</given-names></name></person-group>. <article-title>The role of immune dysfunction in the pathophysiology of autism</article-title>. <source/>Brain Behav Immun. (<year>2012</year>) <volume>26</volume>:<fpage>383</fpage>–<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2011.08.007</pub-id><pub-id pub-id-type="pmid">21906670</pub-id></mixed-citation>
</ref>
<ref id="B191">
<label>191.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>HK</given-names></name><name><surname>Mills Ko</surname><given-names>E</given-names></name><name><surname>Rose</surname><given-names>D</given-names></name><name><surname>Ashwood</surname><given-names>P</given-names></name></person-group>. <article-title>Immune dysfunction and autoimmunity as pathological mechanisms in autism spectrum disorders</article-title>. <source/>Front Cell Neurosci. (<year>2018</year>) <volume>12</volume>:<fpage>405</fpage>. <pub-id pub-id-type="doi">10.3389/fncel.2018.00405</pub-id><pub-id pub-id-type="pmid">30483058</pub-id></mixed-citation>
</ref>
<ref id="B192">
<label>192.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>S-W</given-names></name><name><surname>Zhong</surname><given-names>X-S</given-names></name><name><surname>Jiang</surname><given-names>L-N</given-names></name><name><surname>Zheng</surname><given-names>X-Y</given-names></name><name><surname>Xiong</surname><given-names>Y-Q</given-names></name><name><surname>Ma</surname><given-names>S-J</given-names></name><etal></etal></person-group>. <article-title>Maternal autoimmune diseases and the risk of autism spectrum disorders in offspring: a systematic review and meta-analysis</article-title>. <source/>Behav Brain Res. (<year>2016</year>) <volume>296</volume>:<fpage>61</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbr.2015.08.035</pub-id><pub-id pub-id-type="pmid">26327239</pub-id></mixed-citation>
</ref>
<ref id="B193">
<label>193.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Ding</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Xie</surname><given-names>G</given-names></name><name><surname>Hou</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>Family history of autoimmune diseases is associated with an increased risk of autism in children: a systematic review and meta-analysis</article-title>. <source/>Neurosci Biobehav Rev. (<year>2015</year>) <volume>55</volume>:<fpage>322</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1016/j.neubiorev.2015.05.004</pub-id><pub-id pub-id-type="pmid">25981892</pub-id></mixed-citation>
</ref>
<ref id="B194">
<label>194.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinto</surname><given-names>D</given-names></name><name><surname>Pagnamenta</surname><given-names>AT</given-names></name><name><surname>Klei</surname><given-names>L</given-names></name><name><surname>Anney</surname><given-names>R</given-names></name><name><surname>Merico</surname><given-names>D</given-names></name><name><surname>Regan</surname><given-names>R</given-names></name><etal></etal></person-group>. <article-title>Functional impact of global rare copy number variation in autism spectrum disorders</article-title>. <source/>Nature (<year>2010</year>) <volume>466</volume>:<fpage>368</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1038/nature09146</pub-id><pub-id pub-id-type="pmid">20531469</pub-id></mixed-citation>
</ref>
<ref id="B195">
<label>195.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Rubeis</surname><given-names>S</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Goldberg</surname><given-names>AP</given-names></name><name><surname>Poultney</surname><given-names>CS</given-names></name><name><surname>Samocha</surname><given-names>K</given-names></name><name><surname>Cicek</surname><given-names>AE</given-names></name><etal></etal></person-group>. <article-title>Synaptic, transcriptional and chromatin genes disrupted in autism</article-title>. <source/>Nature (<year>2014</year>) <volume>515</volume>:<fpage>209</fpage>–<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1038/nature13772</pub-id><pub-id pub-id-type="pmid">25363760</pub-id></mixed-citation>
</ref>
<ref id="B196">
<label>196.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daniels</surname><given-names>WW</given-names></name><name><surname>Warren</surname><given-names>RP</given-names></name><name><surname>Odell</surname><given-names>JD</given-names></name><name><surname>Maciulis</surname><given-names>A</given-names></name><name><surname>Burger</surname><given-names>RA</given-names></name><name><surname>Warren</surname><given-names>WL</given-names></name><etal></etal></person-group>. <article-title>Increased frequency of the extended or ancestral haplotype B44-SC30-DR4 in autism</article-title>. <source/>Neuropsychobiology (<year>1995</year>) <volume>32</volume>:<fpage>120</fpage>–<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1159/000119223</pub-id><pub-id pub-id-type="pmid">8544967</pub-id></mixed-citation>
</ref>
<ref id="B197">
<label>197.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>LC</given-names></name><name><surname>Zachary</surname><given-names>AA</given-names></name><name><surname>Leffell</surname><given-names>MS</given-names></name><name><surname>Newschaffer</surname><given-names>CJ</given-names></name><name><surname>Matteson</surname><given-names>KJ</given-names></name><name><surname>Tyler</surname><given-names>JD</given-names></name><etal></etal></person-group>. <article-title>HLA-DR4 in families with autism</article-title>. <source/>Pediatr Neurol. (<year>2006</year>) <volume>35</volume>:<fpage>303</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2006.06.006</pub-id><pub-id pub-id-type="pmid">17074598</pub-id></mixed-citation>
</ref>
<ref id="B198">
<label>198.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stubbs</surname><given-names>EG</given-names></name><name><surname>Magenis</surname><given-names>RE</given-names></name></person-group>. <article-title>HLA and autism</article-title>. <source/>J Autism Dev Disord. (<year>1980</year>) <volume>10</volume>:<fpage>15</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1007/BF02408429</pub-id><pub-id pub-id-type="pmid">6965077</pub-id></mixed-citation>
</ref>
<ref id="B199">
<label>199.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torres</surname><given-names>AR</given-names></name><name><surname>Maciulis</surname><given-names>A</given-names></name><name><surname>Stubbs</surname><given-names>EG</given-names></name><name><surname>Cutler</surname><given-names>A</given-names></name><name><surname>Odell</surname><given-names>D</given-names></name></person-group>. <article-title>The transmission disequilibrium test suggests that HLA-DR4 and DR13 are linked to autism spectrum disorder</article-title>. <source/>Hum Immunol. (<year>2002</year>) <volume>63</volume>:<fpage>311</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/S0198-8859(02)00374-9</pub-id><pub-id pub-id-type="pmid">12039413</pub-id></mixed-citation>
</ref>
<ref id="B200">
<label>200.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashwood</surname><given-names>P</given-names></name><name><surname>Van de Water</surname><given-names>J</given-names></name></person-group>. <article-title>A review of autism and the immune response</article-title>. <source/>Clin Dev Immunol. (<year>2004</year>) <volume>11</volume>:<fpage>165</fpage>–<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1080/10446670410001722096</pub-id><pub-id pub-id-type="pmid">15330453</pub-id></mixed-citation>
</ref>
<ref id="B201">
<label>201.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torres</surname><given-names>AR</given-names></name><name><surname>Sweeten</surname><given-names>TL</given-names></name><name><surname>Cutler</surname><given-names>A</given-names></name><name><surname>Bedke</surname><given-names>BJ</given-names></name><name><surname>Fillmore</surname><given-names>M</given-names></name><name><surname>Stubbs</surname><given-names>EG</given-names></name><etal></etal></person-group>. <article-title>The association and linkage of the HLA-A2 class I allele with autism</article-title>. <source/>Human Immunol. (<year>2006</year>) <volume>67</volume>:<fpage>346</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1016/j.humimm.2006.01.001</pub-id><pub-id pub-id-type="pmid">16720216</pub-id></mixed-citation>
</ref>
<ref id="B202">
<label>202.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guerini</surname><given-names>FR</given-names></name><name><surname>Bolognesi</surname><given-names>E</given-names></name><name><surname>Manca</surname><given-names>S</given-names></name><name><surname>Sotgiu</surname><given-names>S</given-names></name><name><surname>Zanzottera</surname><given-names>M</given-names></name><name><surname>Agliardi</surname><given-names>C</given-names></name><etal></etal></person-group>. <article-title>Family-based transmission analysis of HLA genetic markers in Sardinian children with autistic spectrum disorders</article-title>. <source/>Hum Immunol. (<year>2009</year>) <volume>70</volume>:<fpage>184</fpage>–<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1016/j.humimm.2008.12.009</pub-id><pub-id pub-id-type="pmid">19167444</pub-id></mixed-citation>
</ref>
<ref id="B203">
<label>203.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guerini</surname><given-names>FR</given-names></name><name><surname>Bolognesi</surname><given-names>E</given-names></name><name><surname>Chiappedi</surname><given-names>M</given-names></name><name><surname>De Silvestri</surname><given-names>A</given-names></name><name><surname>Ghezzo</surname><given-names>A</given-names></name><name><surname>Zanette</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>HLA polymorphisms in Italian children with autism spectrum disorders: results of a family based linkage study</article-title>. <source/>J Neuroimmunol. (<year>2011</year>) <volume>230</volume>:<fpage>135</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1016/j.jneuroim.2010.10.019</pub-id><pub-id pub-id-type="pmid">21084121</pub-id></mixed-citation>
</ref>
<ref id="B204">
<label>204.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corbett</surname><given-names>BA</given-names></name><name><surname>Kantor</surname><given-names>AB</given-names></name><name><surname>Schulman</surname><given-names>H</given-names></name><name><surname>Walker</surname><given-names>WL</given-names></name><name><surname>Lit</surname><given-names>L</given-names></name><name><surname>Ashwood</surname><given-names>P</given-names></name><etal></etal></person-group>. <article-title>A proteomic study of serum from children with autism showing differential expression of apolipoproteins and complement proteins</article-title>. <source/>Mol Psychiatry (<year>2007</year>) <volume>12</volume>:<fpage>292</fpage>–<lpage>306</lpage>. <pub-id pub-id-type="doi">10.1038/sj.mp.4001943</pub-id><pub-id pub-id-type="pmid">17189958</pub-id></mixed-citation>
</ref>
<ref id="B205">
<label>205.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mostafa</surname><given-names>GA</given-names></name><name><surname>Shehab</surname><given-names>AA</given-names></name></person-group>. <article-title>The link of C4B null allele to autism and to a family history of autoimmunity in Egyptian autistic children</article-title>. <source/>J Neuroimmunol. (<year>2010</year>) <volume>223</volume>:<fpage>115</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.jneuroim.2010.03.025</pub-id><pub-id pub-id-type="pmid">20452682</pub-id></mixed-citation>
</ref>
<ref id="B206">
<label>206.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Odell</surname><given-names>D</given-names></name><name><surname>Maciulis</surname><given-names>A</given-names></name><name><surname>Cutler</surname><given-names>A</given-names></name><name><surname>Warren</surname><given-names>L</given-names></name><name><surname>McMahon</surname><given-names>WM</given-names></name><name><surname>Coon</surname><given-names>H</given-names></name><etal></etal></person-group>. <article-title>Confirmation of the association of the C4B null allelle in autism</article-title>. <source/>Hum Immunol. (<year>2005</year>) <volume>66</volume>:<fpage>140</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.humimm.2004.11.002</pub-id><pub-id pub-id-type="pmid">15694999</pub-id></mixed-citation>
</ref>
<ref id="B207">
<label>207.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warren</surname><given-names>RP</given-names></name><name><surname>Yonk</surname><given-names>J</given-names></name><name><surname>Burger</surname><given-names>RW</given-names></name><name><surname>Odell</surname><given-names>D</given-names></name><name><surname>Warren</surname><given-names>WL</given-names></name></person-group>. <article-title>DR-positive T cells in autism: association with decreased plasma levels of the complement C4B protein</article-title>. <source/>Neuropsychobiology (<year>1995</year>) <volume>31</volume>:<fpage>53</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1159/000119172</pub-id><pub-id pub-id-type="pmid">7760985</pub-id></mixed-citation>
</ref>
<ref id="B208">
<label>208.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warren</surname><given-names>RP</given-names></name><name><surname>Burger</surname><given-names>RA</given-names></name><name><surname>Odell</surname><given-names>D</given-names></name><name><surname>Torres</surname><given-names>AR</given-names></name><name><surname>Warren</surname><given-names>WL</given-names></name></person-group>. <article-title>Decreased plasma concentrations of the C4B complement protein in autism</article-title>. <source/>Arch Pediatr Adolesc Med. (<year>1994</year>) <volume>148</volume>:<fpage>180</fpage>–<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1001/archpedi.1994.02170020066011</pub-id><pub-id pub-id-type="pmid">8118537</pub-id></mixed-citation>
</ref>
<ref id="B209">
<label>209.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>DB</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Sutcliffe</surname><given-names>JS</given-names></name><name><surname>Persico</surname><given-names>AM</given-names></name><name><surname>Levitt</surname><given-names>P</given-names></name></person-group>. <article-title>Genetic evidence implicating multiple genes in the MET receptor tyrosine kinase pathway in autism spectrum disorder</article-title>. <source/>Autism Res. (<year>2008</year>) <volume>1</volume>:<fpage>159</fpage>–<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1002/aur.27</pub-id><pub-id pub-id-type="pmid">19360663</pub-id></mixed-citation>
</ref>
<ref id="B210">
<label>210.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dinarello</surname><given-names>CA</given-names></name></person-group>. <article-title>Proinflammatory cytokines</article-title>. <source/>Chest J. (<year>2000</year>) <volume>118</volume>:<fpage>503</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1378/chest.118.2.503</pub-id><pub-id pub-id-type="pmid">10936147</pub-id></mixed-citation>
</ref>
<ref id="B211">
<label>211.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bauer</surname><given-names>S</given-names></name><name><surname>Kerr</surname><given-names>BJ</given-names></name><name><surname>Patterson</surname><given-names>PH</given-names></name></person-group>. <article-title>The neuropoietic cytokine family in development, plasticity, disease and injury</article-title>. <source/>Nat Rev Neurosci. (<year>2007</year>) <volume>8</volume>:<fpage>221</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1038/nrn2054</pub-id><pub-id pub-id-type="pmid">17311007</pub-id></mixed-citation>
</ref>
<ref id="B212">
<label>212.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Chauhan</surname><given-names>A</given-names></name><name><surname>Sheikh</surname><given-names>AM</given-names></name><name><surname>Patil</surname><given-names>S</given-names></name><name><surname>Chauhan</surname><given-names>V</given-names></name><name><surname>Li</surname><given-names>X-M</given-names></name><etal></etal></person-group>. <article-title>Elevated immune response in the brain of autistic patients</article-title>. <source/>J Neuroimmunol. (<year>2009</year>) <volume>207</volume>:<fpage>111</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.jneuroim.2008.12.002</pub-id><pub-id pub-id-type="pmid">19157572</pub-id></mixed-citation>
</ref>
<ref id="B213">
<label>213.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashwood</surname><given-names>P</given-names></name><name><surname>Anthony</surname><given-names>A</given-names></name><name><surname>Torrente</surname><given-names>F</given-names></name><name><surname>Wakefield</surname><given-names>AJ</given-names></name></person-group>. <article-title>Spontaneous mucosal lymphocyte cytokine profiles in children with autism and gastrointestinal symptoms: mucosal immune activation and reduced counter regulatory interleukin-10</article-title>. <source/>J Clin Immunol. (<year>2004</year>) <volume>24</volume>:<fpage>664</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1007/s10875-004-6241-6</pub-id><pub-id pub-id-type="pmid">15622451</pub-id></mixed-citation>
</ref>
<ref id="B214">
<label>214.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jyonouchi</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>S</given-names></name><name><surname>Le</surname><given-names>H</given-names></name></person-group>. <article-title>Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression</article-title>. <source/>J Neuroimmunol. (<year>2001</year>) <volume>120</volume>:<fpage>170</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/S0165-5728(01)00421-0</pub-id><pub-id pub-id-type="pmid">11694332</pub-id></mixed-citation>
</ref>
<ref id="B215">
<label>215.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>VK</given-names></name></person-group>. <article-title>Plasma increase of interleukin-12 and interferon-gamma. Pathological significance in autism</article-title>. <source/>J Neuroimmunol. (<year>1996</year>) <volume>66</volume>:<fpage>143</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/0165-5728(96)00014-8</pub-id><pub-id pub-id-type="pmid">8964908</pub-id></mixed-citation>
</ref>
<ref id="B216">
<label>216.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>VK</given-names></name><name><surname>Warren</surname><given-names>RP</given-names></name><name><surname>Odell</surname><given-names>JD</given-names></name><name><surname>Cole</surname><given-names>P</given-names></name></person-group>. <article-title>Changes of soluble interleukin-2, interleukin-2 receptor, T8 antigen, and interleukin-1 in the serum of autistic children</article-title>. <source/>Clin Immunol Immunopathol. (<year>1991</year>) <volume>61</volume>:<fpage>448</fpage>–<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1016/S0090-1229(05)80015-7</pub-id><pub-id pub-id-type="pmid">1934632</pub-id></mixed-citation>
</ref>
<ref id="B217">
<label>217.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Constantino</surname><given-names>JN</given-names></name><name><surname>Todd</surname><given-names>RD</given-names></name></person-group>. <article-title>Autistic traits in the general population: a twin study</article-title>. <source/>Arch Gen Psychiatry (<year>2003</year>) <volume>60</volume>:<fpage>524</fpage>–<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1001/archpsyc.60.5.524</pub-id><pub-id pub-id-type="pmid">12742874</pub-id></mixed-citation>
</ref>
<ref id="B218">
<label>218.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saresella</surname><given-names>M</given-names></name><name><surname>Marventano</surname><given-names>I</given-names></name><name><surname>Guerini</surname><given-names>FR</given-names></name><name><surname>Mancuso</surname><given-names>R</given-names></name><name><surname>Ceresa</surname><given-names>L</given-names></name><name><surname>Zanzottera</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>An autistic endophenotype results in complex immune dysfunction in healthy siblings of autistic children</article-title>. <source/>Biol Psychiatry (<year>2009</year>) <volume>66</volume>:<fpage>978</fpage>–<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2009.06.020</pub-id><pub-id pub-id-type="pmid">19699471</pub-id></mixed-citation>
</ref>
<ref id="B219">
<label>219.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atladóttir</surname><given-names>HÓ</given-names></name><name><surname>Henriksen</surname><given-names>TB</given-names></name><name><surname>Schendel</surname><given-names>DE</given-names></name><name><surname>Parner</surname><given-names>ET</given-names></name></person-group>. <article-title>Autism after infection, febrile episodes, and antibiotic use during pregnancy: an exploratory study</article-title>. <source/>Pediatrics (<year>2012</year>) <volume>130</volume>:<fpage>e1447</fpage>–<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1542/peds.2012-1107</pub-id><pub-id pub-id-type="pmid">23147969</pub-id></mixed-citation>
</ref>
<ref id="B220">
<label>220.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atladóttir</surname><given-names>HÓ</given-names></name><name><surname>Thorsen</surname><given-names>P</given-names></name><name><surname>Østergaard</surname><given-names>L</given-names></name><name><surname>Schendel</surname><given-names>DE</given-names></name><name><surname>Lemcke</surname><given-names>S</given-names></name><name><surname>Abdallah</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Maternal infection requiring hospitalization during pregnancy and autism spectrum disorders</article-title>. <source/>J Autism Dev Disord. (<year>2010</year>) <volume>40</volume>:<fpage>1423</fpage>–<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1007/s10803-010-1006-y</pub-id><pub-id pub-id-type="pmid">20414802</pub-id></mixed-citation>
</ref>
<ref id="B221">
<label>221.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>AS</given-names></name><name><surname>Sourander</surname><given-names>A</given-names></name><name><surname>Hinkka-Yli-Salomäki</surname><given-names>S</given-names></name><name><surname>McKeague</surname><given-names>IW</given-names></name><name><surname>Sundvall</surname><given-names>J</given-names></name><name><surname>Surcel</surname><given-names>HM</given-names></name></person-group>. <article-title>Elevated maternal C-reactive protein and autism in a national birth cohort</article-title>. <source/>Mol Psychiatry (<year>2013</year>) <volume>19</volume>:<fpage>259</fpage>–<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2012.197</pub-id><pub-id pub-id-type="pmid">23337946</pub-id></mixed-citation>
</ref>
<ref id="B222">
<label>222.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chess</surname><given-names>S</given-names></name></person-group>. <article-title>Autism in children with congenital rubella</article-title>. <source/>J Autism Child Schizophr. (<year>1971</year>) <volume>1</volume>:<fpage>33</fpage>–<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1007/BF01537741</pub-id><pub-id pub-id-type="pmid">5172438</pub-id></mixed-citation>
</ref>
<ref id="B223">
<label>223.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deykin</surname><given-names>EY</given-names></name><name><surname>MacMahon</surname><given-names>B</given-names></name></person-group>. <article-title>Viral exposure and autism</article-title>. <source/>Am J Epidemiol. (<year>1979</year>) <volume>109</volume>:<fpage>628</fpage>–<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1093/oxfordjournals.aje.a112726</pub-id><pub-id pub-id-type="pmid">222139</pub-id></mixed-citation>
</ref>
<ref id="B224">
<label>224.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zerbo</surname><given-names>O</given-names></name><name><surname>Iosif</surname><given-names>A-M</given-names></name><name><surname>Walker</surname><given-names>C</given-names></name><name><surname>Ozonoff</surname><given-names>S</given-names></name><name><surname>Hansen</surname><given-names>RL</given-names></name><name><surname>Hertz-Picciotto</surname><given-names>I</given-names></name></person-group>. <article-title>Is maternal influenza or fever during pregnancy associated with autism or developmental delays? Results from the CHARGE (CHildhood Autism Risks from Genetics and Environment) study</article-title>. <source/>J Autism Dev Disord. (<year>2013</year>) <volume>43</volume>:<fpage>25</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1007/s10803-012-1540-x</pub-id><pub-id pub-id-type="pmid">22562209</pub-id></mixed-citation>
</ref>
<ref id="B225">
<label>225.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zerbo</surname><given-names>O</given-names></name><name><surname>Qian</surname><given-names>Y</given-names></name><name><surname>Yoshida</surname><given-names>C</given-names></name><name><surname>Grether</surname><given-names>JK</given-names></name><name><surname>Van de Water</surname><given-names>J</given-names></name><name><surname>Croen</surname><given-names>LA</given-names></name></person-group>. <article-title>Maternal infection during pregnancy and autism spectrum disorders</article-title>. <source/>J Autism Dev Disord. (<year>2013</year>) <volume>45</volume>:<fpage>4015</fpage>–<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1007/s10803-013-2016-3</pub-id><pub-id pub-id-type="pmid">24366406</pub-id></mixed-citation>
</ref>
<ref id="B226">
<label>226.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meldrum</surname><given-names>SJ</given-names></name><name><surname>Strunk</surname><given-names>T</given-names></name><name><surname>Currie</surname><given-names>A</given-names></name><name><surname>Prescott</surname><given-names>SL</given-names></name><name><surname>Simmer</surname><given-names>K</given-names></name><name><surname>Whitehouse</surname><given-names>AJO</given-names></name></person-group>. <article-title>Autism spectrum disorder in children born preterm—role of exposure to perinatal inflammation</article-title>. <source/>Front Neurosci. (<year>2013</year>) <volume>7</volume>:<fpage>123</fpage>. <pub-id pub-id-type="doi">10.3389/fnins.2013.00123</pub-id><pub-id pub-id-type="pmid">23885233</pub-id></mixed-citation>
</ref>
<ref id="B227">
<label>227.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chess</surname><given-names>S</given-names></name></person-group>. <article-title>Follow-up report on autism in congenital rubella</article-title>. <source/>J Autism Child Schizophr. (<year>1977</year>) <volume>7</volume>:<fpage>69</fpage>–<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1007/BF01531116</pub-id><pub-id pub-id-type="pmid">576606</pub-id></mixed-citation>
</ref>
<ref id="B228">
<label>228.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Libbey</surname><given-names>JE</given-names></name><name><surname>Sweeten</surname><given-names>TL</given-names></name><name><surname>McMahon</surname><given-names>WM</given-names></name><name><surname>Fujinami</surname><given-names>RS</given-names></name></person-group>. <article-title>Autistic disorder and viral infections</article-title>. <source/>J Neurovirol. (<year>2005</year>) <volume>11</volume>:<fpage>1</fpage>–<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1080/13550280590900553</pub-id><pub-id pub-id-type="pmid">15804954</pub-id></mixed-citation>
</ref>
<ref id="B229">
<label>229.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sweeten</surname><given-names>TL</given-names></name><name><surname>Posey</surname><given-names>DJ</given-names></name><name><surname>McDougle</surname><given-names>CJ</given-names></name></person-group>. <article-title>Brief report: autistic disorder in three children with cytomegalovirus infection</article-title>. <source/>J Autism Dev Disord. (<year>2004</year>) <volume>34</volume>:<fpage>583</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1007/s10803-004-2552-y</pub-id><pub-id pub-id-type="pmid">15628611</pub-id></mixed-citation>
</ref>
<ref id="B230">
<label>230.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>U</given-names></name><name><surname>Nyffeler</surname><given-names>M</given-names></name><name><surname>Yee</surname><given-names>BK</given-names></name><name><surname>Knuesel</surname><given-names>I</given-names></name><name><surname>Feldon</surname><given-names>J</given-names></name></person-group>. <article-title>Adult brain and behavioral pathological markers of prenatal immune challenge during early/middle and late fetal development in mice</article-title>. <source/>Brain Behav Immun. (<year>2008</year>) <volume>22</volume>:<fpage>469</fpage>–<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2007.09.012</pub-id><pub-id pub-id-type="pmid">18023140</pub-id></mixed-citation>
</ref>
<ref id="B231">
<label>231.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsiao</surname><given-names>EY</given-names></name><name><surname>Patterson</surname><given-names>PH</given-names></name></person-group>. <article-title>Activation of the maternal immune system induces endocrine changes in the placenta via IL-6</article-title>. <source/>Brain Behav Immun. (<year>2011</year>) <volume>25</volume>:<fpage>604</fpage>–<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2010.12.017</pub-id><pub-id pub-id-type="pmid">21195166</pub-id></mixed-citation>
</ref>
<ref id="B232">
<label>232.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>SE</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Garbett</surname><given-names>K</given-names></name><name><surname>Mirnics</surname><given-names>K</given-names></name><name><surname>Patterson</surname><given-names>PH</given-names></name></person-group>. <article-title>Maternal immune activation alters fetal brain development through interleukin-6</article-title>. <source/>J Neurosci. (<year>2007</year>) <volume>27</volume>:<fpage>10695</fpage>–<lpage>702</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.2178-07.2007</pub-id><pub-id pub-id-type="pmid">17913903</pub-id></mixed-citation>
</ref>
<ref id="B233">
<label>233.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lasala</surname><given-names>N</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name></person-group>. <article-title>Effects of maternal exposure to LPS on the inflammatory response in the offspring</article-title>. <source/>J Neuroimmunol. (<year>2007</year>) <volume>189</volume>:<fpage>95</fpage>–<lpage>101</lpage>. <pub-id pub-id-type="doi">10.1016/j.jneuroim.2007.07.010</pub-id><pub-id pub-id-type="pmid">17706793</pub-id></mixed-citation>
</ref>
<ref id="B234">
<label>234.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mandal</surname><given-names>M</given-names></name><name><surname>Marzouk</surname><given-names>AC</given-names></name><name><surname>Donnelly</surname><given-names>R</given-names></name><name><surname>Ponzio</surname><given-names>NM</given-names></name></person-group>. <article-title>Preferential development of Th17 cells in offspring of immunostimulated pregnant mice</article-title>. <source/>J Reprod Immunol. (<year>2010</year>) <volume>87</volume>:<fpage>97</fpage>–<lpage>100</lpage>. <pub-id pub-id-type="doi">10.1016/j.jri.2010.06.156</pub-id><pub-id pub-id-type="pmid">20727596</pub-id></mixed-citation>
</ref>
<ref id="B235">
<label>235.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mandal</surname><given-names>M</given-names></name><name><surname>Marzouk</surname><given-names>AC</given-names></name><name><surname>Donnelly</surname><given-names>R</given-names></name><name><surname>Ponzio</surname><given-names>NM</given-names></name></person-group>. <article-title>Maternal immune stimulation during pregnancy affects adaptive immunity in offspring to promote development of TH17 cells</article-title>. <source/>Brain Behav Immun. (<year>2011</year>) <volume>25</volume>:<fpage>863</fpage>–<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2010.09.011</pub-id><pub-id pub-id-type="pmid">20854892</pub-id></mixed-citation>
</ref>
<ref id="B236">
<label>236.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Surriga</surname><given-names>O</given-names></name><name><surname>Ortega</surname><given-names>A</given-names></name><name><surname>Jadeja</surname><given-names>V</given-names></name><name><surname>Bellafronte</surname><given-names>A</given-names></name><name><surname>Lasala</surname><given-names>N</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name></person-group>. <article-title>Altered hepatic inflammatory response in the offspring following prenatal LPS exposure</article-title>. <source/>Immunol Lett. (<year>2009</year>) <volume>123</volume>:<fpage>88</fpage>–<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1016/j.imlet.2009.02.009</pub-id><pub-id pub-id-type="pmid">19428555</pub-id></mixed-citation>
</ref>
<ref id="B237">
<label>237.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>S</given-names></name><name><surname>Masi</surname><given-names>A</given-names></name><name><surname>Dale</surname><given-names>RC</given-names></name><name><surname>Whitehouse</surname><given-names>AJO</given-names></name><name><surname>Pokorski</surname><given-names>I</given-names></name><name><surname>Alvares</surname><given-names>GA</given-names></name><etal></etal></person-group>. <article-title>Social impairments in autism spectrum disorder are related to maternal immune history profile</article-title>. <source/>Mol Psychiatry (<year>2018</year>) <volume>23</volume>:<fpage>1794</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2017.201</pub-id><pub-id pub-id-type="pmid">28993711</pub-id></mixed-citation>
</ref>
<ref id="B238">
<label>238.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neumeyer</surname><given-names>AM</given-names></name><name><surname>Anixt</surname><given-names>J</given-names></name><name><surname>Chan</surname><given-names>J</given-names></name><name><surname>Perrin</surname><given-names>JM</given-names></name><name><surname>Murray</surname><given-names>D</given-names></name><name><surname>Coury</surname><given-names>DL</given-names></name><etal></etal></person-group>. <article-title>Identifying associations among co-occurring medical conditions in children with autism spectrum disorders</article-title>. <source/>Acad Pediatr. (<year>2018</year>). [Epub ahead of print]. <pub-id pub-id-type="doi">10.1016/j.acap.2018.06.014</pub-id><pub-id pub-id-type="pmid">30053632</pub-id></mixed-citation>
</ref>
<ref id="B239">
<label>239.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Zhou</surname><given-names>JM</given-names></name></person-group>. <article-title>The microbiota–gut–brain axis and its potential therapeutic role in autism spectrum disorder</article-title>. <source/>Neuroscience (<year>2016</year>) <volume>324</volume>:<fpage>131</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2016.03.013</pub-id><pub-id pub-id-type="pmid">26964681</pub-id></mixed-citation>
</ref>
<ref id="B240">
<label>240.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romo-Nava</surname><given-names>F</given-names></name><name><surname>Alvarez-Icaza</surname><given-names>González D</given-names></name><name><surname>Fresán-Orellana</surname><given-names>A</given-names></name><name><surname>Saracco Alvarez</surname><given-names>R</given-names></name><name><surname>Becerra-Palars</surname><given-names>C</given-names></name><name><surname>Moreno</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>Melatonin attenuates antipsychotic metabolic effects: an eight-week randomized, double-blind, parallel-group, placebo-controlled clinical trial</article-title>. <source/>Bipolar Disord. (<year>2014</year>) <volume>16</volume>:<fpage>410</fpage>–<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1111/bdi.12196</pub-id><pub-id pub-id-type="pmid">24636483</pub-id></mixed-citation>
</ref>
<ref id="B241">
<label>241.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sommansson</surname><given-names>A</given-names></name><name><surname>Saudi</surname><given-names>WSW</given-names></name><name><surname>Nylander</surname><given-names>O</given-names></name><name><surname>Sjöblom</surname><given-names>M</given-names></name></person-group>. <article-title>Melatonin inhibits alcohol-induced increases in duodenal mucosal permeability in rats <italic>in vivo</italic></article-title>. <source/>Am J Physiol Liver Physiol. (<year>2013</year>) <volume>305</volume>:<fpage>G95</fpage>–<lpage>105</lpage>. <pub-id pub-id-type="doi">10.1152/ajpgi.00074.2013</pub-id><pub-id pub-id-type="pmid">23639810</pub-id></mixed-citation>
</ref>
<ref id="B242">
<label>242.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eriksson</surname><given-names>SH</given-names></name></person-group>. <article-title>Epilepsy and sleep</article-title>. <source/>Curr Opin Neurol. (<year>2011</year>) <volume>24</volume>:<fpage>171</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1097/WCO.0b013e3283445355</pub-id><pub-id pub-id-type="pmid">21386677</pub-id></mixed-citation>
</ref>
<ref id="B243">
<label>243.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irwin</surname><given-names>MR</given-names></name><name><surname>Olmstead</surname><given-names>R</given-names></name><name><surname>Carroll</surname><given-names>JE</given-names></name></person-group>. <article-title>Sleep disturbance, sleep duration, and inflammation: a systematic review and meta-analysis of cohort studies and experimental sleep deprivation</article-title>. <source/>Biol Psychiatry (<year>2016</year>) <volume>80</volume>:<fpage>40</fpage>–<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2015.05.014</pub-id><pub-id pub-id-type="pmid">26140821</pub-id></mixed-citation>
</ref>
<ref id="B244">
<label>244.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alvares</surname><given-names>GA</given-names></name><name><surname>Dawson</surname><given-names>PA</given-names></name><name><surname>Dissanayake</surname><given-names>C</given-names></name><name><surname>Eapen</surname><given-names>V</given-names></name><name><surname>Gratten</surname><given-names>J</given-names></name><name><surname>Grove</surname><given-names>R</given-names></name><etal></etal></person-group>. <article-title>Study protocol for the Australian autism biobank: an international resource to advance autism discovery research</article-title>. <source/>BMC Pediatr. (<year>2018</year>) <volume>18</volume>:<fpage>284</fpage>. <pub-id pub-id-type="doi">10.1186/s12887-018-1255-z</pub-id><pub-id pub-id-type="pmid">30149807</pub-id></mixed-citation>
</ref>
<ref id="B245">
<label>245.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reilly</surname><given-names>J</given-names></name><name><surname>Gallagher</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>JL</given-names></name><name><surname>Leader</surname><given-names>G</given-names></name><name><surname>Shen</surname><given-names>S</given-names></name></person-group>. <article-title>Bio-collections in autism research</article-title>. <source/>Mol Autism. (<year>2017</year>) <volume>8</volume>:<fpage>34</fpage>. <pub-id pub-id-type="doi">10.1186/s13229-017-0154-8</pub-id><pub-id pub-id-type="pmid">28702161</pub-id></mixed-citation>
</ref>
<ref id="B246">
<label>246.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischbach</surname><given-names>GD</given-names></name><name><surname>Lord</surname><given-names>C</given-names></name></person-group>. <article-title>The Simons Simplex Collection: a resource for identification of autism genetic risk factors</article-title>. <source/>Neuron (<year>2010</year>) <volume>68</volume>:<fpage>192</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2010.10.006</pub-id><pub-id pub-id-type="pmid">20955926</pub-id></mixed-citation>
</ref>
<ref id="B247">
<label>247.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loth</surname><given-names>E</given-names></name><name><surname>Charman</surname><given-names>T</given-names></name><name><surname>Mason</surname><given-names>L</given-names></name><name><surname>Tillmann</surname><given-names>J</given-names></name><name><surname>Jones</surname><given-names>EJH</given-names></name><name><surname>Wooldridge</surname><given-names>C</given-names></name><etal></etal></person-group>. <article-title>The EU-AIMS Longitudinal European Autism Project (LEAP): design and methodologies to identify and validate stratification biomarkers for autism spectrum disorders</article-title>. <source/>Mol Autism. (<year>2017</year>) <volume>8</volume>:<fpage>24</fpage>. <pub-id pub-id-type="doi">10.1186/s13229-017-0146-8</pub-id><pub-id pub-id-type="pmid">28649312</pub-id></mixed-citation>
</ref>
<ref id="B248">
<label>248.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frye</surname><given-names>RE</given-names></name><name><surname>Rossignol</surname><given-names>DA</given-names></name></person-group>. <article-title>Treatments for biomedical abnormalities associated with autism spectrum disorder</article-title>. <source/>Front Pediatr. (<year>2014</year>) <volume>2</volume>:<fpage>66</fpage>. <pub-id pub-id-type="doi">10.3389/fped.2014.00066</pub-id><pub-id pub-id-type="pmid">25019065</pub-id></mixed-citation>
</ref>
<ref id="B249">
<label>249.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>MSC</given-names></name><name><surname>Annaz</surname><given-names>D</given-names></name><name><surname>Ansari</surname><given-names>D</given-names></name><name><surname>Scerif</surname><given-names>G</given-names></name><name><surname>Jarrold</surname><given-names>C</given-names></name><name><surname>Karmiloff-Smith</surname><given-names>A</given-names></name></person-group>. <article-title>Using developmental trajectories to understand developmental disorders</article-title>. <source/>J Speech Lang Hear Res. (<year>2009</year>) <volume>52</volume>:<fpage>336</fpage>–<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1044/1092-4388(2009/07-0144)</pub-id><pub-id pub-id-type="pmid">19252129</pub-id></mixed-citation>
</ref>
<ref id="B250">
<label>250.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zablotsky</surname><given-names>B</given-names></name><name><surname>Kalb</surname><given-names>LG</given-names></name><name><surname>Freedman</surname><given-names>B</given-names></name><name><surname>Vasa</surname><given-names>R</given-names></name><name><surname>Stuart</surname><given-names>EA</given-names></name></person-group>. <article-title>Health care experiences and perceived financial impact among families of children with an autism spectrum disorder</article-title>. <source/>Psychiatr Serv. (<year>2014</year>) <volume>65</volume>:<fpage>395</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1176/appi.ps.201200552</pub-id><pub-id pub-id-type="pmid">24584528</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>